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CHAPTER 1 
GENERAL INTRODUCTION 
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MAGNITUDE OF CARDIOVASCULAR DISEASES 
Cardiovascular disease (CVD), including ischemic heart disease and stroke, is still one 
of the major causes of mortality and morbidity in Western countries. Alarming is the 
expectation that the CVD burden will rise again after decades of decline. Due to the 
epidemic proportions of obesity and ageing, it is expected that the number of patients 
diagnosed with diabetes mellitus type II in The Netherlands is going to rise from the 
current 740.000 to 1.3 million in the year 2025, resulting in an increase of patients 
suffering from CVD [1]. In the USA, in 2009, a total of 787.931 people deceased due to 
CVD [2]. The proportion of mortality caused by CVD was 32.3% of total mortality. 
Moreover, each year an estimated 635.000 Americans will have a new myocardial 
infarction (MI), 280.000 Americans a recurrent MI and 150.000 Americans a silent 
first MI [2]. This is accompanied by high costs; the annual direct and indirect cost of 
CVD in the USA is estimated at $312.6 billion, which is 15% of total health 
expenditures, which is more than any other major diagnostic group [2].  
 Not only in Western countries, but also in developing countries, the prevalence of 
traditional risk factors for CVD has been increasing with consequent increases in 
cardiovascular event rates [3]. Therefore, CVD is a rising major global health problem. 
 
ATHEROSCLEROSIS 
Atherosclerosis, derived from the Greek athero (gruel-like) and sclerosis (hardening) 
is the main cause of coronary artery disease (CAD). Atherosclerosis is a multifactorial, 
chronic inflammatory disease in which immune mechanisms interact with metabolic 
risk factors to initiate, propagate and activate lesions in large and medium-sized 
arteries [4,5]. The atherosclerotic process already begins during adolescence. First, a 
fatty streak is formed, consisting of an accumulation of lipid-rich cells, macrophages 
and T-cells [6]. Fatty streaks can progress to atheromas, which are located in the 
intima layer of the artery (Figure 1) [7]. Atheromas consist of a core of lipids, 
connective tissue, debris and various inflammatory and immune cells like 
macrophages, T-cells and mast cells [8]. This core is surrounded by a protective, 
fibrous cap which forms the demarcation with the lumen of the artery. 
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Atheromas grow in the so-called ‘shoulder region’. In this region, a lot of activated 
immune cells are present which secrete inflammatory cytokines that can weaken the 
fibrous cap. In this way, a stable plaque can convert into an unstable ‘vulnerable’ 
plaque. Rupture of a vulnerable plaque will also preferentially occur in the shoulder 
region of the plaque. As a consequence, prothrombotic material from inside the 
atheromatous plaque comes into contact with blood and forms an occluding 
thrombus, resulting in a MI (Figure 1) [9]. Atherosclerosis is not limited to the 
coronary arteries, but is a systemic disease, giving rise to acute and chronic vascular 
syndromes which can ultimately result in complications like MI, stroke and peripheral 
artery disease (PAD) [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
     1                 2                3                 4                5                 6                7 
 
Figure 1. Initiation, progression, and complication of human coronary atherosclerotic plaque. 
Top, Longitudinal section of an artery depicting “timeline” of human atherogenesis from normal 
artery (1) to atheroma that caused clinical manifestations by thrombosis or stenosis (5-7). Bottom, 
Corresponding cross sections of an artery during various stages of atheroma evolution. 
Reproduced with permission from: Libby P. Current concepts of the pathogenesis of the acute 
coronary syndromes. Circulation 2001;104:365–372 [7].  
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DETECTION OF CORONARY ARTERY DISEASE AND VULNERABLE PLAQUES 
There are various tools available in the search for patients with CAD and patients at 
high risk of a vulnerable plaque, ranging from basic office-based risk score algorithms 
to innovative invasive diagnostic imaging procedures like intravascular ultrasound 
(Figure 2) [10]. 
 
 
 
 
 
 
 
 
 
Figure 2. The “vulnerable plaque pyramid”, which shows a possible step-by-step method in order 
to detect a vulnerable plaque. Adapted and reproduced with permission from: Naghavi M, Libby P, 
Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk 
assessment strategies: Part II. Circulation 2003;15:1772–1778 [10]. CT indicates computed 
tomography; ICA, invasive coronary angiography; IVUS, intravascular ultrasound; NIR, near 
infrared; OCT, optical coherence tomography. 
Risk Score Algorithms 
There are several known traditional cardiovascular risk factors which are associated 
with the occurrence and progression of CAD, including male gender, age, diabetes 
mellitus, smoking, family history of premature atherosclerosis, obesity, hypertension, 
dyslipidemia and a sedentary lifestyle. These risk factors can be used in risk score 
algorithms in order to estimate the long term cardiovascular risk in patients. 
Frequently used risk score algorithms are the Framingham risk score (predicts 10-
year risk of suffering any cardiovascular event), the PROCAM risk score (predicts 10-
year risk of acute coronary events), the SCORE risk score (predicts 10-year risk of 
fatal cardiovascular disease) and the Diamond and Forrester score (predicts 
significant CAD on invasive coronary angiography) [11-14].  
ICA, IVUS, OCT, NIR spectroscopy 
Molecular imaging 
Coronary CT-angiography 
Coronary calcium score 
Biomarkers 
Invasive imaging 
Office based screening 
Exercise stress testing 
     Risk score algorithms 
Non-invasive imaging 
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Partly because the use of risk score algorithms is cost- and time-efficient, this 
approach is preferable and recommended in clinical practice as a first step in 
cardiovascular risk assessment [15]. Detection of CAD in an early stage is useful, since 
the atherosclerotic process can be modified by lifestyle changes or pharmacological 
treatment, in order to prevent major adverse cardiac events (MACE) [16-18].  
 
Exercise Stress Testing 
Exercise stress testing, including exercise electrocardiography, exercise 
echocardiography and myocardial perfusion imaging, is a non-invasive, less expensive 
procedure. In guidelines it has been described in which scenarios exercise stress 
testing is recommended [19]. Exercise stress testing can be used for risk stratification 
beyond risk score algorithms. Moreover, it provides diagnostic and prognostic 
information [20-23]. However, diagnostic accuracy is variable and depends on age, 
gender, clinical patient characteristics and test modality [24]. Sensitivity and 
specificity rates for detection of CAD range from 68-88% (sensitivity) and from 73-
84% (specificity) [25].  
 
Biomarkers 
In literature, several biomarkers are described which are related to CAD and the 
occurrence of MACE. C-reactive protein, a marker of systemic inflammation, is 
associated with cardiovascular events such as MI, coronary mortality and stroke in 
both men and women, with or without previous CVD [26-30]. These findings support 
the hypothesis that atherothrombosis is partly an inflammatory disease [31]. 
Experimental data indicate that blood coagulation proteins, including thrombin, are 
also involved in the pathophysiology of atherosclerosis. Beyond its central role in the 
process of thrombus formation, thrombin is described as a strong pro-inflammatory 
protein. It has the potential to activate different protease-activated receptors, 
resulting in pro-atherogenic and plaque destabilizing effects such as endothelial 
dysfunction, platelet activation, monocyte recruitment, oxidative stress and 
inflammation (Figure 3) [32,33]. However, evidence from clinical studies is lacking. 
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Figure 3. Involvement of thrombin in the atherosclerotic process. Thrombin, factor Xa and tissue 
factor-factor VIIa complexes have the ability to activate protease-activated receptors, which 
results in a plethora of proatherogenic cellular responses. These proatherogenic actions are able 
to destabilize an atherosclerotic plaque. Reproduced with permission from: Borissoff JI, Spronk 
HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 
2011;364:1746–1760 [32]. 
 
Not only thrombin, but also neutrophils are involved in the atherosclerotic process 
[34,35]. Neutrophils are able to release extracellular traps (neutrophil extracellular 
traps [NETs]), which compose of chromatin threads, histones and granular proteins. 
NETs appear to be a form of innate immune response and were observed in cases of 
acute inflammation, in order to kill bacteria [36]. However, their role in the human 
atherosclerotic process remains unclear and needs further investigation.  
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Matrix Gla-protein (MGP), a vitamin K-dependent protein, is an inhibitor of 
calcification of arteries and cartilage [37]. Some studies already described the 
association between treatment with vitamin K-antagonists and increased calcification 
[38,39]. Furthermore, MGP is independently associated with mortality and CVD 
events, including MI, stroke, transient ischemic attack and heart failure, in outpatients 
with stable CAD [40]. These data support the hypothesis that calcification  may 
contribute to the occurrence of MACE. 
 Another intriguing biomarker is the protein troponin. Cardiac troponin I and T are 
components of the contractile apparatus of myocardial cells and are expressed almost 
exclusively in the heart. They are released into the blood as a result of cardiomyocyte 
injury. Nowadays, cardiac troponin is the preferred biomarker to diagnose an acute MI 
[41]. Moreover, it can be used as a key diagnostic tool for decision making in patients 
presenting with chest pain. A few studies are published which focused on the 
prognostic value of hs-cTnT. However, these studies were performed in the elderly or 
in the general population, while less is known about the incremental value of hs-cTnT 
on top of other risk stratification tools in patients with stable chest pain [42-44]. 
 
Coronary Calcium Score 
With the use of CT it is possible to visualize the presence and localization of calcium in 
the coronaries. The amount of calcium can be measured with software and expressed 
as total number of calcified lesions, calcium volume (mm3), calcium mass (mg calcium 
hydroxyapatite) and Agatston score, which is the most widely used parameter to 
express the calcium score. An increased calcium score, which is associated with an 
increased risk of significant luminal stenosis, independently predicts MACE [45-47]. 
Moreover, it has incremental value on top of clinical risk stratification [48-50]. Despite 
advances in reconstruction techniques, the presence of coronary calcification leads to 
high levels of signal attenuation, causing blooming artifacts [51]. This leads to the 
effect of overestimating the calcium and thus potentially overestimating the degree of 
luminal stenosis. The higher the calcium score, the greater the risk of blooming 
artifacts, and the more difficult to reliable assess the CT-scan, possibly resulting in a 
non-diagnostic scan [52,53]. The choice whether to proceed with contrast enhanced 
CT-angiography in the presence of extensive calcification remains controversial [54]. 
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Coronary Computed Tomographic Angiography 
Coronary CT-angiography (CCTA) is a non-invasive, diagnostic imaging technique to 
visualize the coronary arteries. It provides valuable information regarding the 
presence, extent, degree and morphology of coronary plaques. The extent of CAD can 
be defined as the number of coronary segments with a plaque, irrespective of the 
degree of luminal stenosis. The degree of luminal stenosis can be classified as absent 
(no luminal stenosis), mild (<50% luminal stenosis), moderate (50-70% luminal 
stenosis) or severe (>70% luminal stenosis) [55]. Regarding plaque morphology, 
different plaques can be distinguished: calcified plaques (exclusively content with 
density >130 HU), non-calcified plaques (exclusively content with density <130 HU) 
and mixed plaques (characteristics of both calcified and non-calcified plaques) [55].  
 CCTA possesses reasonable diagnostic accuracy to detect obstructive CAD, but is 
also established to rule out obstructive CAD with a negative predictive value of 99% 
[56,57]. Moreover, CCTA has also proven prognostic value in predicting MACE, both in 
patients with acute chest pain and in outclinic patients with suspected CAD [58,59]. 
 Recently, CCTA characteristics of vulnerable plaques are described, including large 
plaque volume, low plaque attenuation, large proportion of non-calcified plaque, 
spotty calcification and a high positive remodeling index (Figure 4) [60-63].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Example of an axial coronary CT-image. The proximal part of the left anterior 
descending artery shows a large, non-calcified atherosclerotic plaque with positive outward 
remodeling (white arrow). These characteristics fits into the profile of a vulnerable plaque. 
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Molecular Imaging 
The field of molecular imaging has grown rapidly during the last decade and has 
brought new insights into cardiovascular disease. Molecular imaging focuses on the 
immunobiology behind the endothelium and can be helpful in identifying culprit 
atherosclerotic lesions [64,65]. An extensively studied concept is the possibility to 
image vascular inflammation by 18FDG uptake with positron emission tomography 
(PET). However, not all clinical studies found a clear association between plaque 
vulnerability and 18FDG uptake [66]. An alternative approach is PET/CT imaging using 
18F-NaF to depict calcification. 18F-NaF is a promising marker of plaque biology, which 
has the potential to provide key insights into the role that calcification plays in the 
progression of atherosclerosis [67]. Moreover, molecular imaging remains expensive 
as well as time-consuming. In the future, once molecular imaging is successfully 
introduced in clinical practice, it has the potential to offer new therapeutic strategies 
in order to offer patients a personalized treatment [66]. 
 
Invasive Coronary Imaging Techniques 
Invasive coronary angiography (ICA) is a widely used imaging technique, which is still 
considered as the reference standard for detecting obstructive CAD. However, one of 
the major disadvantages is that ICA only provides little information regarding 
characteristics of plaque vulnerability. The technique is limited or even inappropriate 
in its ability to visualize the vessel wall, fibrous cap thickness and plaque composition 
as well as plaque volume [68]. Degree of coronary artery stenosis is unreliable as a 
single parameter for plaque vulnerability, which is confirmed by a study in patients 
with a non-Q-wave MI. In more than 35% of these patients, ICA was not able to 
identify the culprit lesion [69].  
 In the past decade, complimentary intravascular imaging techniques have been 
developed which can be performed during ICA, including intravascular ultrasound 
(IVUS) and optical coherence tomography (OCT). IVUS uses ultrasound technology, 
while OCT uses depth-resolved back-reflection of infrared light in order to accurately 
visualize plaque characteristics as well as the vessel wall [63]. IVUS allow 
identification of four different tissue types including dense calcium, fibrous tissue, 
fibrofatty tissue and necrotic core [70].  
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Positive vascular remodeling, a feature which is associated with culprit and ruptured 
coronary plaques, is also visible with IVUS [71,72]. OCT offers a high resolution 
measurement of the fibrous cap thickness, which plays a critical role in plaque rupture 
as discussed earlier. Moreover, it is possible to image ruptures, thrombi, lipid cores 
and calcium. A major technical limitation of OCT is its lack of penetration, making it 
difficult to measure the true vessel size and plaque burden [63]. 
 
DETECTION OF CAD AND VULNERABLE PLAQUES IN DAILY CLINICAL PRACTICE 
As previously discussed, it is expected that the number of patients suffering from CVD 
will rise in the near future. Therefore, improving risk profiling as presented in the 
vulnerable plaque pyramid is of paramount importance. Given the increasing burden 
of CVD and the ever rising health care expenditures, a focus on relatively low costs 
test, such as the development of novel serum biomarkers, is a desirable strategy.  
In addition, development of a more precise diagnostic algorithm for risk profiling will 
help to decrease both cardiovascular risk and health care costs.  
 In daily clinical practice, it is not possible and not necessary for all patients to go 
through all ‘phases’ of the pyramid. This would even be undesirable since all tests 
have potential complications, especially the invasive procedures. Moreover, invasive 
techniques like molecular imaging, IVUS and OCT are not yet widespread available. In 
contrast, CCTA is available in an increasing number of hospitals. All procedures have 
their own strengths and weaknesses, and it is therefore crucial to require the most 
appropriate test and to extract as much information as possible from the chosen test.  
 
AIM AND OUTLINE OF THIS THESIS 
The aim of this thesis was to relate characteristics of CAD, as measured with CCTA, 
with (bio)markers, as a first step in order to improve risk stratification in patients 
with suspected CAD. Moreover, by using biomarkers that are not yet suitable for use 
in daily clinical practice, we tried to gain more insight into underlying mechanisms.  
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 Chapters 2 and 3 focus on clinical markers. Chapter 2 describes gender differences 
in clinical risk profile as well as gender differences in CAD. Chapter 3 studies the 
relationship between mild to moderate chronic kidney disease and CAD. 
 Chapters 4-6 are reserved for more novel and specific biomarkers. Chapter 4 
studies the incremental value of high-sensitivity cardiac troponin T as a risk 
stratification tool in patients with symptoms of chest discomfort suspected for 
CAD.  
Chapters 5 and 6 build a bridge between atherosclerosis, coagulation and 
immunity. Chapter 5 describes the association between in vivo thrombin formation 
and the presence and severity of coronary atherosclerosis. Chapter 6 describes the 
association between markers of neutrophil extracellular traps and coronary 
atherosclerosis. 
 Chapter 7 demonstrates that vitamin K antagonists are able to accelerate the 
process of atherosclerotic calcification. Moreover, we show that vitamin K 
antagonists can induce vulnerable plaques in mice.  
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BACKGROUND 
To investigate gender differences in coronary CT-angiography (CCTA) defined 
coronary artery disease (CAD) as well as gender differences in the relationship 
between clinical risk profiling, extent and degree of CAD and short-term outcome. 
METHODS 
This retrospective study is approved by the Institutional Review Board and compliant 
to the Declaration of Helsinki. 1,042 patients (527 men, 515 women; mean age 56 
years) with stable chest discomfort symptoms underwent CCTA to assess the extent 
(number of coronary segments with plaque) and degree (no, mild, moderate, severe) 
of CAD. Framingham risk score (FRS) was calculated in all patients. Binary logistic 
regression models were used to describe the relationship between gender and CAD. 
Presence of any plaque, presence of severe plaque, and different numbers of segments 
with plaque were used as dependent variables. 
RESULTS 
After adjustment for cardiovascular risk factors, men significantly more often 
harbored any plaque (OR: 2.6, 95%CI: 1.9-3.6), severe plaque (OR: 2.9, 95%CI: 1.7-
4.9), 4-6 segments with plaque (OR: 3.3, 95%CI: 2.2-5.1) and >6 segments with plaque 
(OR: 4.0, 95%CI: 2.2-7.5), compared with women (all P<0.001). Although individual 
women had more risk factors, FRS was significantly lower in women as compared to 
men. A total of 28 patients suffered an event: 24 revascularizations, 2 acute coronary 
syndromes and 2 deaths. 
CONCLUSION 
Women had significantly lower FRS than men, regardless the extent and degree of 
CAD. This suggests that relative to men, the FRS underestimates the extent and degree 
of CAD in women as assessed with CCTA. 
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INTRODUCTION 
Despite a significant decline in the incidence of cardiovascular diseases (CVD) in the 
last decades, ischemic heart disease and stroke are still major causes of morbidity and 
mortality. CVD is often regarded as a problem mostly seen in men. However, health 
statistics in Europe show that about 54% of all deaths in females are caused by CVD, 
compared to 43% of all deaths in males [1]. Despite these statistics, the risk of CVD is 
still underestimated in women. This has led the European Society of Cardiology to 
launch the ‘Woman at Heart’ program [2,3]. Similar programs have been initiated in 
the USA, such as the ‘Go Red For Women’ campaign [4]. These programs should 
improve risk stratification, diagnosis and therapy in women at risk for CVD. The 
importance of these programs is emphasized by studies showing that healthcare 
professionals often fail to identify cardiovascular risk factors in women, resulting in 
underdiagnosis and undertreatment [5-8]. As a consequence, women with CVD 
experience a worse quality of life [9,10] and have lower survival rates as compared 
with men [11,12]. 
Cardiovascular risk stratification algorithms, such as the Framingham risk score 
(FRS) are powerful tools to classify patients into risk groups [13]. The ability of FRS to 
predict for coronary artery disease (CAD) is similar or even better compared to other 
risk score algorithms like PROCAM and Diamond Forrester, in stable chest pain 
patients referred for coronary CT-angiography (CCTA) [14].  
  The aim of the present study was to investigate gender differences in CCTA 
defined CAD. Moreover, because the potential mismatch between clinical risk profiling 
and the extent and degree of CAD, we also investigate gender differences in the 
relationship between clinical risk profiling, extent and degree of CAD and short-term 
outcome. 
 
METHODS 
Study Population 
We retrospectively studied 1,153 patients, referred from the cardiology outpatient 
department for CCTA because of stable chest discomfort, suspicious for CAD.  
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Scans were performed between June 2010 and July 2012, as part of the diagnostic 
work-up, using a second generation dual-source CT-scanner (Somatom Definition 
Flash, Siemens Medical Solutions, Forchheim, Germany). Included were patients who 
underwent coronary calcium scoring (CCS) as well as CCTA. Excluded were patients 
with a known history of CAD, patients with unavailable data regarding their 
cardiovascular risk profile and patients with an inconclusive scan (Figure 1).  
 This study is approved by the Institutional Review Board (IRB) and Ethics 
Committee. Written informed consent was waived because data were analyzed 
anonymously in accordance with IRB guidelines. The study complies with the ethical 
principles of the Declaration of Helsinki. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart of the study design. 
 
Traditional Cardiovascular Risk Factors and Framingham Risk Score 
Traditional cardiovascular risk factors were collected prior to the scan in order to 
calculate the FRS, which is an index of 10 year risk for adverse cardiovascular events. 
n=28 excluded because of known previous coronary artery disease 
n=59 excluded because of unavailable data regarding cardiovascular 
risk profile 
n=24 excluded because of inconclusive coronary CT-angiography 
1,153 patients with chest discomfort symptoms, suspected for 
coronary artery disease, were referred for coronary CT-angiography 
Study population included in analysis: n=1,042 
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Risk variables which are used for calculating the FRS are age, systolic blood pressure, 
smoking, diabetes mellitus, total cholesterol and high-density lipoprotein cholesterol 
[13]. Patients were classified as smoker if they were current smoker. A family history 
of premature CAD was defined as having a first-degree relative with a history of 
myocardial infarction or sudden cardiac death before the age of sixty [15]. Patients 
were classified as diabetic if diabetes mellitus was diagnosed according to the 
guidelines [16].  
 
Coronary Calcium Score 
A non-contrast-enhanced high pitch spiral scan was performed to determine the CCS, 
using the Agatston method [17]. Data acquisition parameters were: pitch 3.4, slice 
collimation 2 x 128 x 0.6 mm, gantry rotation time 280 ms, tube voltage 120 kV, tube 
current 100 mAs, slice thickness 3 mm/1.5 mm and dedicated reconstruction kernels 
for cardiac CT (B26f / I26f). CCS was calculated using dedicated software (Syngo 
Calcium Scoring, Siemens). An attenuation threshold of 130 Hounsfield units (HU) was 
used to identify calcifications in the main coronary branches. All individual 
calcifications were manually picked, summed and expressed as Agatston score. 
 
Coronary CT-angiography 
Adjacent to the CCS scan we performed CCTA. Data acquisition parameters for CCTA 
were: slice collimation 2 x 128 x 0.6 mm, gantry rotation time 280 ms and tube voltage 
80-120 kV, depending on the individual patient size. Patients received 50 mg 
Metoprolol tartrate (AstraZeneca, Zoetermeer, The Netherlands) orally, two hours 
before CCTA. When indicated, an additional dose of 5-20 mg Metoprolol tartrate was 
administered intravenously on site, in an attempt to lower the heart rate <60 beats 
per minute (bpm). All patients received 0.8 mg Nitroglycerin spray (Pohl-Boskamp, 
Hohenlockstedt, Germany) sublingually just prior to CCTA. Heart rate and ECG were 
monitored prior and during CCTA. A 20 mL contrast test bolus was injected to assess 
the time to peak in the ascending aorta. CCTA was performed using 75–120 mL 
iopromide (Ultravist 300; Bayer Healthcare, Leverkusen, Germany), injected in the 
antecubital vein at a flow rate of 5.2–7.4 mL/s, directly followed by 40 mL intravenous 
saline at the same flow rate, using a dual-head power injector (Stellant, Bayer). 
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Amount of contrast agent as well as flow rate were dependent on individual patient 
characteristics.  
 Patients with a stable heart rate <60 bpm underwent a prospectively ECG-
triggered high pitch spiral protocol (“Flash”). Patients with a stable heart rate 
between 60–90 bpm underwent a prospectively ECG-triggered protocol (“Adaptive 
sequence”). In patients with a heart rate >90 bpm or in case of arrhythmia, a 
retrospectively ECG-gated “Helical” low-pitch protocol with online dose modulation 
was performed.  
 All scans were independently analyzed by a cardiologist and radiologist, each with 
4 years experience in CCTA assessment and blinded for patient details. In case of 
disagreement, consensus was reached by reviewing findings jointly. Dedicated 
software (Syngo CT 2010A, Siemens) was used to assess the source images. The 
coronary artery tree was analyzed for presence and severity of CAD, according to the 
16-segment classification of the American Heart Association [18]. Plaques were 
defined as visible structures within or adjacent to the coronary artery lumen, which 
could be clearly distinguished from the vessel lumen and the surrounding pericardial 
tissue. The degree of CAD was visually estimated and classified as absent (no luminal 
stenosis), mild (1-50% luminal stenosis), moderate (50-70% luminal stenosis) or 
severe (>70% luminal stenosis) [19]. The extent of CAD was defined as the number of 
coronary segments with plaque, irrespective the degree of luminal stenosis. 
 
Radiation Dose 
The estimated effective radiation dose was calculated by multiplying the dose length 
product by a conversion factor of 0.014 mSv/(mGy x cm) for the chest region [20,21]. 
 
Follow-up and Outcome 
Electronic patient records were monitored for 90-days outcome, including occurrence 
of revascularization procedures (percutaneous coronary intervention [PCI] or 
coronary artery bypass grafting [CABG]), acute coronary syndrome (ACS) and 
mortality. ACS was defined as typical angina pectoris, troponin T elevation (>0.01 
μg/L), ST-segment elevation or depression of ≥ 1 mm, or two of these characteristics 
together with invasive angiographic confirmation of a culprit lesion [22].  
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Patients were seen by their cardiologist on a regular basis, and all hospital visits, 
including outpatient and emergency department visits, were recorded in the 
electronic patient system. 
 
Statistical Analysis 
Categorical baseline characteristics are expressed as absolute number and 
percentages, while continuous variables are expressed as means ± standard deviation 
(SD) or as median with interquartile range (IQR), for normal and non-parametric 
distributions, respectively. To test differences between men and women for statistical 
significance, we used the Pearson chi-square test for categorical variables and the 
Student t-test or Mann-Whitney test for continuous variables.  
Odds ratios (OR) with corresponding 95% confidence intervals (CI) were used to 
quantify the association between gender and degree as well as extent of CAD, where 
women were used as reference category (OR=1.00). Three models were used to 
describe these associations: 1) an unadjusted model, 2) an age-adjusted model, and 3) 
a model adjusting for the FRS variables (age, diabetes mellitus, smoking, systolic blood 
pressure, total cholesterol and HDL-cholesterol) as well as other traditional 
cardiovascular risk factors (body mass index, family history of premature CAD and 
LDL-cholesterol). For these analyses we used binary logistic regression models with 
presence of any plaque, presence of severe plaque, 1-3 segments with plaque, 4-6 
segments with plaque and >6 segments with plaque as dependent variables. 
P values less than 0.05 were considered significant. Statistical analyses were 
performed using IBM SPSS software (version 19.0, SPSS Inc., Chicago, IL, USA).  
 
RESULTS 
Study Population 
From 1,153 patients, 28 patients had a history of CAD, 59 patients had unavailable 
data regarding their risk profile and 24 patients had an inconclusive scan due to 
movement or breathing artefacts (Figure 1). Baseline characteristics of the remaining 
1,042 patients (527 men; 515 women) are listed in Table 1.  
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Women were older and more likely to have diabetes, a family history of premature 
CAD and a higher systolic blood pressure as compared with men. The mean FRS was 
significantly lower in women compared to men (14.9 vs. 22.8; P<0.001). 
 
Table 1. Baseline characteristics of the study population. 
 
Overall 
(n=1042) 
Men   
(n=527) 
Women 
(n=515) 
P value 
Age (years) 56 ± 11 55 ± 11 57 ± 11 <0.001 
Body Mass Index (kg/m2) 27.2 ± 6.8 27.4 ± 8.1 26.9 ± 5.0 0.25 
Diabetes mellitus 80 (7.7) 32 (6.1) 48 (9.3) 0.05 
Current smoking 223 (21.4) 122 (23.1) 101 (19.6) 0.16 
Family history  of premature CAD 375 (36.0) 183 (34.7) 192 (37.3) 0.46 
Systolic blood pressure (mmHg) 142 ± 20 141 ± 18 143 ± 22 0.03 
Total cholesterol (mg/dL)  217 ± 46 209 ± 46 220 ± 46 <0.001 
HDL-C (mg/dL) 54 ± 19 46 ± 16 58 ± 19 <0.001 
LDL-C (mg/dL) 135 ± 43 135 ± 43 135 ± 39 0.46 
Triglycerides (mg/dL) 159 ± 115 168 ± 115 151 ± 106 <0.01 
Glucose (mg/dL) 106 ± 23 106 ± 27 105 ± 22 0.65 
Framingham risk  score 18.9 ± 13.8 22.8 ± 15.1 14.9 ± 11.0 <0.001 
Coronary calcium score 3 (0-88) 11 (0-155) 0 (0-41) <0.001 
Values are presented as absolute number (percentage), or as mean ± standard deviation, except for 
calcium score, which is presented as median (interquartile range). CAD, coronary artery disease; HDL-C, 
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. 
 
Radiation Dose 
Estimated effective radiation dose for the CCS scan was 0.4 ± 0.2 mSv. Estimated 
effective radiation doses on top of the CCS scan were 1.2 ± 0.5 mSv for the “Flash” 
protocol (n=510), 3.4 ± 2.0 mSv for the “Adaptive sequence” protocol (n=465) and 
11.0 ± 6.2 mSv for the “Helical” protocol (n=67). 
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Coronary Calcium Score, Extent and Degree of Coronary Artery Disease 
Men had a significantly higher CCS as compared with women (P<0.001), Table 1. 
Coronary plaques, irrespective of the degree of luminal stenosis, were present in 346 
(65.7%) men and 265 (51.5%) women. Men significantly more often harbored 
plaques with 50-70% luminal stenosis (16.3% vs. 11.1%; P=0.01) and plaques with 
>70% luminal stenosis (13.5 % vs. 4.9%; P<0.001) as compared with women. 
Moreover, both three vessel disease (23.3% vs. 9.1%; P<0.001) as well as left main 
vessel disease (17.1% vs. 11.8%; P=0.02) were significantly more often present in 
men. Regarding extent of CAD, a larger proportion of men had plaques in at least four 
coronary segments as compared with women (31.0% vs. 12.8%; P<0.001), Table 2. 
 
Table 2. Extent and degree of coronary artery disease, according to gender. 
 Men (n=527) Women (n=515) P value 
Presence of any plaque 346 (65.7) 265 (51.5) <0.001 
Maximal diameter luminal stenosis    
     No plaque 181 (34.3) 250 (48.5) <0.001 
     1-49% 189 (35.9) 183 (35.5) 0.91 
     50-70% 86 (16.3) 57 (11.1) 0.01 
     >70% 71 (13.5) 25 (4.9) <0.001 
Number of vessels with plaque    
     None 181 (34.3) 250 (48.5) <0.001 
     1-vessel 121 (23.0) 130 (25.2) 0.39 
     2-vessel 102 (19.4) 88 (17.1) 0.34 
     3-vessel 123 (23.3) 47 (9.1) <0.001 
     Left main-vessel 90 (17.1) 61 (11.8) 0.02 
Number of segments with plaque    
     None 181 (34.3) 250 (48.5) <0.001 
     1-3 183 (34.7) 199 (38.6) 0.19 
     4-6 112 (21.3) 50 (9.7) <0.001 
     >6 51 (9.7) 16 (3.1) <0.001 
Values are presented as absolute number (percentage). 
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Adjustment for Traditional Cardiovascular Risk Factors 
Table 3 shows the results of the binary logistic regression models, used to describe 
gender differences regarding presence of any and severe plaques. In both the 
unadjusted and the age-adjusted model (models 1 and 2), men had approximately 2-3 
times greater odds of having any plaque as well as severe plaque, as compared with 
women. When adjusted for traditional cardiovascular risk factors (model 3), the odds 
ratios for men were 2.61 (95% CI 1.91-3.56) for the presence of any plaque and 2.89 
(95% CI 1.71-4.88) for the presence of severe plaque (both P<0.001). 
 
Table 3. Odds ratios of risk factors in relation to presence of any and severe plaque. 
 Presence of any plaque Presence of severe plaque 
 OR 95% CI P value OR 95% CI P value 
Model 1       
     Male gender 1.80 1.41-2.31 <0.001 3.05 1.90-4.90 <0.001 
Model 2       
     Male gender 2.74 2.05-3.66 <0.001 3.62 2.23-5.87 <0.001 
     Age 1.11 1.09-1.13 <0.001 1.06 1.03-1.08 <0.001 
Model 3       
     Male gender 2.61 1.91-3.56 <0.001 2.89 1.71-4.88 <0.001 
     Age 1.12 1.10-1.13 <0.001 1.08 1.05-1.10 <0.001 
     Body mass index 1.01 0.98-1.03 0.58 1.00 0.98-1.03 0.83 
     Diabetes mellitus 1.52 0.83-2.76 0.18 0.85 0.34-2.15 0.73 
     Current smoking 1.74 1.21-2.51 <0.01 1.71 1.01-2.90 0.05 
     Family history 1.43 1.06-1.93 0.02 1.44 0.90-2.31 0.13 
     Systolic BP 1.01 1.01-1.02 <0.01 1.00 0.99-1.01 0.97 
     Total cholesterol 0.99 0.73-1.34 0.94 0.79 0.47-1.34 0.39 
     HDL-C 0.75 0.53-1.04 0.09 0.44 0.21-0.91 0.03 
     LDL-C 1.04 0.75-1.44 0.83 1.44 0.81-2.54 0.21 
Female gender is used as reference category. Binary logistic regression analysis was performed using 
three models. Model 1 = unadjusted model; Model 2 = age-adjusted model; Model 3 = risk factor adjusted 
model. BP, blood pressure. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol. 
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Table 4 describes gender differences regarding extent of CAD in the same way. In all 
three models, men had 2.5-4 times greater odds of having 4-6 coronary segments as 
well as >6 coronary segments with a plaque, as compared to women (all P<0.001). 
Regarding the presence of 1-3 segments with plaque, odds ratios for men were in all 
models smaller than 1.00. 
 
Table 4. Odds ratios of risk factors in relation to extent of CAD. 
 1-3 segments with plaque 4-6 segments with plaque >6 segments with plaque 
 OR 95% CI P OR 95% CI P OR 95% CI P 
Model 1          
   Male gender 0.85 0.66-1.09 0.19 2.51 1.75-3.59 <0.001 3.34 1.88-5.94 <0.001 
Model 2          
   Male gender 0.91 0.71-1.18 0.48 3.53 2.39-5.20 <0.001 4.00 2.22-7.20 <0.001 
   Age 1.03 1.02-1.05 <0.001 1.10 1.08-1.12 <0.001 1.06 1.04-1.09 <0.001 
Model 3          
   Male gender 0.89 0.67-1.17 0.39 3.34 2.19-5.09 <0.001 4.01 2.15-7.49 <0.001 
   Age 1.03 1.02-1.05 <0.001 1.11 1.09-1.14 <0.001 1.05 1.02-1.09 <0.001 
   BMI 1.01 0.99-1.04 0.21 0.99 0.95-1.03 0.54 1.00 0.96-1.04 0.85 
   Diabetes 1.24 0.75-2.06 0.41 0.90 0.43-1.87 0.77 1.85 0.74-4.62 0.19 
   Smoking 1.08 0.77-1.50 0.67 1.57 0.97-2.52 0.06 2.15 1.14-4.05 0.02 
   Fam. history 1.21 0.92-1.59 0.17 1.93 1.30-2.85 <0.01 0.74 0.40-1.34 0.32 
    Systolic BP 1.00 1.00-1.01 0.60 1.01 1.00-1.02 0.20 1.01 1.00-1.03 0.04 
   Total-C 1.26 0.93-1.71 0.13 1.07 0.68-1.69 0.77 0.62 0.38-1.02 0.06 
   HDL-C 0.77 0.55-1.07 0.12 0.55 0.32-0.95 0.03 1.69 1.06-2.71 0.03 
   LDL-C 0.84 0.61-1.16 0.29 0.99 0.61-1.60 0.96 1.54 0.91-2.61 0.11 
Female gender is used as reference category. Binary logistic regression analysis was performed using three 
models. Model 1 = unadjusted model; Model 2 = age-adjusted model; Model 3 = risk factor adjusted model.  BMI, 
body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; Total-C, total cholesterol. 
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Framingham Risk Score Versus Degree and Extent of Coronary Artery Disease 
As shown in Figure 2, FRS is significantly higher in men as compared with women in 
all categories. Moreover, FRS in men shows a progressive increase as the degree of 
CAD becomes more severe (mean FRS 14.4% in absence of CAD, FRS 25.0% in mild 
CAD, FRS 29.3% in moderate CAD, and FRS 30.7% in severe CAD). An equal trend is 
visible in women for categories ‘no CAD’ (FRS 10.7%), ‘mild CAD’ (FRS 18.2%) and 
‘moderate CAD’ (FRS 21.1%). However, women with severe CAD have a lower mean 
FRS (FRS 18.4%), probably explained by the small sample size in this subgroup. Figure 
3 shows the relation between FRS and extent of CAD. As more segments show 
evidence of CAD, FRS increases in both men and women. Interestingly, patients with 
>6 affected coronary segments have, regardless of gender, a lower mean FRS as 
compared with patients with 4-6 affected segments, most likely due to the small 
number of patients with >6 affected segments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Framingham risk score in relation to degree of coronary artery disease, according to 
gender. CAD = coronary artery disease; * P<0.001; ** P=0.002.  
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Figure 3: Framingham risk score in relation to extent of coronary artery disease, according to 
gender. * P<0.001; ** P=0.001; *** P=0.104.  
 
Follow-up and Outcome 
During the 90-days follow-up period, which was available for all patients, a total of 28 
patients (2.7%) suffered an event. Coronary revascularization was performed in 24 
patients: 19 PCI’s (13 men, 6 women) and 5 CABG’s (all men). Additionally, 2 men 
suffered an ACS, 1 man died (cardiovascular cause), while 1 woman died (non-
cardiovascular cause). 
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DISCUSSION 
Gender Differences in Coronary Artery Disease 
Despite women in our study were having more traditional cardiovascular risk factors, 
they had a lesser extent and degree of CAD. This is consistent with previous CCTA 
studies, which observed that women were less likely to have obstructive CAD in 
symptomatic [23,24] and asymptomatic populations [25]. A possible explanation is 
that premenopausal women are relatively ‘protected’ from obstructive CAD due to 
favorable estrogen levels, while postmenopausal women are “catching up” in terms of 
developing CAD. On the other hand, several studies have shown that the prognosis of 
non-obstructive CAD in women is less benign than initially considered and even 
comparable with the more obstructive pattern of CAD in men [26,27]. Unfortunately, 
due to the short follow-up time we were not able to establish this theory in our cohort. 
 
Gender Differences in Clinical Risk Profiling 
In the past decades, several clinical risk profiling algorithms have been developed to 
estimate the long term cardiovascular risk in patients. These algorithms consist of 
traditional cardiovascular risk factors [13,28], more recently supplemented by 
biomarkers such as high-sensitivity C-reactive protein [29]. Risk factor analysis is an 
epidemiologic concept meant to be used in patient populations rather than in 
individuals. Nevertheless, it has proven to be a powerful tool in clinical practice. In 
addition to the fact that risk profiling is cost- and time-efficient, one of the major 
strengths is that several risk factors in one individual can be combined to calculate 
cardiovascular risk. When combined, risk factors increase the risk of cardiovascular 
events not in a linear but in an exponential way. Therefore, clinical risk profiling is 
preferable and recommended in clinical practice [30].  
 Although several studies have claimed to improve on the FRS algorithm, a recent 
review showed little evidence for any clinically relevant improvement beyond the FRS 
[31]. All risk factors used to calculate the FRS have a gender specific weighting factor. 
In the current study, women had a significant lower FRS compared to men, despite the 
fact that women had more individual risk factors, which is not an uncommon finding 
[32].  
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This implies that cardiovascular risk factors in women are not sufficiently translated 
into the FRS algorithm, resulting in much lower FRS. Our data showed that women, 
irrespective of the extent and degree of CAD, had significant lower FRS than men with 
corresponding extent and degree of CAD. This suggests that relative to men, the FRS 
underestimates extent and degree of CAD in women. This finding is supported by 
another study on the association between obstructive CAD and FRS. The authors 
found that a significant proportion of the patients categorized with a low (<10%) and 
intermediate (10–20%) FRS had obstructive CAD. Most women (93%) belonged to the 
low FRS category, which means that a significant proportion of them were having 
obstructive CAD [33]. However, underestimation of cardiovascular risk in women may 
not be a matter of inability of healthcare professionals to identify risk factors in 
women, but may be the result of underestimation of the weighting of risk factors in 
women by the FRS algorithm. This is supported by the multi-ethnic study of 
atherosclerosis. After excluding women with diabetes and those older than 79 years, 
90% of women were classified as low risk, based on FRS [34]. This may contribute to 
the relative underuse of diagnostic and therapeutic care in women, resulting in worse 
outcomes. In the recent 2011 AHA prevention guidelines for women, it had therefore 
been proposed to introduce an additional category of “ideal cardiovascular health” to 
the FRS [35]. 
 Our data also show that FRS in men increases as the degree of CAD becomes more 
severe. In our female patients however, this trend is only partially visible, which 
enhances the concept that there are gender differences in the pattern of CAD [36]. 
Based on the calculated FRS it is therefore almost impossible to predict the degree of 
CAD in women. In contrast, CCTA may provide incremental information beyond 
traditional cardiovascular risk factors, which may improve therapeutic decisions. This 
is strengthened by a study, in which the cardiac event rate was assessed after 
detection or exclusion of obstructive CAD by CCTA. This event rate was compared 
with the event rate as predicted by FRS. In patients without obstructive CAD, 
significantly fewer events occurred than predicted by FRS. Therefore, exclusion of 
obstructive CAD by CCTA identifies a patient population with an event risk lower than 
predicted by traditional risk factors [37].  
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Follow-up and Short-term Outcome 
In the current study, almost 90% (1,024/1,153) of the initial patients who underwent 
CCTA were eligible for follow-up. These patients provide the basis for our general 
conclusions. The patient exclusion rate due to technical limitations of the scanning 
procedure was very low (24/1,153; 2%). This emphasizes that modern CT technology 
in combination with adequate medical preparation ensures robust CCTA assessment. 
 The vast majority of cardiovascular events in this study were revascularizations, 
driven by CCTA results. ‘Hard’ events, including ACS and cardiac death, were recorded 
in three male patients. Possibly, CAD remains silent for a longer time in women. 
Therefore, it is not inconceivable that women are catching up in developing adverse 
events in the long-term.  
Study Limitations 
Our study has several limitations that merit comment. First, because our population 
underwent CCTA recently, we were only able to report short-term outcome. However, 
although FRS is an index of 10 year risk of an adverse cardiovascular event, we believe 
that this risk finds its main origin in today’s extent and degree of CAD. Therefore we 
felt justified to consider FRS in relation to the extent and degree of CAD. Second, 
although invasive coronary angiography is still the gold standard for assessment of 
CAD, CCTA is a well-established diagnostic imaging modality to evaluate extent and 
degree of CAD. Third, we had no available data regarding the menopausal state of our 
female patients and the use and duration of oral contraceptives or hormonal 
replacement therapy. 
 
CONCLUSION 
Men had a higher burden of CAD than women, as assessed with CCTA. Although 
individual women had more risk factors, FRS were significantly lower in women as 
compared with men, regardless extent and degree of CAD. This suggests that relative 
to men, the FRS underestimates the extent and degree of CAD in women.  
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BACKGROUND 
The aim of this study was to investigate whether mild to moderate chronic kidney 
disease (CKD) is independently associated with coronary plaque burden beyond 
traditional cardiovascular risk factors. 
METHODS 
A total of 2,038 patients with symptoms of chest discomfort suspected for coronary 
artery disease (CAD) underwent coronary CT-angiography. We assessed traditional 
risk factors, coronary calcium score and coronary plaque characteristics. Patients 
were subdivided in three groups, based on their estimated glomerular filtration rate 
(eGFR): Normal renal function (eGFR ≥90 mL/min/1.73 m2); mild CKD (eGFR 60-89 
mL/min/1.73 m2); and moderate CKD (eGFR 30-59 mL/min/1.73 m2).  
RESULTS 
Coronary calcium score increased significantly with decreasing renal function 
(P<0.001). Coronary plaque prevalence was higher in patients with mild CKD (OR 
1.83, 95%CI 1.52-2.21) and moderate CKD (OR 2.46, 95%CI 1.69-3.59), compared to 
patients with normal renal function (both P<0.001). Coronary plaques with >70% 
luminal stenosis were found significantly more often in patients with mild CKD (OR 
1.67 (95%CI 1.16-2.40) and moderate CKD (OR2.36, 95%CI 1.35-4.13), compared to 
patients with normal renal function (both P<0.01). After adjustment for traditional 
cardiovascular risk factors, the association between renal function and the presence of 
any coronary plaque as well as the association between renal function and the 
presence of coronary plaques with >70% luminal stenosis becomes weaker and were 
no longer statistically significant.  
CONCLUSION 
Although decreasing renal function is associated with increasing extent and severity 
of CAD, mild to moderately CKD is not independently associated with coronary plaque 
burden after adjustment for traditional cardiovascular risk factors. 
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INTRODUCTION 
Coronary artery disease (CAD) remains one of the leading causes of morbidity and 
mortality in developed countries. In 2007, a total of 406,351 people died due to CAD in 
the United States. Each year, an estimated 785,000 Americans will suffer a new 
coronary attack, and 470,000 will have a recurrent attack. It is estimated that an 
additional 195,000 silent first myocardial infarctions occur each year [1]. Chronic 
kidney disease (CKD) is also recognized as a major worldwide public health problem, 
as evidenced by an increasing incidence and prevalence of patients with kidney failure 
requiring renal replacement therapy, with poor outcomes and high costs [2]. Nearly 
26 million people (13%) in the United States have CKD, and most are undiagnosed, 
while another 20 million Americans are at increased risk for CKD [3,4]. 
Several studies have found an increased prevalence of CAD, congestive heart 
failure and left ventricular hypertrophy in patients with end-stage CKD [5,6]. More 
recently, earlier stages of CKD have also been associated with a worse prognosis in 
patients with as well as without known CAD [7,8]. In order to further elucidate the 
interplay between renal function and symptomatic CAD, more detailed knowledge 
about coronary artery disease burden is desired in patients with different degrees of 
renal impairment.  
 Coronary computed tomographic angiography (CCTA) is a noninvasive diagnostic 
imaging tool, which provides precise information regarding the presence and extent of 
coronary calcium deposits as well as coronary plaque localization, degree of luminal 
stenosis and plaque morphology. Several studies already found an inverse association 
between renal function and coronary artery calcification, but it remains unclear if this 
association is independent from traditional cardiovascular risk factors [9-14]. 
 Therefore, the aim of this retrospective cross-sectional study was to investigate 
whether mild to moderate chronic kidney disease is independently associated with 
coronary plaque burden beyond traditional cardiovascular risk factors. 
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METHODS 
Ethics Statement 
This study was approved by the Institutional Review Board (IRB) and Ethics 
Committee at the Maastricht University. Involved data were collected on a routine 
basis within the Maastricht Biomarker CT study. Analyses were carried out 
retrospectively. Informed consent was not obtained from individual patients because 
the data were analyzed anonymously in accordance with IRB guidelines. The study 
complies with the ethical principles of the Helsinki Declaration of 1964, revised by the 
World Medical Organization in Edinburgh in 2000. 
 
Study Population 
We studied 2,180 consecutive adult patients who were referred from the cardiology 
outpatient department for CCTA because of chest discomfort symptoms, suspected for 
CAD. All scans were performed in the Maastricht University Medical Center between 
2008 and 2012 as part of the diagnostic work-up. Included were patients with a 
recently (not older than 1 month) measured creatinine, who underwent coronary 
calcium scoring (CCS) scan as well as CCTA. Excluded were patients with a known 
history of CAD, patients with missing data regarding their cardiac risk profile, patients 
with an inconclusive scan and patients with severely impaired renal function, defined 
as an estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m2 (Figure 1).  
 
Traditional Cardiovascular Risk Factors 
Traditional cardiovascular risk factors were collected prior to the scan. Patients were 
classified as smoker if they were current smoker. A positive family history was 
defined as having a first-degree relative with a history of myocardial infarction or 
sudden cardiac death before the age of sixty. Patients were classified as diabetic if 
diabetes mellitus was diagnosed by a medical doctor according to the guidelines [15]. 
The body mass index (BMI) is defined as the individual’s body mass (kg) divided by 
the square of the height (m2). 
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Figure 1. Flowchart of the study design. 
 
Chronic Kidney Disease Categories 
For all patients, the eGFR was calculated using the CKD-EPI Equation: eGFR = 141 x 
min(Scr/κ,1)α x max(Scr/κ,1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black], 
where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max 
indicates the maximum of Scr/κ or 1 [16]. The eGFR is expressed as mL/min/1.73 m2. 
Patients were divided into three categories: normal renal function (eGFR ≥90 
mL/min/1.73 m2), mildly impaired renal function (eGFR 60-89 mL/min/1.73 m2) and 
moderately impaired renal function (eGFR 30-59 mL/min/1.73 m2) based on the 
National Kidney Foundation Kidney Disease Outcomes Quality Initiative practice 
guidelines for classification [17]. 
 
Coronary CT-angiography Protocol 
Scans were performed using a 64–slice multidetector-row CT-scanner (Brilliance 64; 
Philips Healthcare, Best, The Netherlands, n=1,026) or a dual-source CT-scanner 
(Somatom Definition Flash, Siemens Medical Solutions, Forchheim, Germany, 
n=1,012).  
n=29 excluded because of known previous coronary artery disease 
n=56 excluded because of unavailable cardiovascular risk profile 
n=55 excluded because of inconclusive coronary CT-angiography 
2,180 patients with chest discomfort symptoms, suspected for 
coronary artery disease, were referred for coronary CT-angiography 
Study population included in analysis: n=2,038 
n=2 excluded because of severely impaired renal function 
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Data acquisition parameters for the Brilliance 64 were a 64 x 0.625 mm slice 
collimation, a gantry rotation time of 420ms and a tube voltage of 80-120 kV, 
depending on the patient’s height and weight. Data acquisition parameters for the 
Somatom Definition Flash were a 2 x 128 x 0.600 mm slice collimation, a gantry 
rotation time of 280 ms and a tube voltage of 80-120 kV. Patient preparation was 
identical for both CT-scanners. Patients received 50 mg Metoprolol tartrate 
(AstraZeneca, Zoetermeer, The Netherlands) orally, two hours before CCTA. When 
indicated, an additional dose of 5-20 mg Metoprolol tartrate was administered 
intravenously to lower the heart rate to <60 beats per minute (bpm). 0.8 mg 
Nitroglycerin spray (Pohl-Boskamp, Hohenlockstedt, Germany) was given 
sublingually just prior to CCTA. Heart rate and ECG were monitored during CCTA.  
A non-enhanced scan was performed to determine the CCS using the Agatston 
method [18]. Subsequently, CCTA was performed using 75–120 mL of contrast agent 
(Xenetix 350; Guerbet, Roissy CdG Cedex, France or Ultravist 300; Bayer Pharma AG, 
Berlin, Germany), which was injected in the antecubital vein at a rate of 5.2–7.4 mL/s, 
directly followed by 40 mL intravenous saline (6.0 mL/s) using a dual-head power 
injector (Medrad Inc, Indianola, Pennsylvania, USA). Both the amount of contrast 
agent as well as the flow rate were dependent on individual patient characteristics.  
Scan protocols were different for both CT-scanners.  For the Brilliance 64, a 
prospectively gated “Step and shoot” protocol was used in all patients with a stable 
heart rate <65 bpm. In patients with a heart rate >65 bpm, we used a retrospectively 
gated “Helical” protocol with dose modulation to obtain the best image quality at 
minimal radiation dose [19,20]. For the Somatom Definition Flash, a prospectively 
gated high pitch spiral “Flash” protocol was used in patients with a stable heart rate 
<60 bpm. In patients with a stable heart rate between 60–90 bpm, we used a 
prospectively gated axial “Adaptive sequence” protocol. In patients with a heart rate 
>90 bpm or in case of an irregular heart rhythm, we used a retrospectively gated 
“Helical” protocol with dose modulation. 
 
Coronary CT-angiography Analysis 
Dedicated workstations (Philips Brilliance Workspace Portal and Siemens Syngo 
MultiModality Workplace) were used to assess the source images.  
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Scans were independently analyzed by a cardiologist and a radiologist, both 
experienced in the assessment of coronary CT-angiography and both blinded for 
patient details. In case of disagreement, consensus was reached by reviewing findings 
jointly.  
CCS was expressed as the Agatston score using dedicated calcium scoring software 
with a threshold of 130 Hounsfield units (HU). The coronary artery tree was analyzed 
for the presence and severity of CAD, according to the classification of the American 
Heart Association [21]. Coronary plaques were defined as visible structures within or 
adjacent to the coronary artery lumen, which could be clearly distinguished from the 
vessel lumen and the surrounding pericardial tissue. Plaques were categorized as 
calcified (exclusively content >130 HU), non-calcified (exclusively content <130 HU) 
or mixed (characteristics of both calcified and non-calcified plaques). The degree of 
CAD was visually estimated and classified as absent (no luminal stenosis), mild (<50% 
luminal stenosis), moderate (50-70% luminal stenosis) or severe (>70% luminal 
stenosis) [22]. 
 
Statistical Analysis  
Categorical baseline characteristics are expressed as percentages, while continuous 
variables are expressed as means (standard deviation; SD) or as median (interquartile 
range; IQR). To test differences between the CKD groups for statistical significance, we 
used analysis of variance (ANOVA). 
Odds ratios (OR) with corresponding 95% confidence intervals (CI) were used to 
quantify the association between renal function and characteristics of coronary 
plaques, where patients with normal renal function (eGFR ≥90 mL/min/1.73 m2) 
were used as reference category (OR=1.00). To adjust for traditional risk factors, 
multivariable logistic regression analysis was performed with presence of any plaque 
and presence of severe plaque as dependent variables. Included in the models were 
traditional cardiovascular risk factors as well as eGFR as categorical variable, where 
patients with normal renal function were used as reference category. 
The smallest detectable OR (alpha = 5%, power = 80%) for the detection of any 
coronary plaque was 1.3 for patients with mild CKD and 1.6 for patients with 
moderate CKD (proportion exposed among controls = 50%).  
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For the detection of severe coronary plaque, the smallest detectable OR (alpha = 5%, 
power = 80%) was 1.6 for patients with mild CKD and 2.1 for patients with moderate 
CKD, respectively (proportion exposed among controls = 6%). A P-value <0.05 was 
considered significant. Statistical analyses were performed using SPSS software 
(version 19.0, SPSS Inc., Chicago, IL, USA).  
 
RESULTS 
Study Population 
Patients with chest discomfort symptoms, suspected for CAD were studied. From 
2,180 patients, 29 patients had a history of CAD, 56 patients had missing data 
concerning their risk profile, 55 patients had an inconclusive CCTA due to poor image 
quality because of movement and/or breathing artifacts and 2 patients suffered from 
severely impaired renal function (Figure 1). Baseline characteristics of the remaining 
2,038 patients are listed in Table 1.  
 A total of 1,778 patients underwent a prospectively gated scan protocol (mean 
radiation dose 3.2 mSv), whereas 260 patients underwent a retrospectively gated scan 
protocol (mean radiation dose 11.1 mSv).  
Among the 2,038 patients, 745/2,038 (36.6%) had normal renal function, 
1,138/2,038 (55.8%) had mildly impaired renal function, and 155/2,038 (7.6%) had 
moderately impaired renal function. Compared to patients with normal renal function, 
patients with mild or moderately impaired renal function were older, had a higher 
mean body mass index and a higher mean systolic blood pressure. On the other hand, 
they were less likely to have a positive family history and they were less often male 
and smoker, Table 1. 
 
Coronary Calcium Score and Coronary CT-angiography 
The mean CCS increased significantly with decreasing renal function. The mean CCS 
was 94 in patients with normal renal function, 103in patients with mildly impaired 
renal function and 148 in patients with moderately impaired renal function (all 
P<0.01), (Figure 2). 
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Table 1.  Baseline characteristics of the study population, stratified by eGFR. 
 eGFR (mL/min/1.73m2) 
 All ≥90 60-89 30-59  
Baseline characteristics (n=2,038) (n=745) (n=1,138) (n=155) P value 
Age (years) 56 ± 11 50 ± 10 59 ± 9 66 ± 9 <0.001 
Body Mass Index (kg/m2) 26.8 ± 4.5 26.5 ± 4.7 26.8 ± 4.2 27.7 ± 4.8 0.01 
Male gender 51.5 56.1 51.0 32.9 <0.001 
Diabetes mellitus 7.5 7.5 6.6 13.5 <0.01 
Smoking 22.3 28.6 19.1 15.5 <0.001 
Positive family history 37.0 41.1 36.1 23.9 <0.001 
Systolic BP (mmHg) 142 ± 19 138 ± 18 143 ± 19 149 ± 21 <0.001 
Total cholesterol (mg/dL)  213 ± 46 209 ± 43 213 ± 43 201 ± 50 <0.01 
HDL-C (mg/dL) 50 ± 19 50 ± 19 50 ± 19 50 ± 19 0.71 
LDL-C (mg/dL) 131 ± 39 131 ± 39 135 ± 39 124 ± 46 <0.01 
Triglycerides (mg/dL)* 159 ± 106 159 ± 106 159 ± 106 151 ± 80 0.92 
Glucose (mg/dL)** 105 ± 34 106 ± 27 105 ± 27 108 ± 36 0.50 
Coronary calcium score 4 (0-95) 0 (0-40) 10 (0-115) 38 (0-220) <0.001 
Presence of any plaque 59.6 49.8 64.5 71.0 <0.001 
Presence of severe plaque 8.4 5.9 9.5 12.9 <0.01 
Values are presented as percentage, or as mean ± standard deviation, except for calcium score, which is 
presented as median (interquartile range). BP, blood pressure; eGFR, estimated glomerular filtration rate; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. * Measured in n= 
1,786. ** Measured in n= 1,568. 
 
Coronary plaques were found in 1,215 of 2,038 patients (59.6%). Patients with mildly 
(OR 1.83, 95%CI 1.52-2.21) or moderately (OR 2.46, 95%CI 1.69-3.59) impaired renal 
function significantly more often harbored coronary plaques compared to patients 
with normal renal function (both P<0.001). This observation extended to the presence 
of severe coronary plaques (luminal stenosis >70%), which were also found 
significantly more often in patients with mildly  (OR 1.67, 95%CI 1.16-2.40) or 
moderately  (OR 2.36, 95% CI 1.35-4.13) impaired renal function compared to 
patients with normal renal function (both P<0.01), Table 2.  
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Figure 2. Mean coronary calcium score in the different CKD-categories. The graph shows that the 
mean calcium score increased significantly with decreasing renal function. 
 
 
Table 2. Presence of any and severe coronary plaque in patients, stratified by eGFR. 
 (n=2,038) eGFR ≥90 eGFR 60-89 eGFR 30-59 
Any plaque 
OR (95% CI) 1.00 (reference) 1.83 (1.52-2.21) 2.46 (1.69-3.59) 
P value --- <0.001 <0.001 
Severe plaque 
OR (95% CI) 1.00 (reference) 1.67 (1.16-2.40) 2.36 (1.35-4.13) 
P value --- <0.01 <0.01 
Odds ratios for the presence of any and severe coronary plaques, stratified by eGFR. Patients with normal 
renal function (eGFR ≥90 mL/min/1.73m2) were used as reference category (OR=1.00). 
 
As expected, patients with mild (OR 1.70, 95%CI 1.28-2.26, P<0.001) or moderately 
(OR 1.68, 95%CI 1.01-2.79, P=0.05) impaired renal function had significantly higher 
proportions of calcified plaques, while there were no significant differences regarding 
the presence of mixed and non-calcified plaques, Table 3.  
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Table 3. Plaque morphology in patients, stratified by eGFR. 
 (n=1,215) eGFR ≥90 eGFR 60-89 eGFR 30-59 
Calcified plaque 
OR (95% CI) 1.00 (reference) 1.70 (1.28-2.26) 1.68 (1.01-2.79) 
P value --- <0.001 0.05 
Mixed plaque 
OR (95% CI) 1.00 (reference) 1.00 (0.78-1.28) 1.02 (0.66-1.56) 
P value --- 0.98 0.94 
Non-calcified plaque 
OR (95% CI) 1.00 (reference) 0.91 (0.70-1.19) 0.90 (0.57-1.43) 
P value --- 0.48 0.66 
Odds ratios for plaque morphology, stratified by eGFR. Patients with normal renal function (eGFR ≥90 
mL/min/1.73m2) were used as reference category (OR=1.00). 
 
Correction for Traditional Cardiovascular Risk Factors  
The results of multivariable logistic regression analysis are presented in Table 4. Age, 
male gender, smoking, diabetes mellitus, systolic blood pressure and positive family 
history are independent risk factors for the presence of any coronary plaque. Age, 
male gender and smoking remain the only independent risk factors for the presence of 
severe coronary plaques. 
 After adjustment for traditional cardiovascular risk factors, the association 
between impaired renal function (expressed by eGFR as categorical variable where 
patients with normal renal function were used as reference category) and the 
presence of any coronary plaque as well as the association between impaired renal 
function and the presence of severe coronary plaque becomes weaker and were no 
longer statistically significant.  
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Table 4. Multivariable logistic regression of risk factors for the presence of any and severe 
coronary plaque. 
 Presence of any plaque Presence of severe plaque 
Characteristic OR 95% CI P value OR 95% CI P value 
Age 1.11 1.09-1.12 <0.001 1.06 1.04-1.08 <0.001 
Gender (male = 1) 2.85 2.30-3.52 <0.001 3.18 2.22-4.57 <0.001 
Smoking (yes = 1) 1.94 1.51-2.50 <0.001 1.84 1.27-2.66 0.001 
Diabetes mellitus (yes = 1) 1.81 1.18-2.78 <0.01 0.64 0.32-1.29 0.21 
Systolic blood pressure 1.01 1.01-1.02 <0.001 1.00 0.99-1.01 0.48 
Fam. history (positive = 1) 1.37 1.11-1.69 <0.01 1.38 0.98-1.94 0.07 
Total cholesterol 0.98 0.89-1.07 0.58 1.00 0.87-1.15 1.00 
Normal renal function 1.00 (reference) --- 1.00 (reference) --- 
Mild CKD 0.92 0.73-1.15 0.45 1.21 0.81-1.80 0.36 
Moderate CKD 0.75 0.48-1.18 0.21 1.52 0.80-2.90 0.21 
Multivariable logistic regression analysis was performed with known traditional cardiovascular risk 
factors as well as the CKD categories. Patients with normal renal function (eGFR ≥90 mL/min/1.73m2) 
were used as reference category (OR=1.00). CKD, chronic kidney disease. 
 
DISCUSSION 
Our results demonstrate that patients with mild or moderately impaired renal 
function have a higher coronary plaque burden including a higher prevalence of 
severe coronary plaques compared to patients with normal renal function. Moreover, 
coronary plaques in patients with impaired renal function exhibit an increased degree 
of calcification. However, after adjustment for traditional cardiovascular risk factors, 
mild to moderately impaired renal function is not an independent risk factor for the 
presence of any coronary plaque nor for the presence of severe plaques. This means 
that variations in coronary plaque burden in this study can be explained by variations 
in traditional cardiovascular risk factors. 
Our study was motivated by the paucity of data regarding the association between 
mild to moderately impaired renal function and CAD. Several studies investigated the 
association between CKD and coronary artery calcification [13-18].  
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Although all studies found that impaired renal function was associated with an 
increasing coronary calcium score, it still remains unclear whether this association is 
independent from traditional cardiovascular risk factors. Some of these studies found 
an independent association [13-15], while other studies did not [16-18]. CCS is a 
marker for atherosclerotic plaque burden and has been shown to be a predictor for 
the occurrence of myocardial infarction and cardiovascular death [23]. On the other 
hand, in case of a CCS of zero, it is still possible to have a so called ‘vulnerable’ plaque, 
which may rupture and cause an acute coronary event [24]. By means of contrast 
enhanced CT-angiography, it is possible to visualize these non-calcified plaques. 
Therefore, we were also able to focus on plaque morphology and degree of luminal 
stenosis, instead of only using CCS as determinant of CAD. However, in our study, non-
calcified plaques were not found more often in patients with an impaired renal 
function compared to patients with a normal renal function.  
At present, a limited number of reports have been published regarding the 
relationship between impaired renal function and coronary plaque morphology. Cho 
et al. studied 4,297 asymptomatic subjects undergoing CCTA as part of a general 
health evaluation. They found that subjects with early CKD (eGFR ≥45 mL/min/1.73 
m2) had significantly higher prevalence of (obstructive) CAD and CCS >100 compared 
to subjects without CKD. However, after adjustment for proteinuria and other 
traditional risk factors, there was no significant association between a decrease in 
eGFR and the risk of (obstructive) CAD or CCS >100 [25]. Although these findings are 
in line with our results, the main difference is that our population consists of 
symptomatic patients with suspected CAD, whereas Cho et al. studied asymptomatic 
subjects. Also other studies did not found an independent correlation between CKD 
and coronary plaque burden [26] or did not adjust for traditional cardiovascular risk 
factors [27]. 
The search for novel markers that better predict cardiovascular events in patients 
with impaired renal function is of considerable clinical interest as it may lead to 
improved strategies to prevent major adverse cardiovascular events (MACE). 
Recently, Clase et al. examined the contribution of eGFR and urinary albumin-
creatinine ratio beyond traditional cardiovascular risk factors in a large cohort of 
patients with high cardiovascular risk. They conclude that eGFR as well as the urinary 
albumin-creatinine ratio add only little to traditional cardiovascular risk factors. 
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However, in contrast to our study, their study outcomes were all-cause mortality and 
long-term dialysis [28]. It would be of interest to investigate the possible additional 
contribution of renal impairment over traditional cardiovascular risk factors in the 
prediction of MACE instead of all-cause mortality and long-term dialysis. Because of 
the relatively short follow-up time, we did not yet focus on the cardiovascular event 
rate in our population. 
Question remains what precise mechanism can explain the relationship between 
CKD and MACE. It is well known that traditional risk factors, such as age, 
hyperlipidemia, smoking and hypertension are associated with the development of 
both CAD and CKD. However, non-traditional risk factors like albuminuria, 
proteinuria, homocysteinemia and elevated levels of uric acid are also established 
factors for the progression of renal disease. Other factors which are suggested in the 
literature to contribute to this mechanism are anemia, oxidative stress, derangements 
in calcium-phosphate homeostasis, inflammation and conditions promoting 
coagulation, which are all associated with accelerated atherosclerosis and endothelial 
dysfunction [29-34]. 
This study is among the first coronary CT-angiography studies in which various 
degrees of CKD were compared with coronary plaque characteristics in patients with 
symptoms of chest discomfort, suspected for CAD. In order to calculate the eGFR, we 
used the CKD-EPI equation instead of other equations like the Cockcroft-Gault 
equation or the Modification of Diet in Renal Disease (MDRD) equation since the CKD-
EPI equation intends to be more generalizable across various clinical settings [16]. 
 
Study Limitations 
Our study has several limitations that merit comment. First, the eGFR was based on a 
single creatinine measurement. We did not take information into account regarding 
the course of renal function over time. This may have influenced the results since the 
serum creatinine concentration depends on various. However, we only used 
creatinine values less than 1 month old. Second, we did not have information 
regarding proteinuria and albuminuria because we did not collect urine samples. 
Third, although CCTA is a well-established imaging technique for detection of 
coronary plaques, the functional relevance of the plaques remains unsubstantiated. 
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Fourth, this study was performed in outpatient department patients presenting with 
symptoms of chest discomfort.  Results in the general population might have been 
different. Finally, we were not able yet to investigate patient outcomes because of the 
relatively short follow-up time.  
 
CONCLUSION 
Although decreasing renal function is associated with increased extent and severity of 
coronary artery disease in patients with symptoms of chest discomfort, mild to 
moderate CKD is not independently associated with coronary plaque burden after 
adjustment for traditional cardiovascular risk factors. 
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BACKGROUND 
Recent studies demonstrated the association between increased concentrations of 
high-sensitivity cardiac troponin T (hs-cTnT) and the incidence of myocardial 
infarction, heart failure, and mortality in elderly and the general population. The value 
of hs-cTnT in symptomatic outclinic patients remains unclear. Aim of this study was to 
investigate the prognostic value of hs-cTnT as a biomarker in patients with symptoms 
of chest discomfort suspected for coronary artery disease and to assess its additional 
value in combination with other risk stratification tools in predicting cardiac events. 
METHODS 
We studied 1,088 patients (follow-up 2.2  0.8 years) with chest discomfort who 
underwent coronary calcium scoring and coronary CT-angiography. Traditional 
cardiovascular risk factors and concentrations of hs-cTnT, N-terminal pro-brain-type 
natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) were 
assessed. Study endpoint was the occurrence of late coronary revascularization (>90 
days), acute coronary syndrome, and cardiac mortality.  
RESULTS 
Hs-cTnT was a significant predictor for the composite endpoint (highest quartile 
[Q4]>6.7 ng/L, HR 3.55; 95%CI 1.88-6.70; P<0.001). Survival analysis showed that hs-
cTnT had significant predictive value on top of risk stratification tools (Chi-square 
change P<0.01). In patients with hs-cTnT in Q4 versus <Q4, a 2- to 3-fold increase in 
cardiovascular risk was noticed, either when corrected for high or low Framingham 
risk score, coronary calcium scoring, or CT-angiography assessment (HR 3.11; 2.73; 
2.47; respectively; all P<0.01). This was not the case for hsCRP and NT-proBNP. 
CONCLUSION 
Hs-cTnT is a useful prognostic biomarker in patients with suspected CAD and an 
independent predictor for cardiac events when corrected for cardiovascular risk 
profiling, calcium score and CT-angiography results. 
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INTRODUCTION 
Identification of patients at risk for acute cardiovascular events remains a challenge. 
One promising avenue to improve the identification of these patients is the use of 
serum biomarkers, which could provide a relatively easy and cost-effective step in risk 
stratification. Several biomarkers have been evaluated with respect to their 
incremental diagnostic and prognostic value [1,2]. Elevated concentrations of high-
sensitivity C-reactive protein (hsCRP), an inflammatory biomarker, are associated 
with future cardiovascular events, which supports the hypothesis that 
atherothrombosis is partly an inflammatory disease [3]. Elevated concentrations of N-
terminal pro-B-type natriuretic peptide (NT-proBNP), the inactive fragment from BNP 
which is secreted by the cardiomyocytes in response to ventricular wall stretch, have 
also been associated with an increased risk of death and cardiovascular events [4]. 
However, none of these biomarkers have achieved widespread acceptance in daily 
practise as a risk stratification tool for the detection of coronary artery disease (CAD). 
 With the development of more accurate high-sensitivity cardiac troponin (hs-cTn) 
assays, new possibilities become available to improve risk stratification [5-7]. 
Recently, we demonstrated the association between hs-cTnT and CAD, as determined 
by coronary computed tomographic angiography (CCTA), in patients with stable chest 
pain [8]. We found that even mild CAD is associated with quantifiable circulating 
levels of hs-cTnT, which was confirmed by others [9]. This could be the result of 
episodes of cardiac ischemia due to a mismatch between metabolic demand and 
supply. An alternative mechanism could be that cardiac troponin T release is the 
result of dislodgement of small localized thrombi, causing micro-injury in small 
coronary vessels. Recently, a number of studies were published, which focused on the 
prognostic value of hs-cTnT. Most of these studies were performed in the elderly or 
the general population [10-13]. Less is known about the possible incremental value of 
hs-cTnT on top of existing risk stratification tools in patients visiting the cardiology 
outpatient department because of symptoms of chest discomfort suspected for CAD. 
 In the present study, we investigated the prognostic value of hs-cTnT in 
symptomatic patients with suspected CAD, and assessed its additional value in 
combination with other risk stratification tools in predicting cardiac events. As a 
comparison, we also studied  hsCRP and NT-proBNP. 
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METHODS 
Ethics Statement 
This study complies with the Declaration of Helsinki and all patients gave written 
informed consent. The study was approved by the Institutional Review Board and 
Ethics Committee at the Maastricht University. 
 
Study Population 
We studied 1,114 patients with symptoms of chest discomfort  who were referred 
from the cardiology outpatient department for CCTA because of suspected CAD, 
according to the appropriateness criteria for cardiac computed tomography [14]. All 
scans were performed in our university medical center between 2007 and 2009. Part 
of this population was studied previously [8].  Included were patients with a 
recent history of chest discomfort symptoms in the presence of additional 
cardiovascular risk factors and/or inconclusive diagnostic test results, resulting in a 
population with an intermediate pretest probability of CAD. Excluded were eight 
patients with missing data regarding their cardiovascular risk profile and eighteen 
patients with a history of proven CAD, acute myocardial infarction (AMI), 
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). 
The remaining 1,088 patients were subject of this study (Figure 1). Patients who were 
referred from the emergency department for CCTA because of acute chest pain, 
suspect for an acute coronary syndrome (ACS), were not included in this study. In 
general, patients with an allergy to iodinated contrast agent, pregnant patients and 
patients with an impaired renal function (defined as an estimated glomerular 
filtration rate <45 mL/min/1.73m2) were ineligible for CCTA.  
 
Cardiovascular Risk Factors 
Cardiovascular risk factors were prospectively gathered in order to calculate the 
Framingham risk score (FRS). The FRS is used to estimate the 10-year risk of suffering 
a myocardial infarction or cardiovascular death, based on age, gender, diabetes 
mellitus, smoking, systolic blood pressure, total cholesterol, and high-density 
lipoprotein (HDL) [15].  
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Patients were classified as smokers if they had smoked in the 12 weeks before CCTA. 
A positive family history was defined as having a first-degree relative with a history of 
myocardial infarction or sudden cardiac death before the age of sixty. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart of the study design. * Early revascularizations within 90 days after CCTA were 
censored at the time of PCI or CABG. 
 
Echocardiography Acquisition 
Echocardiography (Sonos 5500, Hewlett Packard, Palo Alto, CA, USA) was performed 
in 612 patients, using Xcelera software (Philips Healthcare, Best, the Netherlands). 
The left ventricular ejection fraction (LVEF) was assessed using 2D echo images. To 
assess the presence of left ventricular hypertrophy (LVH), we used three parameters: 
interventricular septum end-diastolic wall thickness (IVSEDWT), posterior wall end-
diastolic wall thickness (PWEDWT) and left ventricular mass (LVMASS). Measurement 
of the IVSEDWT and PWEDWT were performed in the parasternal long axis. 
 
Coronary CT-angiography Acquisition 
CT-scans were performed in all patients using a 64-slice multidetector-row CT-
scanner (Brilliance 64, Philips Healthcare) with a 64 x 0.625-mm slice collimation, a 
gantry rotation time of 420 ms and a tube voltage of 80-120 kV.  
CCS and CCTA assessment, blood samples and questionnaire 
n=26 excluded because of history of cardiovascular event 
n=1,114 with (a)typical chest pain at cardiology outpatient department 
n=1,046 without 
an event 
n=1 cardiac 
mortality 
n=26 PCI or CABG >90 
days after CCTA 
n=15 ACS 
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Patients received 50 mg metoprolol tartrate orally, two hours before CCTA, to lower 
the heart rate (HR). When the HR was >65 beats per minute (bpm), 5-20 mg 
metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands) was administered 
intravenously. All patients received 0.8 mg nitroglycerin spray (Pohl-Boskamp, 
Hohenlockstedt, Germany). HR and ECG were continuously monitored.  
 A non-enhanced scan was performed to determine the CCS using the Agatston 
method [16]. Subsequently, CCTA was performed using 85-110 mL contrast agent 
(Xenetix 350, Guerbet, Roissy CdG Cedex, France), which was injected in the 
antecubital vein with a flow rate of 6.0 mL/s, directly followed by 40 mL saline (6.0 
mL/s) using a dual-head power injector. In patients with a stable HR <65 bpm, a 
prospective ECG-gated ‘step and shoot’ protocol was used (radiation dose 3.5 ± 1.2 
mSv). In patients with a HR >65 bpm, a retrospective ECG-gated ‘helical’ protocol with 
dose modulation was used (radiation dose 11.8 ± 3.6 mSv).  
 
Coronary Plaque Assessment 
All scans were independently analyzed by two cardiologists, both with level III 
expertise in coronary CT-angiography and blinded for patient details, using source 
images in Cardiac Comprehensive Analysis software (Philips Healthcare). In case of 
disagreement, consensus was reached by reviewing findings jointly.  
 CCS was expressed as Agatston score using calcium scoring software (Philips 
Healthcare) with a threshold of 130 Hounsfield units. The coronary tree was analyzed 
for the presence and severity of CAD, according to the 16-segment classification of the 
American Heart Association [17]. The extent of CAD was classified as absent, mild 
(<50% luminal stenosis), moderate (50-70% luminal stenosis) or severe (≥70% 
luminal stenosis), according to the guidelines of the Society of Cardiovascular 
Computed Tomography [18]. 
 
Biomarker Measurement 
Samples were collected just before the scan, processed within two hours, and stored 
at -80°C until analysis. Total cholesterol, HDL and triglycerides concentrations were 
measured using the Synchron LX20 (Beckman Coulter Inc., Brea, CA, USA).  
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Low-density lipoprotein (LDL) was calculated using the Friedewald equation [19] 
except for subjects with triglycerides >400 mg/dL and total cholesterol <50 mg/dL, in 
which case LDL was determined on the Cobas Mira Plus (Roche Diagnostics, Basel, 
Switzerland). HsCRP was measured on the BN ProSpec using the CardioPhase hsCRP 
assay (Siemens Diagnostics, Deerfield, IL, USA). Hs-cTnT (high sensitivity fifth 
generation cTnT assay) and NT-proBNP were measured on the Elecsys 2010 (Roche 
Diagnostics).  
 
Study Endpoint and Follow-up 
The composite study endpoint was the occurrence of revascularization (PCI/CABG) 
>90 days after CCTA, cardiac mortality and ACS, including myocardial infarction and 
unstable angina requiring hospitalization. ACS was defined as typical angina pectoris, 
troponin T elevation (>0.01 μg/L) and ST-segment elevation/depression of ≥1 mm, or 
at least two of these characteristics together with invasive angiographic confirmation 
of a culprit lesion [20]. So, this means that patients with only troponin T elevation did 
not meet the criteria for an ACS. We censored follow-up when revascularization was 
performed within 90 days and after occurrence of the study endpoint. Patients were 
seen by their cardiologist on a regular basis, and all hospital visits, both outpatient 
department visits as well as emergency room visits, were recorded in the electronic 
patient records. Additionally, the national mortality records were checked. None of 
the attending clinicians had access to the results of the hs-cTnT, hsCRP and NT-
proBNP measurements. 
 
Statistical Analysis 
To test for differences in baseline patient characteristics, we used the Pearson 2 test 
for discrete variables and the t-test for continuous variables. Logistic regression and 
survival analysis were used to study prediction of the composite endpoint of late 
revascularization procedures, ACS, and cardiac mortality. Confounding was 
considered for baseline characteristics that differed significantly between the event 
group and non-event group. For Kaplan-Meier analysis, categories of independent 
variables were compared using the log-rank test. Cox proportional hazard regression 
was validated for proportionality using log-minus-log and for time dependency.  
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It was used to evaluate the additive value of the cardiac biomarkers, based on the Chi-
square change (-2 log likelihood ratio) and whether biomarkers remained significant 
predictors. Biomarker concentrations less than the limit of detection were set equal to 
the limit of detection. The threshold for statistical significance was P<0.05, two-sided 
unless stated otherwise. All data were analyzed using SPSS Statistics 18.0 (SPSS Inc., 
Chicago, IL, USA).  
 
RESULTS 
The baseline characteristics of the 1,088 patients who met the inclusion and exclusion 
criteria are presented in Table 1. Follow-up information was available for all patients 
(mean follow-up time 2.2  0.8 years). As a result of CCTA, 50 patients underwent 
(early) revascularization within 90 days (35x PCI, 15x CABG) and these were censored 
at the time of revascularization. Final survival analysis included a total of 42 patients 
who suffered a cardiac event: 26 patients underwent (late) revascularization >90 days 
after CCTA (20x PCI and 6x CABG), 15 patients suffered an ACS (6x AMI and 9x 
unstable angina requiring hospitalization), and one patient died due to heart failure. 
The overall cardiac event rate was 4%. 
 Table 1 shows that patients who suffered a cardiac event consisted of significantly 
more smokers, had higher systolic blood pressure and FRS, higher hs-cTnT 
concentrations, lower LVEF, higher CCS, and more severe lesions on CCTA. 
 
Prognostic Value of hs-cTnT 
Logistic regression revealed that 1-unit increase in hs-cTnT concentration resulted in 
a significant increase in cardiac risk (HR 1.04, 95% CI 1.01-1.06, P=0.004), in contrast 
to NT-proBNP (HR 1.00, 95% CI 1.00-1.00, P=0.645) and hsCRP (HR 1.00, 95% CI 
0.98-1.03, P=0.712). Comparable results were obtained when biomarker 
concentrations were corrected for age and gender.  
 Kaplan-Meier analysis shows that hs-cTnT and NT-proBNP concentrations were 
both significant predictors for the occurrence of cardiac events (P<0.001 and P=0.009, 
respectively), in contrast to hsCRP (P=0.355).   
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Table 1. Baseline characteristics of the study population. 
 All Participants No Event Cardiac Event P value 
Baseline characteristics (n=1,088) (n=1,046) (n=42)  
Age, years 56 ± 11 56 ± 11 59 ± 11 0.067 
Male gender 53.8 53.6 57.1 0.655 
Systolic BP, mmHg 142 ± 19 141 ± 19 149 ± 16 0.010 
Smoking 26.5 25.6 50.0 0.001 
Diabetes mellitus 8.4 8.3 12.5 0.347 
Positive family history 39.7 39.2 51.2 0.123 
Framingham risk score 16.7 (9.3-27.2) 16.4 (9.2-26.4) 25.1 (14.6-48.1) <0.001 
Total cholesterol,  mg/dL 206.1 ± 46.3 205.7 ± 46.2 215.7 ± 47.1 0.179 
LDL cholesterol,  mg/dL 127.6 ± 41.4 127.3 ± 41.5 134.0 ± 40.5 0.303 
HDL cholesterol,  mg/dL 50.4 ± 29.9 50.5 ± 30.3 47.9 ± 16.0 0.581 
Triglycerides, mg/dL 153.2 ± 102.6 152.6 ± 102.9 166.5 ± 93.3 0.391 
hsCRP, mg/dL 0.14 (0.07-0.31) 0.14 (0.07-0.31) 0.16 (0.10-0.48) 0.079 
hs-cTnT, pg/mL 4.1 (<3.0-6.7) 4.0 (<3.0-6.6) 6.8 (<3.0-10.3) 0.015 
NT-proBNP, pg/mL 75.5 (34.3-153.2) 74.2 (33.4-155.4) 92.3 (55.2-136.6) 0.218 
LVEF, % † 60.3 ± 7.8 60.4 ± 7.7 57.2 ± 9.4 0.048 
IVSEDWT, mm † 8.9 ± 1.7 8.9 ± 1.7 9.5 ± 1.7 0.103 
PWEDWT, mm † 8.7 ± 1.1 8.7 ± 1.1 9.3 ± 1.4 0.060 
LVMASS, gram † 185 ± 55 185 ± 54 198 ± 72 0.252 
Coronary calcium score 7  (0-122) 6 (0-110) 252 (8-644) <0.001 
CCTA luminal stenosis, %    <0.001 
     No CAD 36.8 37.9 9.5  
     Mild CAD (<50%) 38.1 39.0 16.7  
     Moderate CAD (50-70%) 14.5 14.0 28.6  
     Severe CAD (>70%) 10.5 9.2 45.2  
Values are presented as %, as mean ± SD or as median (interquartile range). † n=612 underwent 
echocardiography. hsCRP, high-sensitive CRP; hs-cTnT, high-sensitivity cardiac troponin T; IVSEDWT, 
interventricular septum end-diastolic wall thickness; LVEF, left ventricular ejection fraction; LVMASS, left 
ventricular mass; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; PWEDWT, posterior wall 
end-diastolic wall thickness.  
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Moreover, Cox regression reveals that hs-cTnT was the only significant biomarker 
predicting for cardiac events, either when testing the biomarker concentrations as a 
continuous variable (Table 2: Model 1, 4, and 7, respectively) or when present in the 
highest quartile Q4 (Table 2: Model 2, 5, and 8, respectively).  
 
Table 2. Cox regression analysis of cardiac biomarkers for the composite endpoint. 
Model Cardiac biomarker Chi-square P HR 95% CI P 
1 hs-cTnT 28.93 <0.001 1.03 1.01-1.04 <0.001 
2 hs-cTnT in Q4 (>6.7 ng/L) * 17.30 <0.001 3.55 1.88-6.70 <0.001 
3 hs-cTnT > URL (14 ng/L) *,† 1.08 0.299 1.85 0.57-6.02 0.307 
4 NT-proBNP 0.84 0.359 1.00 1.00-1.00 0.380 
5 NT-proBNP in Q4 (>18 pmol/L) * 0.72 0.396 0.70 0.31-1.60 0.399 
6 NT-proBNP > URL (36 pmol/L) *,† 0.47 0.492 0.66 0.20-2.16 0.495 
7 hsCRP 0.11 0.742 1.00 0.98-1.02 0.746 
8 hsCRP in Q4 (>3.1 mg/L) * 0.86 0.355 1.38 0.70-2.73 0.357 
9 hsCRP > URL (3 mg/L) *,† 0.61 0.436 1.31 0.66-2.60 0.437 
* Dichotomous variable (yes or no); † URL = upper reference limit (used for diagnosis). hsCRP, high-
sensitive C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-
brain-type natriuretic peptide; Q4, fourth quartile. 
 
Additional Value of hs-cTnT on Top of FRS 
Clinical risk profiling using FRS predicted significantly for the occurrence of cardiac 
events (Table 1, P<0.001). This was confirmed using logistic and Cox regression for 
FRS as a continuous variable or when categorized as follows: <5% (low risk), 5-20% 
(intermediate risk), >20% (high risk) (all P<0.05). Kaplan-Meier analysis confirmed 
this relation, as shown in Figure 2A (P=0.018). Noticeably, almost no cardiac events 
were observed in patients with FRS <5%. When regarding time to event using Cox 
regression, hs-cTnT concentrations were predictive on top of FRS (Table 3, without 
versus with hs-cTnT). This was true when hs-cTnT was added to the individual 
parameters of the FRS (Model 1: HR hs-cTnT 1.02, P=0.007 and Chi-square change 
5.23, P=0.022) or marginally significant when added to the complete FRS algorithm 
(Model 2: HR hs-cTnT 1.02, P=0.018 and Chi-square change 3.58, P=0.058).  
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To further illustrate, we noticed a 3-fold increase in cardiac risk in patients with hs-
cTnT concentrations in Q4 as compared to <Q4, independent from high or low FRS 
(cut-off 20%) (Model 3: HR hs-cTnT 3.11, P=0.001 and Chi-square change 10.56, 
P=0.001). In patients with FRS <20%, the cardiac event rate increased from 2.1% to 
5.9% when hs-cTnT concentrations were in Q4 compared to <Q4. In patients with FRS 
>20%, the cardiac event rate increased from 3.6% to 10.6%, respectively. This is also 
illustrated using Kaplan-Meier analysis in Figure 2B (P=0.001). In contrast, no 
significant additional value was found for NT-proBNP and hsCRP.  
 
Table 3. Cox regression analysis of Framingham risk profiling for the composite endpoint of 
cardiac events. 
 Without hs-cTnT With hs-cTnT 
 HR 95% CI P value HR 95% CI P value 
Model 1       
Age 1.03 1.00-1.07 0.074 1.02 0.98-1.06 0.332 
Male gender * 1.26 0.61-2.63 0.531 1.12 0.53-2.36 0.770 
Total cholesterol 1.11 0.84-1.47 0.468 1.16 0.87-1.54 0.308 
HDL cholesterol 0.92 0.45-1.88 0.812 0.92 0.44-1.88 0.811 
Systolic blood pressure 1.02 1.00-1.03 0.071 1.02 1.00-1.04 0.030 
Smoking * 3.73 1.83-7.60 <0.001 3.34 1.62-6.92 0.001 
Diabetes mellitus * 1.32 0.44-3.94 0.618 0.95 0.27-3.35 0.939 
hs-cTnT - - - 1.02 1.01-1.04 0.007 
Model 2       
Framingham 1.03 1.02-1.04 <0.001 1.03 1.01-1.04 <0.001 
hs-cTnT - - - 1.02 1.00-1.03 0.018 
Model 3       
Framingham >20% * 2.33 1.19-4.55 0.013 1.79 0.89-3.57 0.101 
hs-cTnT in Q4 * - - - 3.11 1.58-6.11 0.001 
* Dichotomous variable (yes or no). HDL, high-density lipoprotein; hs-cTnT, high-sensitivity cardiac 
troponin T; Q4, fourth quartile. 
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Figure 2 (previous page). Kaplan-Meier analysis illustrating improved classification by including 
hs-cTnT to current risk stratification tools. Figures on the left shows Kaplan-Meier curves for FRS 
(A), CCS (C) and CCTA assessment (E). Figures on the right shows Kaplan-Meier curves when hs-
cTnT was added to FRS (B), CCS (D) and CCTA assessment (F). Q4 = fourth quartile of hs-cTnT 
concentrations.  
 
Finally, Table 1 shows that LVEF was significantly lower in the cardiac event group as 
compared to the non-event group (P=0.048). Cox regression confirmed LVEF as a 
significant predictor (HR 0.96, 95% CI 0.93-1.00, P=0.049). Nevertheless, the 
predictive value of hs-cTnT remained significant when corrected for LVEF (HR hs-
cTnT 1.02, 95% CI 1.01-1.04, P=0.002 and HR LVEF 0.97, 95% CI 0.93-1.01, P=0.124). 
When LVEF was added to risk profiling as presented in Table 4, smoking (Model 
without hs-cTnT) or smoking and hs-cTnT (Model with hs-cTnT) remained the only 
significant predictors. 
 
Additional Value of hs-cTnT on Top of CCS and CCTA 
Kaplan-Meier analysis shows an apparent gradient of adverse survival for more 
severe CAD (Figure 2C and 2E). Furthermore, hs-cTnT concentrations (median, IQR) 
were significantly higher in mild (4.2 pg/mL, <3.0-7.3), moderate (4.7 pg/mL, <3.0-
7.3), and severe CAD (6.5 pg/mL, 3.6-9.4) as compared to patients without CAD (3.3 
pg/mL, <3.0-5.3), all P<0.001. A similar trend was found for CCS (P<0.001). These data 
show that increasing concentrations of hs-cTnT were associated with the severity of 
CAD, which is in line with our previous results in part of this population [8].  
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Table 4. Cox regression analysis of risk profiling and coronary plaque assessment including 
LVEF for the composite endpoint of cardiac events. 
 Without hs-cTnT With hs-cTnT 
 HR 95% CI P value HR 95% CI P value 
Model FRS       
Age 1.03 0.98-1.08 0.249 1.01 0.96-1.06 0.747 
Male gender * 0.82 0.31-2.18 0.697 0.68 0.25-1.90 0.464 
Total cholesterol 1.22 0.86-1.74 0.259 1.32 0.92-1.91 0.135 
HDL cholesterol 0.59 0.14-2.53 0.475 0.63 0.14-2.78 0.540 
Systolic blood pressure 1.02 1.00-1.04 0.104 1.02 1.00-1.05 0.051 
Smoking * 6.85 2.57-18.2 <0.001 5.94 2.19-16.1 <0.001 
Diabetes mellitus * 2.06 0.58-7.38 0.265 1.35 0.29-6.27 0.700 
LVEF 0.97 0.93-1.02 0.262 0.97 0.93-1.02 0.267 
hs-cTnT  - - - 1.02 1.00-1.04 0.041 
Model CCS       
CCS 1.00 1.00-1.00 0.012 1.00 1.00-1.00 0.057 
LVEF 0.98 0.93-1.02 0.337 0.99 0.94-1.04 0.653 
hs-cTnT  - - - 1.02 1.00-1.04 0.022 
Model CCTA       
CCTA luminal stenosis, %   <0.001   <0.001 
     No CAD = reference 1.00   1.00   
     Mild CAD (<50%) 0.45 0.04-4.91 0.509 0.44 0.04-4.84 0.501 
     Moderate CAD (50-70%) 7.07 1.36-36.7 0.020 7.26 1.40-37.7 0.018 
     Severe CAD (>70%) 29.2 6.58-129 <0.001 27.3 6.10-122 <0.001 
LVEF 0.98 0.94-1.02 0.313 0.99 0.95-1.03 0.570 
hs-cTnT  - - - 1.01 1.00-1.02 0.183 
* Dichotomous variable (yes or no). HDL, high-density lipoprotein; hs-cTnT, high-sensitivity cardiac 
troponin T; LVEF, left ventricular ejection fraction; Q4, fourth quartile. 
 
  
 
77 
Table 5. Cox regression analysis of coronary plaque assessment for the composite endpoint of 
cardiac events. 
Models Without hs-cTnT With hs-cTnT 
 HR 95% CI P value HR 95% CI P value 
Model 1 (CCS)       
CCS  1.00 1.00-1.00 <0.001 1.00 1.00-1.00 <0.001 
hs-cTnT  - - - 1.02 1.01-1.04 0.006 
Model 2 (CCS)       
CCS >400 * 5.68 2.72-11.86 <0.001 4.53 2.13-9.64 <0.001 
hs-cTnT in Q4 * - - - 2.73 1.32-5.62 0.007 
Model 3 (CCTA)       
CCTA luminal stenosis, %   <0.001   <0.001 
     No CAD = reference 1.00   1.00   
     Mild CAD (<50%) 1.47 0.42-5.22 0.549 1.44 0.41-5.11 0.571 
     Moderate CAD (50-70%) 7.25 2.27-23.11 0.001 7.09 2.22-22.62 0.001 
     Severe CAD (>70%) 23.98 8.10-70.96 <0.001 21.76 7.27-65.10 <0.001 
hs-cTnT  - - - 1.01 1.00-1.03 0.028 
Model 4 (CCTA)       
Severe CAD (>70%) * 11.33 5.98-21.47 <0.001 9.23 4.79-17.82 <0.001 
hs-cTnT in Q4 * - - - 2.47 1.29-4.77 0.007 
* Dichotomous variable (yes or no). CCS, coronary calcium score; CCTA, coronary CT-angiography; hs-
cTnT, high-sensitivity cardiac troponin T; CAD, coronary artery disease; Q4, fourth quartile. 
 
Cox regression in Table 5 shows the additional value of hs-cTnT on top of CAD 
assessment with CCS and CCTA. One unit increase in hs-cTnT resulted in a minor 
increase in cardiac risk (Model 1 CCS: HR hs-cTnT 1.02, P=0.006 and Chi-square 
change 4.23, P=0.040; Model 3 CCTA: HR hs-cTnT 1.01, P=0.028 and Chi-square 
change 3.04, P=0.081). To illustrate, a 2- to 3-fold increase in cardiac risk was noticed 
in patients with hs-cTnT concentrations in Q4, independent from high or low CCS (cut-
off Agatston score 400) or luminal stenosis on CCTA (cut-off 70%)  (Model 2 CCS: HR 
hs-cTnT 2.73, P=0.007 and Chi-square change 7.20, P=0.007; Model 4 CCTA: HR hs-
cTnT 2.47, P=0.007 and Chi-square change 7.24, P=0.007.  
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In patients with high CCS (Agatston score >400, n=85), the cardiac event rates 
increased from 4.3% to 24% when hs-cTnT concentrations were in Q4 as compared to 
<Q4. In patients with a CCTA lesion of >70% luminal stenosis (n=103), the cardiac 
event rates were 8.8% and 28% when hs-cTnT concentrations were in <Q4 and Q4, 
respectively. This is also illustrated using Kaplan-Meier analysis in Figure 2D and 2F 
for CCS and CCTA assessment, respectively (both P=0.001). Again, no significant 
additional value was found for NT-proBNP and hsCRP.  
 
DISCUSSION 
Our study shows that in patients with symptoms of chest discomfort suspected for 
CAD, hs-cTnT was a significant predictor for the composite endpoint of late 
revascularizations, ACS and cardiac mortality. Over three times as much cardiac 
events were found in patients with hs-cTnT concentrations in the fourth quartile (cut-
off 6.7 ng/L, HR 3.55, P<0.001) as compared to patients with hs-cTnT concentrations 
in the lowest three quartiles. Moreover, survival analysis showed that hs-cTnT 
significantly contributed to the identification of a subgroup of patients with higher 
risk for cardiac events. When using traditional risk factors, smoking (HR 3.34, 
P=0.001), hs-cTnT (HR 1.02, P=0.007), and systolic blood pressure (HR 1.02, P=0.030) 
remained the only significant predictors. Hs-cTnT remained significantly predictive 
independent from FRS (HR 1.02-3.11, dependent whether variables were continuous 
or categorized). In addition, hs-cTnT improved classification on top of the extent of 
CAD as assessed with CCS and CCTA. To illustrate, a 2- to 3-fold increase in cardiac 
risk was noticed in patients with hs-cTnT concentrations in the highest quartile, 
independent from high or low CCS (cut-off Agatston score 400) or luminal stenosis on 
CCTA (cut-off 70%) (HR 2.73 and 2.47, both P=0.007). 
 In a previous study, Reichlin et al showed that the positive predictive value of hs-
cTnT in diagnosing acute myocardial infarction was only 19% (cut-off 2 pg/mL, limit 
of detection) or 50% (cut-off 14 pg/mL, 99th percentile of healthy reference 
population), while the negative predictive value was nearly perfect (99-100%, 
dependent on cut-off) [5]. This indicates that it is of great importance to exclude false 
positives before widespread introduction of hs-cTn as a risk factor.  
 
79 
On the other hand, the present study as well as other studies has shown the adverse 
outcome of elevated hs-cTn on cardiovascular events [10-12,21,22]. The reference 
change value for hs-cTnT concentrations, that is based on biological variations in 
healthy individuals and analytical variations, was 58% and around 95% for the short-
term (4 hours) and long-term (8 weeks), respectively [23]. There are no results 
reported on optimal delta cut-offs considering a longer follow-up period of years apart 
from the study of deFilippi et al, who recently showed that for an increase in hs-cTnT 
concentrations >50% over two to three years, the risk for heart failure and 
cardiovascular death were 1.7 and 1.8-fold, respectively [11]. 
 Question remains what the underlying pathophysiological mechanisms of elevated 
hs-cTnT concentrations in these patients are. Korosoglou and colleagues concluded 
that the presence of non-calcified coronary plaques may result in continuous leakage 
of troponins, possibly due to repetitive micro-embolization of atherosclerotic debris 
[9]. In our study, we observed a stepwise increase in hs-cTnT concentrations with 
increasing atherosclerotic plaque burden which supports this explanation. Alternative 
explanations for troponin leakage which have been supposed are demand ischemia, 
myocardial ischemia (for example due to coronary vasospasm), direct myocardial 
damage, chronic renal insufficiency, or myocardial strain because of volume or 
pressure overload [24]. Other possible causes of elevated hs-cTnT concentrations 
could be chest trauma, strenuous exercise, pericarditis, myocarditis and cardiac 
amyloidosis. However,  in the present study we could exclude chest trauma and 
strenuous exercise as causes. Furthermore, ECG findings, CCTA and echocardiography 
did not reveal convincing evidence for alternative diagnoses like pericarditis, 
myocarditis or amyloidosis. Since concentrations of NT-proBNP were not increased in 
our patients, we felt we could exclude digestive heart failure as cause of the increased 
hs-cTnT concentrations. 
 Recently, two papers were published which feed the thought that the identification 
of patients at risk for a cardiovascular event may soon become easier and more 
accurate using hs-cTnT [10,11]. DeFilippi et al performed serial measures of hs-cTnT 
in community-dwelling older adults [11]. They found a significant association 
between baseline hs-cTnT concentrations, changes in hs-cTnT concentrations and the 
development of heart failure and cardiovascular death.  
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De Lemos et al found an association between increased hs-cTnT and structural heart 
disease, especially left ventricular hypertrophy, and subsequent risk for all-cause 
mortality [10]. However, the study by deFilippi was focusing on elderly with a mean 
age above 70 years, while in the study of de Lemos the vast majority of the population 
(77%) consisted of patients with FRS <10%. These characteristics are not typical for 
the patients presenting at the cardiology outpatient department. Therefore, it is not 
clear from those studies to what extent hs-cTnT would be of incremental value in 
patients presenting with symptoms of chest discomfort at the cardiology outpatient 
department. Moreover, the published studies focused on left ventricular hypertrophy 
and heart failure, respectively. It is not inconceivable that the main cause of the 
elevated hs-cTnT is the presence of atherosclerosis, because it is known that the 
majority of patients with heart failure have underlying coronary atherosclerotic 
disease [25]. Moreover, hypertension is an important risk factor for atherosclerosis 
and also the major determinant of left ventricular hypertrophy. In this study, we show 
that although the predictive value of LVEF for events was significant, this did not seem 
to confound our results. In previous work, we demonstrated that even mild CAD is 
associated with increased concentrations of hs-cTnT and we suggested that hs-cTnT 
may become a potential serum biomarker to improve the identification of patients at 
risk for developing cardiovascular events [8]. There is increasing evidence that ACS 
may be predominantly caused by such mild stenoses [26]. On the other hand, it is 
known that the extent of CAD provides important prognostic information in both 
asymptomatic and symptomatic patients. Both high CCS and ≥50% luminal stenosis on 
CCTA deprive prognosis significantly [27]. In this study we show that measuring hs-
cTnT provides additional value on these already strong prognostic parameters. In our 
opinion, these findings strengthen the hypothesis that hs-cTnT is a prognostic clinical 
biomarker. In addition, we provide new insights into the use of hs-cTnT, which can 
help the physician to better identify the patient at risk of a cardiovascular event. 
 
Study Limitations 
This study has several limitations that merit comment. First, the follow-up period is 
relatively short and therefore we found relatively few events. However, the event rate 
which we found is comparable to other previously published large CCTA-trials. 
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Second, clinicians were not blinded for CCTA findings. Therefore, early 
revascularizations (within 90 days) were censored for survival analysis. However, the 
knowledge of the CCTA findings could still bias the clinician’s behaviour after the 90 
day time period. It would be interesting to blind clinicians for CCTA results, but since 
CCTA is part of the diagnostic work-up in our university medical center, this would be 
unethical. On the other hand, none of the clinicians had access to the results of the hs-
cTnT, hsCRP and NT-proBNP measurements. Third, all patients were of Western 
European descent. It remains uncertain whether our results can be generalized to 
other populations. Fourth, we performed a single hs-cTnT measurement and it 
remains unclear in which manner hs-cTnT varies in time. Fifth, despite the fact that 
invasive coronary angiography is still the golden standard for coronary artery 
stenosis, we are convinced that the use of CCTA gives an adequate reflection of the 
extent and severity of plaque burden in our study population. 
 
CONCLUSION 
Hs-cTnT is a useful prognostic biomarker in patients with symptoms of chest 
discomfort suspected for CAD. Hs-cTnT is associated with the extent of CAD, assessed 
by CCS and CCTA, and is a significant predictor for the occurrence of a future cardiac 
event (late revascularization, ACS, and cardiac mortality). Even better performance 
was obtained when hs-cTnT concentrations were combined with Framingham risk 
profiling. Finally, hs-cTnT also provided additional value to the assessment of CAD by 
coronary computed tomographic angiography. 
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BACKGROUND 
Besides its pivotal role in thrombus formation, experimental data indicate that 
thrombin also plays a role in the pathophysiology of atherosclerosis progression and 
vascular calcification. Nevertheless, the clinical evidence remains limited. The 
objective of this study was to investigate the relationship between thrombin 
generation and the presence and severity of coronary artery disease (CAD). 
METHODS 
Using 64-slice coronary CT-angiography, we assessed the presence and characteristics 
of CAD in patients (n=295; median age: 58 years) with stable chest pain. Coronary 
artery calcification (CAC) was graded as absent (Agatston 0), mild (Agatston 1-100), 
moderate (Agatston 101-400) and severe (Agatston >400). Calibrated automated 
thrombography was used to assess endogenous thrombin potential in plasma in vitro. 
Thrombin-antithrombin complexes (TATc) levels were measured as a marker for 
thrombin formation in vivo.  
RESULTS 
TATc levels were substantially higher in patients with CAD vs. patients without CAD 
(p=0.004). Significant positive correlations were observed between steadily 
increasing TATc levels and the severity of CAD (r=0.225, P<0.001). In multinomial 
logistic regression models, after adjusting for established risk factors, TATc levels 
predicted the degree of CAC: mild (OR:1.56, P=0.006); moderate (OR:1.56, P=0.007); 
and severe (OR:1.67, P=0.002). Trends were comparable between the groups when 
stratified according to the degree of coronary luminal stenosis.  
CONCLUSION 
This study provides novel clinical evidence indicating a positive independent 
association between enhanced in vivo thrombin generation and the presence and 
severity of coronary atherosclerosis, which may suggest that thrombin plays a role in 
atherogenesis. 
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INTRODUCTION 
Atherosclerosis is a multifactorial chronic inflammatory vascular disorder [1,2]. Given 
the abundant experimental evidence showing extensive interactions between the 
hemostatic, immune and inflammation systems, we have proposed a role for the 
clotting proteins in modulating atherosclerosis progression and atherosclerotic 
plaque phenotype [3]. In particular, thrombin, which is the most central coagulation 
protein, is also recognized as a strong pro-inflammatory mediator. Endowed with a 
potent cell signaling capacity, thrombin can induce an array of pro-atherogenic and 
plaque-destabilizing effects such as inflammation, vascular smooth muscle cell 
migration and proliferation, leukocyte chemotaxis, proteolysis, apoptosis, 
angiogenesis, etc. [3,4]. Recently, we demonstrated that thrombin, as well as other 
coagulation proteins, are widely expressed and functionally active throughout distinct 
compartments of the arterial vessel wall [5], supporting an active cell-based 
coagulation network within human atherosclerotic plaques. G-protein-coupled 
protease-activated receptors (PARs), which are selectively cleaved by thrombin, are 
also abundantly distributed in the vasculature under normal conditions and 
overexpressed in atherosclerotic lesions [6]. Experimental animal studies have clearly 
indicated that variations in the clotting activity affect the progression and 
thrombogenicity of atherosclerotic plaques [3].  
 Antithrombotic therapy is a cornerstone in the management and prevention of 
atherothrombosis in patients [2]. Experimental data demonstrate that direct thrombin 
inhibition substantially attenuates atherosclerosis development in ApoE-null mice [7] 
and protects against severe plaque progression in prothrombotic mice [8]. However, 
the role of blood coagulation proteins in atherogenesis, in particular thrombin, has not 
been adequately addressed in previously conducted clinical research. Cardiac 
computed tomographic angiography (CCTA) is a well-established non-invasive 
imaging modality, which has high diagnostic accuracy for detection and 
characterization of coronary plaques [9,10].  
 Using CCTA, we investigated the association between thrombin formation in 
plasma and the presence and severity of coronary atherosclerosis in patients with 
suspected coronary artery disease (CAD). 
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METHODS 
Study Population 
We studied 295 adult patients who were referred from the cardiology outpatient 
department for CCTA because of stable chest pain, suspected for CAD. Scans were 
performed in our university medical center between January 2008 and June 2010 as 
part of the diagnostic work-up in these patients. Included were patients with a recent 
history of (a)typical chest pain, who underwent a coronary calcium score scan as well 
as CCTA. Excluded were patients with acute chest pain suspected for an acute 
coronary syndrome (ACS), patients with a history of acute myocardial infarction 
(AMI), percutaneous coronary intervention and/or coronary artery bypass grafting 
surgery, patients with missing data regarding their cardiac risk profile, patients with 
an inconclusive CT-scan and patients currently on anti-coagulation therapy (oral 
vitamin K antagonist/selective anticoagulants or low-molecular weight heparins). In 
vitro hemolysis of blood samples was also an exclusion criterion. We calculated the 
Framingham risk score (FRS) in all patients to estimate the 10-year risk of suffering a 
myocardial infarction or cardiovascular death [11]. The Institutional Review Board 
and Ethics Committee at the Maastricht University Medical Center approved the study, 
and all patients gave written informed consent.  
 
CCTA Protocol 
Scans were performed using a 64–slice CT-scanner (Brilliance 64; Philips Healthcare, 
Best, The Netherlands) with a 64 x 0.625 mm slice collimation, a gantry rotation time 
of 420 ms and a tube voltage of 80-120 kV. Tube current varied from 150-210 mAs for 
the prospectively gated “Step and shoot” protocol and from 600-1000 mAs for the 
retrospectively gated “Helical” protocol. Patients received 50 mg Metoprolol tartrate 
orally, two hours before CCTA. When indicated, an additional dose of 5–20 mg 
Metoprolol tartrate (AstraZeneca, Zoetermeer, The Netherlands) was administered 
intravenously to lower the heart rate <65 beats per minute (bpm). 0,8 mg 
Nitroglycerin spray (Pohl-Boskamp, Hohenlockstedt, Germany) was given 
sublingually just prior to CCTA. Heart rate and ECG were monitored during CCTA.  
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A non-enhanced scan was performed to determine the amount of coronary artery 
calcification (CAC), using the Agatston method [12]. Subsequently, CCTA was 
performed using 85–110 mL of contrast agent (Xenetix 350; Guerbet, Roissy CdG 
Cedex, France), which was injected in the antecubital vein at a rate of 6.0 mL/s, 
directly followed by 40 mL intravenous saline (6.0 mL/s) using a dual-head power 
injector. A prospectively gated “Step and shoot” protocol was used in all patients with 
a stable heart rate <65 bpm. In patients with an irregular heart rate or a stable heart 
rate >65 bpm, we used a retrospectively gated “Helical” protocol with dose 
modulation to obtain the best image quality at minimal radiation dose [13,14]. 
 
CCTA Analysis 
All scans were independently analyzed by two cardiologists with level III expertise in 
coronary CT-angiography, blinded for patient details, using source images in the 
Cardiac Comprehensive Analysis software (Philips Healthcare). In case of 
disagreement, consensus was reached by reviewing findings jointly. 
 CAC was expressed as the Agatston score using calcium scoring software (Philips 
Healthcare) with a threshold of 130 Hounsfield units (HU). The coronary artery tree 
was analyzed for the presence and severity of CAD, according to the 16-segment 
classification of the American Heart Association [15]. Coronary plaques were defined 
as visible structures within or adjacent to the coronary artery lumen, which could be 
clearly distinguished from the vessel lumen and the surrounding pericardial tissue. 
Plaques were categorized as calcified (exclusively content with density >130 HU), 
non-calcified (exclusively content with density <130 HU) or mixed (characteristics of 
both calcified and non-calcified plaques). The degree of CAD was classified as absent 
(no luminal stenosis), mild (<50% luminal stenosis), moderate (50-70% luminal 
stenosis) or severe (>70% luminal stenosis) [16]. The degree of CAC was classified as 
absent (Agatston score 0), mild (Agatston score 1-100), moderate (Agatston score 
100-400) or severe (Agatston score >400) [17]. 
 
Blood Samples and Laboratory Measurements 
Blood samples were taken just before the scan, processed within 2 hours and plasma 
was stored at -80°C until analysis.  
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Continuous thrombin generation in clotting platelet-poor plasma was monitored in 
vitro by using the Calibrated Automated Thrombography (CAT) method 
(Thrombinoscope B.V., Maastricht, The Netherlands) [18]. The reaction was triggered 
by adding 5pM tissue factor (PPP Reagent, Thrombinoscope B.V., Maastricht, The 
Netherlands) in the presence of 4 μM phospholipids and 16 mM added CalCl2 (in 
duplicate). Endogenous thrombin potential (ETP) was analyzed (corresponds to the 
area under the curve). ETP values were normalized based on platelet-poor normal 
pooled plasma (NPP) obtained from healthy volunteers, the latter used as a reference 
[19]. Data are expressed as % of NPP [20]. In addition, using a commercially available 
micro-enzyme immunoassay kit (Enzygnost® TAT Micro, Siemens Healthcare 
Diagnostics, Deerfield, IL, USA) we established thrombin-antithrombin complexes 
(TATc) levels in all patients (in duplicate) as a highly specific marker for thrombin 
formation in vivo. 
 
Statistical Analysis 
Statistical analyses were performed using IBM SPSS Statistics 19.0.0 (SPSS Inc., 
Chicago, IL, USA). Categorical variables are presented as numbers (percentages), 
whereas continuous data are expressed as mean ± SD (standard deviation), unless 
otherwise indicated. TATc plasma levels were normalized by natural logarithm 
transformation. We used the score plus 1 to also include patients with a TATc plasma 
level below 1 ng/mL. Demographic differences between patients with or without CAD 
were tested either using a Student’s t-test or Mann-Whitney U test, depending on the 
distribution characteristics of the data. Pearson's chi-square test (χ2) was used to 
compare proportions (binary or categorical), whereas continuous variables were 
analysed via one-way analysis of variance test (ANOVA), including Bonferroni 
correction. Correlations are presented as Pearson or Spearman’s coefficients 
according to the observed distribution.  
 Multivariate analyses were conducted using binary/multinomial logistic 
regression, computed in a multiple main effects or forward stepwise manner, 
including variables with P<0.05. χ2 and odds ratios with 95% CI were calculated to 
determine which variables demonstrated significant independent associations with 
atherosclerotic plaque presence, degree of luminal stenosis and CAC.  
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Receiver operating characteristic (ROC) analysis was carried out to evaluate the 
potential of using TATc and Framingham risk score (separately or in combination) for 
determining the presence or absence of CAD. Areas under the ROC curve (AUROC) 
were compared using the Hanley and McNeil’s method. We performed the net 
reclassification index to evaluate the incremental effect of adding TATc to the 
Framingham risk score for predicting the presence of coronary plaques. A 2-sided P 
value <0.05 was considered statistically significant.  
 
RESULTS 
Study Population Characteristics  
The study population consisted of 295 individuals [182 males (61.7%) and 113 
females (38.3%)] with a median age of 57 years (min-max: 30-87). A total of 226 
patients underwent a “Step and shoot” scan (mean radiation dose 3.6 mSv), whereas 
69 patients underwent a “Helical” scan (mean radiation dose 11.6 mSv). CAD was 
detected in 205 (69.5%) patients. The prevalence of absent, mild, moderate and 
severe CAD was 30.5%, 22.7%, 26.4% and 20.3%, respectively. Compared to the non-
CAD group, patients with CAD were predominantly male (65.4%) and older, showed 
increased systolic blood pressure and had lower LDL plasma concentrations. 
However, the prevalence of statin use in the CAD group was significantly higher 
compared to the non-CAD group [100 (48.8%) vs. 22 (24.4%)]. Baseline 
characteristics are presented in Table 1. 
 
Increased In Vivo Thrombin Formation Independently Reflects Presence of CAD 
As depicted in Figure 1A, among the population with CAD (n=205), the average 
baseline (lg 10 transformed) TATc levels were significantly higher compared to the 
group without CAD (mean 0.41; 95% CI 0.38–0.45 vs. mean 0.32; 95% CI 0.29–0.36, 
P=0.001). Multivariate logistic regression analysis showed that higher TATc levels 
(OR: 1.47, 95% CI 1.10–1.97, P=0.010), in addition to other established risk factors 
such as male gender (OR: 3.36; 95% CI 1.75–6.45, P<0.001), age (OR: 1.09; 95% CI 
1.05–1.12, P<0.001) and smoking (OR: 2.17; 95% CI 1.09–4.33, P<0.001), were all 
independently associated with the presence of CAD (data not shown).  
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Table 1. Baseline characteristics of subjects stratified into groups per presence of CAD. 
 All patients Patients without CAD Patients with CAD  
Characteristics (n = 295) (n = 90) (n = 205) P 
Age, years 57 (30–87) 54 (30–76) 59 (36–87) <0.001 
Male 182 (61.7) 48 (53.3) 134 (65.4) 0.053 
Body Mass Index, kg/m2 26.4 (24.2–29.4) 26.6 (23.8–29.7) 26.4 (24.3–29.3) 0.620 
Systolic BP, mmHg 143 (130–156) 139 (127–153) 145 (132–157) 0.023 
Diastolic BP, mmHg 80 (73–87) 80 (71–86) 81 (74–87) 0.615 
Smoking 71 (24.1) 18 (20.0) 53 (25.9) 0.304 
Diabetes mellitus 26 (8.8) 6 (6.7) 20 (9.8) 0.505 
Positive family history 126 (42.7) 36 (40.0) 90 (43.9) 0.609 
Lipid-lowering therapy 122 (41.4) 22 (24.4) 100 (48.8) <0.005 
Anticoagulation therapy 0 (0) 0 (0) 0 (0) --- 
Framingham Risk Score 18.9 (12.3–30.0) 14.1 (9.8–21.4) 21.6 (13.4–33.1) <0.001 
Total cholesterol, mg/dL 213 (174–244) 217 (192–240) 205 (170–247) 0.077 
LDL, mg/dL 128 (101–166) 135 (116–163) 124 (97–166) 0.043 
HDL, mg/dL 46 (35–58) 46 (35–57) 44 (37–58) 0.980 
Triglycerides, mg/dL 134 (90–208) 146 (91–231) 130 (89–202) 0.180 
Coronary lesions, n 2 (0–5) 0 (0–0) 4 (2–7) <0.001 
Coronary calcium score 27 (0–214) 0 (0–0) 117 (23–355) <0.001 
Values are median (interquartile range), or n (%). BP, blood pressure; CAD, coronary artery disease; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; n, number. 
 
AUROC for coronary plaque presence, calculated by using the Framingham risk score, 
was 0.663 (95% CI 0.61–0.72; P<0.001). Addition of TATc as a marker to the FRS 
improved the predictive value, resulting in a significant increase of the AUROC to 
0.676 (95% CI 0.62–0.73; P=0.048 – difference between areas).  The net 
reclassification index to assess the incremental value of TATc over the Framingham 
risk score in predicting the presence of coronary plaques was 3.1%, which was not 
significant (p=0.68). 
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CAT measurement, which was carried out to assess the potential to generate thrombin 
in vitro, resulted in ETP values, which are almost the same in the non-CAD group and 
the CAD group (Figure 1B). 
 
 
 
 
 
 
 
 
 
 
Figure 1. In vivo/in vitro thrombin formation and the presence of CAD. Panel A shows that 
patients with CAD exhibit significantly higher in vivo thrombin generation compared to patients 
without CAD (P=0.001). Bars represent average lg 10 transformed TATc levels, whereas data 
distribution is presented in mean (95% CI) in the table below the bars. Panel B shows that patients 
with CAD show comparable thrombin generation potential compared to patients without CAD 
(P<0.004). Bars represent average ETP levels, whereas data distribution is presented in mean 
(95% CI) in the table below the bars. NPP = normal pool plasma. 
 
TATc as Determinant of CAC and Luminal Stenosis 
In the entire study population, TATc levels showed a significant positive association 
with the degree of CAC (Agatston score, r=0.209, P<0.001), as presented in Figure 2A. 
In contrast, no significant relationship was noted between TATc concentrations and 
the number of non-calcified plaques (r=0.052, P=0.376). Multivariate logistic 
regression analyses, using multiple main effects and forward stepwise techniques, 
identified higher TATc formation as an independent risk factor for developing CAC 
(Table 2). Compared to a reference group, consisting of all patients without any 
coronary calcifications, the odds ratios associated with CAC burden were as follows: 
mild CAC (OR: 1.60, 95% CI 1.18–2.16, P<0.005); moderate CAC (OR: 1.58, 95% CI 
1.16–2.15, P<0.005); and severe CAC (OR: 1.71, 95% CI 1.26–2.33, P<0.005).  
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Figure 2. TATc as an independent predictor of CAC. Panel A: Association between increasing TATc 
and severity of CAC. Bars represent lg 10 transformed TATc levels, presented as mean (95% CI) in 
the table below, stratified per CAC group. * Statistical significance at P<0.05 when compared with 
the severe CAC group. Panel B: Distribution of TATc quartiles between CAC score groups. 
 
As shown in Figure 2B, we also found a significant difference in the distribution of the 
TATc quartiles (Q1-Q4) between the different CAC groups (P=0.002). While in the no 
CAC group, 35.9% of the patients had TATc values in the lowest quartile (Q1) and only 
14.6% of them had values in the highest quartile (Q4), the distribution of the TATc 
quartiles in the severe CAC group was 9.3% and 41.9% in Q1 and Q4, respectively.  
 There was a strong positive association between Agatston score and severity of 
CAD (r=0.712, P<0.001). Nevertheless, we also tested the relationship between TATc 
formation and the degree of luminal stenosis by performing multivariate logistic 
regression analyses with degree of luminal stenosis as a dependent variable. Similarly, 
TATc concentrations accurately identified worsening atherosclerosis. The odds ratios 
associated with mild, moderate and severe CAD are depicted in Table 3. 
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Table 2. Multivariate models of factors associated with odds of CAC. 
 Mild CAC Moderate CAC Severe CAC 
 Agatston 1–100 Agatston 100–400 Agatston >400 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Model 1: “Multinomial Logistic Regression: Main Effects Model” 
No CAC, 
Agatston 0 
1.00 (reference) 1.00 (reference) 1.00 (reference) 
Age 1.05 (1.01–1.09) 0.021 1.12 (1.07–1.17) <0.005 1.15 (1.09–1.22) <0.005 
Gender  
(male = 0) 
2.61 (1.22–5.57) 0.014 3.46 (1.50–8.01) 0.004 6.09 (2.17–17.07) <0.005 
Smoking  
(yes = 1) 
0.71 (0.32–1.53) 0.377 0.51 (0.21–1.22) 0.132 0.34 (0.12–0.95) 0.039 
Diabetes  
(yes = 1) 
1.04 (0.30–3.61) 0.951 0.71 (0.19–2.61) 0.603 0.50 (0.12–2.17) 0.355 
Fam. history  
(yes = 1) 
0.60 (0.31–1.16) 0.127 0.42 (0.20–0.88) 0.021 0.41 (0.16–1.01) 0.053 
BMI 0.99 (0.91–1.08) 0.788 1.02 (0.93–1.12) 0.687 0.94 (0.83–1.06) 0.329 
Total Chol 0.88 (0.66–1.15) 0.346 0.96 (0.71–1.29) 0.769 0.84 (0.59–1.21) 0.354 
Systolic BP 1.01 (0.99–1.04) 0.219 1.02 (0.99–1.04) 0.130 1.03 (1.00–1.06) 0.051 
Diastolic BP 1.00 (0.96–1.03) 0.911 1.00 (0.96–1.04) 0.973 0.99 (0.95–1.04) 0.752 
TATc 1.56 (1.14–2.15) 0.006 1.56 (1.13–2.15) 0.007 1.67 (1.21–2.31) 0.002 
       
Model 2: “Multinomial Logistic Regression: Forward Stepwise Model” 
No CAC, 
Agatston 0 
1.00 (reference) 1.00 (reference) 1.00 (reference) 
Age 1.05 (1.01–1.09) 0.010 1.12 (1.07–1.17) <0.005 1.16 (1.10–1.21) <0.005 
Gender  
(male = 0) 
2.45 (1.25–4.81) 0.009 3.14 (1.49–6.61) <0.005 4.86 (1.98–11.95) <0.005 
Fam. history  
(yes = 1) 
0.59 (0.31–1.11) 0.104 0.40 (0.20–0.82) 0.012 0.40 (0.17–0.93) 0.034 
TATc 1.60 (1.18–2.16) <0.005 1.58 (1.16–2.15) <0.005 1.71 (1.26–2.33) <0.005 
BMI, body mass index; BP, blood pressure; CAC, coronary artery calcification; TATc, thrombin-antithrombin 
complex; Total chol, total cholesterol. 
 
96 
Table 3. Multinomial logistic regression models for CAD severity as the dependent variable. 
 Mild CAD Moderate CAD Severe CAD 
 Stenosis <50% Stenosis 50–70% Stenosis >70% 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Model 1: “Multinomial Logistic Regression: Main Effects Model” 
No CAD 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Age 1.08 (1.03–1.12) <0.005 1.09 (1.04–1.13) <0.005 1.10 (1.05–1.15) <0.005 
Gender  
(male = 0) 
2.50 (1.12–5.55) 0.025 3.02 (1.37–6.69) 0.006 5.70 (2.33–13.94) <0.005 
Smoking  
(yes = 1) 
0.62 (0.26–1.47) 0.276 0.54 (0.23–1.28) 0.161 0.28 (0.12–0.67) 0.004 
Diabetes  
(yes = 1) 
0.69 (0.20–2.36) 0.557 0.82 (0.23–2.89) 0.756 0.98 (0.23–4.28) 0.980 
Fam. history 
(yes = 1) 
0.60 (0.30–1.22) 0.160 0.62 (0.31–1.25) 0.177 0.63 (0.30–1.34) 0.226 
BMI 0.98 (0.90–1.08) 0.704 1.04 (0.95–1.14) 0.356 1.00 (0.90–1.10) 0.944 
Total Chol 0.77 (0.57–1.04) 0.093 0.82 (0.61–1.11) 0.198 0.97 (0.72–1.32) 0.861 
Systolic BP 1.01 (0.98–1.03) 0.524 1.02 (0.99–1.04) 0.207 1.02 (0.99–1.04) 0.232 
Diastolic BP 1.00 (0.96–1.04) 0.939 1.00 (0.97–1.04) 0.870 1.01 (0.97–1.05) 0.745 
TATc 1.37 (0.99–1.88) 0.056 1.57 (1.16–2.14) 0.004 1.47 (1.07–2.02) 0.017 
 
Model 2: “Multinomial Logistic Regression: Forward Stepwise Model” 
No CAD 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Age 1.08 (1.03–1.12) <0.005 1.09 (1.05–1.13) <0.005 1.09 (1.05–1.14) <0.005 
Gender  
(male = 0) 
2.46 (1.20–5.08) 0.014 3.12 (1.52–6.41) 0.002 5.35 (2.38–12.03) <0.005 
Smoking  
(yes = 1) 
0.73 (0.32–1.65) 0.443 0.65 (0.29–1.46) 0.296 0.31 (0.14–0.69) 0.004 
TATc 1.39 (1.02–1.89) 0.036 1.59 (1.18–2.14) 0.002 1.50 (1.11–2.04) 0.009 
BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; TATc = thrombin-antithrombin 
complex; Total chol, total cholesterol. 
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Furthermore, we found a U-shaped relationship between the potential to generate 
thrombin in vitro and the extent of CAD (Figure 3). Within the group of patients with 
detected CAD, ETP did not correlate to the extent of CAC (r=-0.036, P=0.604), whereas 
it was significantly associated with the degree of CAD (r=0.271, P<0.001). In a 
multivariate logistic regression analysis, when compared to mild CAD, the odds ratios 
associated with moderate and severe CAD were as follows: moderate (OR: 1.02, 95% 
CI 1.00–1.04, P=0.056) and severe (OR: 1.04, 95% CI 1.02–1.06, P<0.001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: U-shaped relationship between ETP and CAD. Bars represent endogenous thrombin 
potential (ETP) values (% of normal pool plasma [NPP]), presented as mean (95% confidence 
interval), stratified according to degree of luminal stenosis. * Statistical significance at the P<0.05 
level when compared with the severe coronary artery disease group. 
 
DISCUSSION 
Major Findings 
The present study examines the relationship between thrombin formation and CAD. In 
a cohort of 295 patients with suspected CAD, we established baseline TATc 
concentrations in plasma and used CCTA imaging to assess the presence and severity 
of coronary atherosclerotic plaques.  
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We found several novel findings of potential clinical relevance. The primary 
observation of this study is that higher TATc levels, the latter considered a sensitive 
marker of thrombin formation in vivo, are independently related to the presence and 
severity of CAD. Net reclassification index analysis showed that incorporation of TATc 
as an additional test did not significantly improves the cardiovascular risk 
stratification capacity of the Framingham risk score. On the other hand, the amount of 
CAC and degree of luminal stenosis were consistently higher with increasing thrombin 
generation, indicating that TATc measurement is useful to detect even mild-grade 
coronary artery calcification or stenosis. In daily practice, TATc concentrations may 
therefore contribute to predict which patients are more likely to have CAD. However, 
as a single biomarker it seems not to have enough power to be a substitute for other 
diagnostic imaging tools like CCTA, magnetic resonance imaging, ultrasound, nuclear 
imaging tests or invasive coronary angiography. 
 The detrimental role of thrombin in atherothrombosis is not a matter of dispute 
[21]. Numerous previously published reports have documented increased rates of 
thrombin synthesis and blood coagulation activation upon the onset of major adverse 
cardiovascular events [22-25].  However, besides being linked to blood 
thrombogenicity and determining the magnitude of thrombus formation upon 
atherosclerotic plaque rupture, thrombin activity per se may be also relevant to the 
pathophysiology of atherosclerosis progression [3,4]. Several research groups have 
attempted to study the relationship between hypercoagulability and atherosclerosis 
progression by assessing ankle brachial pressure index (ABPI) in patients with 
peripheral artery disease [26-28] or evaluating other markers of subclinical 
atherosclerosis such as carotid intima-media thickness (cIMT) [29,30]. Nevertheless, 
these studies do not provide sufficient insight into this problem due to the very 
limited potential of ABPI and cIMT techniques to evaluate CAD.  
 To our knowledge, this is the first study to precisely examine the relationship 
between thrombin generation and the angiographic presence, severity and 
calcification of coronary artery plaques by using CCTA in a population with suspected, 
but not previously established CAD. 
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Enhanced In Vivo Thrombin Generation During Atherogenesis: Potential Clinical 
Implications 
Given the capacity of thrombin to modulate pro-atherogenic actions related to plaque 
destabilization, it becomes important to define what the clinical implications of these 
findings may be. Previously, we have demonstrated that early atherosclerotic lesions 
exert an enhanced pro-coagulant state in comparison to stable advanced ones [5]. This 
phenomenon was partially explained by the increased activity of many key 
coagulation proteins (incl. thrombin), but also by the ability of different vascular cell 
types to synthesize coagulation factors at a local level. There is abundant 
histopathological and experimental evidence to demonstrate that thrombosis occurs 
long before an atherosclerotic plaque ruptures, named as subclinical or “buried” 
thrombosis [8,31,32]. The latter is also considered a potential trigger of plaque 
vulnerability [33-35].  
 Furthermore, blood coagulation is an important component of the host-defence 
system to fight tissue injury and infection [36]. Despite that the exact mechanisms of 
the enhanced TATc formation in blood during atherosclerosis progression remain 
unclear to date, one may speculate that inflammation and coagulation operate in a 
perpetual mode to repair worsening atherosclerosis vascular damage. While oral 
vitamin K-antagonists and antiplatelet therapy remain the cornerstone in primary and 
secondary prevention therapy against atherothrombosis and reduce cardiovascular 
mortality by ~ 30%, numerous clinical trials have failed to account a clear 
atheroprotective effect [3]. In contrast, a few experimental studies have indicated that 
administration of direct thrombin inhibitors in atherosclerotic mice substantially 
inhibits plaque volume and results in plaque stability [7,8]. Given the improved safety 
profile that these novel therapeutic agents show [37,38], it becomes important to 
further investigate the effects of selective thrombin inhibition on plaque volume and 
phenotype determination in patients.  
 Although the CAT method is meant to determine the potential to generate 
thrombin in plasma in vitro, the U-shaped association between ETP and CAD, which 
we demonstrate, may also be of physiological relevance. We have previously reported 
that early atherosclerotic lesions show an increased thrombin generation potential in 
comparison to stable advanced lesions [5].  
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Since the absence of angiographic CAD does not exclude early-stage morphological 
changes of the arterial vessel wall, one may assume that the increased thrombin-
forming capacity in the non-CAD group may be due to first signs of atherosclerotic 
alterations. Thrombin is a central enzyme in the coagulation-inflammation axis and 
represents a potential therapeutic target via which atherosclerosis might be 
modulated.  Moreover, thrombin is well-known for its dual-faceted character in both 
hemostasis and cell signaling [4]. At very low concentrations, thrombin can mediate 
atheroprotective effects such as endothelial barrier protection, reduction in apoptosis 
and trans-endothelial migration of leukocytes, and promote atheroprotective IL-10 
synthesis [39-41]. Some of those actions are dependent on the occupancy of 
endothelial protein C receptor by its natural ligand protein C/activated protein C. 
Hence, the net effect of specific long-term thrombin inhibition remains hard to predict.  
 
Other Findings 
The role of CAC in inducing plaque vulnerability remains controversial. Clinical 
evidence shows that CAC is associated with coronary vasomotor dysfunction and 
reduced myocardial perfusion, even in the absence of luminal stenosis [42]. Novel 
concepts of plaque vulnerability propose that atherosclerotic plaque hypoxia may 
induce angiogenesis, intraplaque hemorrhage and increased risk for rupture [43,44]. 
Besides serving as a precise indicator of the presence and severity of coronary plaque 
burden [45], the Agatston score is considered a better predictor of cardiovascular 
outcomes than the Framingham risk score [46]. In the current study, we present new 
evidence indicating higher thrombin generation as an independent determinant of 
CAC. Despite that the clinical significance of these findings remains to be further 
investigated, a recent ex vivo human study reports that aortic valve calcification can 
be induced through increased thrombin generation [47]. 
 
Study Limitations 
Our study has several limitations. First, we performed a single-center study in which 
all patients were of Western European descent. Second, the patient number was 
relatively small, which limits the options for analyzing the relevance of TATc for 
predicting follow-up events.  
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Moreover, because the relatively healthy population, we did not found a high rate of 
(hard) cardiovascular events, especially not in short term, which is in line with other 
CT-studies. Third, while we screened for angiographic CAD, these findings may reflect 
other existing atherosclerosis settings (carotid or peripheral artery lesions), which we 
did not assess in this study. Therefore, the association between thrombin formation 
and atherosclerosis in other vascular beds remain open. Fourth, the purpose of this 
study was to investigate the association of thrombin formation and CAD and was not 
meant to unravel this complex causal relationship. 
 
CONCLUSION 
Thrombin formation is a useful tool in determining the presence and severity of 
coronary artery disease, but more importantly, may be also involved in the 
pathophysiology of vascular calcification and atherosclerosis progression. 
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BACKGROUND 
Aberrant neutrophil activation occurs during the advanced stages of atherosclerosis. 
Once primed, neutrophils can undergo apoptosis or release neutrophil extracellular 
traps (NETs). This extracellular DNA exerts potent pro-inflammatory, pro-thrombotic 
and cytotoxic properties. The goal of this study was to examine the relationships 
among extracellular DNA formation, coronary atherosclerosis, and the presence of a 
prothrombotic state. 
METHODS 
In a prospective, observational cohort of 282 individuals with suspected coronary 
artery disease (CAD), we examined the severity, extent, and phenotype of coronary 
atherosclerosis using coronary CT-angiography. Double-stranded DNA, nucleosomes, 
citrullinated histone H4 and myeloperoxidase-DNA complexes, considered in vivo 
markers of cell death and NETosis, respectively, were established. We further 
measured plasma markers of coagulation activation and inflammation. 
RESULTS 
Plasma double-stranded DNA, nucleosomes and myeloperoxidase-DNA complexes 
were positively associated with thrombin generation and significantly elevated in 
patients with severe coronary atherosclerosis or extremely calcified coronary arteries. 
Multinomial regression analysis, adjusted for confounding factors, identified high 
plasma nucleosome levels as an independent risk factor of severe coronary stenosis 
(odds ratio: 2.14, 95% confidence interval: 1.26-3.63; P=0.005). Markers of neutrophil 
extracellular traps, such as myeloperoxidase-DNA complexes, predicted the number of 
atherosclerotic coronary vessels and the occurrence of major adverse cardiac events. 
CONCLUSION 
Markers of cell death and NET formation are independently associated with CAD, 
prothrombotic state, and occurrence of adverse cardiac events. These biomarkers 
potentially aid in the prediction of cardiovascular risk in patients with chest pain. 
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INTRODUCTION 
Atherosclerotic plaque disruption and subsequent intraluminal thrombus formation 
are the pathological hallmark of both acute coronary syndrome (ACS), including 
myocardial infarction (MI), and ischemic stroke. Discharge of plaque or thrombotic 
debris from unstable or ulcerated lesions into the circulation is considered the inciting 
cause of arterial thromboembolic complications. Despite all modern advances in 
pharmacological and interventional therapy, atherothrombosis remains one of the 
most significant clinical and burdens worldwide [1]. 
 During the progression of atherosclerosis, circulating cells and cellular 
constituents of the vessel wall become more prone to DNA damage. As a result of 
inadequate DNA repair capacity, processes such as cellular senescence, necrosis and 
apoptosis could prevail, thus inducing extracellular DNA and nucleosome (chromatin 
fragments/histone-DNA complexes) release [2]. There is also a distinct cell death 
pathway, named extracellular trap formation (ETosis), via which neutrophils and 
other cell types, such as monocytes, mast cells, and eosinophils, can dismantle and 
expel nuclear or mitochondrial DNA [3]. This process serves as host defense against 
infection, wherein highly decondensed chromatin threads, carrying both histones and 
granule proteins, are cast out, providing an extracellular scaffold to trap and kill 
microbial pathogens [4]. There is growing evidence showing the relationship among 
different infective pathogens, atherosclerosis progression, and atherothrombosis [5]. 
In addition to the well-established anti-bacterial properties, pioneer experimental 
studies have documented that excessive generation of circulating DNA, nucleosomes 
and histones can be deleterious in several disease settings (eg, sepsis, pulmonary 
inflammation, thrombocytopenia, venous thrombosis, cancer) [6-11]. Given their 
potent cytotoxic and pro-thrombotic effects, extracellular DNA may establish a new 
interface between inflammation and coagulation [12]. 
 There are different imaging techniques to assess the presence and severity of 
coronary atherosclerosis. Coronary computed tomography angiography (CCTA) has 
evolved as a widely available, highly accurate noninvasive diagnostic imaging tool for 
the assessment of coronary artery disease (CAD) [13,14].  
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The primary aim of this study was to determine the associations between circulating 
levels of markers of cell death and NETosis and the severity, extent, and phenotype of 
CCTA-assessed coronary atherosclerosis in individuals with suspected CAD. We 
further sought to examine the relationship between extracellular DNA and 
nucleosomes released in plasma, the presence of a prothrombotic state, and the 
occurrence of major adverse cardiac events during follow-up. 
 
METHODS 
Study Population 
We studied 282 adult patients who were referred from the cardiology outpatient 
department for CCTA because of chest discomfort symptoms, suspected for CAD. All 
patients were referred according to the AHA 2010 Appropriate Use Criteria for 
Cardiac Computed Tomography [15]. Scans were performed in the Maastricht 
University Medical Center between September 2010 and February 2012 as part of the 
diagnostic work-up. Excluded were patients with an acute onset of chest pain 
suspected for an ACS, patients with a known history of CAD, patients with unavailable 
data regarding their cardiac risk profile and patients with an inconclusive CT-scan. A 
history of systemic inflammatory disease, myocarditis, pericarditis, active infection or 
cancer were also exclusion criteria. 
 The Institutional Review Boards and Ethics Committees at Maastricht University 
Medical Center and Boston Children’s Hospital approved the study, and all patients 
and healthy volunteers gave written informed consent. The study was performed in 
compliance with the ethical standards laid down in the 1975 Declaration of Helsinki.  
 
Cardiovascular Risk Profile 
In all patients, traditional cardiovascular risk factors were collected prior to the scan. 
Patients were classified as smokers if they were current smoker. A family history of 
premature CAD was defined as having a first-degree relative with a history of MI or 
sudden cardiac death before the age of sixty. Patients were classified as diabetic or 
hypertensive if diagnosed according to current guidelines [16,17]. 
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Coronary CT-angiography Acquistion 
CCTA was performed using a dual-source CT scanner (Somatom Definition Flash, 
Siemens Medical Solutions, Germany). Scan parameters were: slice collimation 
2x128x0.6 mm, gantry rotation time 280 ms, tube voltage 80-120 kV and temporal 
resolution 75 ms. Patients took 50 mg Metoprolol tartrate (AstraZeneca, The 
Netherlands) orally, 2 hours before CT, unless contra-indicated. An additional dose of 
5-20 mg Metoprolol tartrate was administered intravenously just before the scan 
when the heart rate was >60 beats per minute (bpm). All patients received 0.8 mg 
nitroglycerin (Pohl-Boskamp, Germany) sublingually just prior to CT.  
 First, a native scan was performed to calculate the calcium score by the Agatston 
method. Subsequently, a 20 mL contrast test bolus was injected to assess the time to 
peak in the ascending aorta. CT-angiography was performed by administrating 80-100 
mL of contrast agent (Ultravist 300, Bayer Pharma AG, Germany) in the antecubital 
vein, at a flow rate of 5.4-7.6 mL/s, followed by a 60 mL saline flush (6.0 mL/s) using a 
dual-head power injector (Medrad Inc, PA, USA). The amount of contrast agent, as well 
as the flow rate, were dependent on individual patient characteristics. In patients with 
a stable heart rate <60 bpm, we used a prospectively ECG-gated high pitch spiral 
protocol. In patients with a stable heart rate between 60-90 bpm, a prospectively ECG-
gated sequential axial protocol was used. In patients with higher or irregular heart 
rates, we used a retrospectively ECG-gated helical protocol with dose modulation. 
 
Coronary CT-angiography Analysis 
All scans were independently analyzed by a cardiologist and a radiologist, both 
experienced in reading CCTA’s and blinded to clinical information. In case of 
disagreement, consensus was reached by discussion. The coronary calcium score 
(CCS) was expressed as the Agatston score using dedicated calcium scoring software 
with a threshold of 130 Hounsfield Units (HU). The coronary artery tree was analyzed 
for the presence and severity of CAD according to the 16 coronary segments model of 
the American Heart Association [18], using the source images on the provided 
software (Syngo, Siemens Medical Solutions, Germany). The degree of stenosis was 
visually defined as absent (no luminal stenosis), mild (1-50% luminal stenosis), 
moderate (50-70% luminal stenosis) or severe (>70% luminal stenosis) [19].  
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In addition, an involvement score was calculated by counting all diseased vessel 
segments (irrespective of degree of stenosis), with a score ranging from 0-16 [20]. 
Plaques were categorized as calcified (exclusively content with density >130 HU), 
non-calcified (exclusively content with density <130 HU), or mixed (characteristics of 
both calcified and non-calcified plaques). 
 
Blood Samples, Laboratory Measurements and Platelet-poor Normal Pooled 
Plasma Preparation 
Venous blood was collected in 3.2% citrate (w/v) prior to the exercise ECG testing and 
scan, processed within one hour and samples were stored at -80°C until analysis. 
Double-stranded DNA was established by using Sytox® Green nucleic acid stain 
(S7020, Invitrogen, CA, USA), lambda DNA standard (Quant-iT™ PicoGreen® dsDNA 
Assay Kit, Invitrogen, CA, USA) and a microplate fluorometer (Fluoroskan Ascent, 
Thermo Fisher Scientific Inc., MA, USA) at 485 nm excitation and 538 nm emission 
[21]. Circulating mono- and oligo-nucleosome levels were quantified with an ELISA 
kit, following the manufacturer’s instructions (Cell Death Detection ELISAPLUS, Cat. 
No.11774425001, Roche Diagnostics, IN, USA). Citrullinated histone H4 was identified 
using an in-house capture ELISA method. Briefly, plasma samples were added 
together with a monoclonal mouse anti-histone biotinylated antibody (Component 1) 
to a streptavidin-coated plate (Component 9, Cell Death Detection ELISAPLUS, Clone 
H11-4, Roche Diagnostics). Rabbit polyclonal anti-histone H4 (citrulline 3) (ab81797; 
Abcam Inc., MA, USA) antibody was used as a secondary step. Detection was 
accomplished via incubation with peroxidase-labeled tertiary antibody. 
Myeloperoxidase-DNA (MPO-DNA) complexes and von Willebrand factor (VWF) levels 
were established as previously published [22,23]. Commercially available human 
ELISA kits were used for measuring thrombin-antithrombin complexes (ab108907; 
Abcam Inc., MA, USA) as a sensitive marker of in vivo thrombin formation, and PMN 
Elastase-α1-PI complexes (ab119553; Abcam Inc., MA, USA), soluble (s)CD163 
(Human CD163 Quantikine ELISA Kit DC1630, R&D Systems, MN, USA) and 
CXCL4/platelet factor 4 levels (Human ELISA Kit DY795, R&D Systems, MN, USA) as 
markers of neutrophil, monocyte and platelet activation, respectively.  
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Both platelet-poor normal poor plasma (NPP) and plasma obtained from healthy 
volunteers (separate group, n=10) were used as a reference for all measured markers. 
NPP was prepared at the departments of Hematology and Clinical Chemistry of the 
Maastricht University Medical Center, The Netherlands, by pooling plasma from 85 
healthy volunteers, not using any medication. Venous blood from healthy volunteers 
was collected in 3.2% (w/v) citrate using a 21-gauge needle (Becton, Dickinson and 
Company, UK) or a Winged Infusion Set (Becton, Dickinson and Company, UK) 
through venapuncture. The first 10 ml of venous blood were discarded. Platelet-poor 
plasma was prepared by two centrifugation steps: the first at 2,000x g for 15 minutes 
(min) and the second at 11,000x g for 10 min. Plasma aliquots were snap-frozen in 
liquid nitrogen and stored at –80°C until use. Data are expressed as a fold change over 
NPP (nucleosomes, MPO-DNA complexes, citrullinated histone H4, and VWF) or as 
concentration (ng/ml). 
 
Study Endpoint and Follow-up 
The composite study endpoint was the occurrence of MACE including 
revascularization >60 days following CCTA (percutaneous coronary intervention [PCI] 
or coronary artery bypass grafting [CABG]), ACS and cardiac mortality. ACC/AHA 
guidelines were applied as clinical criteria for the diagnosis of ACS (MI or unstable 
angina requiring hospitalization) [24]. Follow-up was censored in case when 
revascularization was performed within 60 days of CCTA or following the occurrence 
of MACE, as these events are primarily CCTA-driven. Patients were regularly 
examined by their cardiologist. All outpatient visits, emergency room visits and 
hospital admissions were accordingly recorded in the electronic patient records. 
National mortality records were also checked. 
 
Statistical Analysis 
Continuous variables are expressed as median (interquartile range [IQR]), and 
categorical data as numbers (percentages), unless otherwise indicated. Based on the 
distribution characteristics of the data, non-normally distributed continuous variables 
were transformed by using natural logarithm of score plus 1, to account for patients 
with levels less than 1, and to provide improved normality before further analyses. 
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Student’s t-test, Mann-Whitney U test or one-way analysis of variance (ANOVA) test 
including Bonferroni correction were used as appropriate. Pearson's chi-square test 
(χ2) was utilized to detect differences among categorical data (binary or ordinal). 
Pearson or Spearman’s correlation coefficients were established depending on the 
observed data distribution. Multinomial logistic regression analyses were performed 
to identify the factors that independently determine ordinal variables such as the 
degree of luminal stenosis/atherosclerotic plaque severity. Multiple linear regression 
models were created to describe the impact of multiple predictors on a single 
continuous dependent variable. Accordingly, standardized coefficients β were 
calculated as measures of association. Pearson's chi-square test (χ2) and odds ratio 
(OR) with 95% confidence interval (CI) were used to calculate the association 
between dichotomized parameters (via a median split – high versus low levels) and 
outcomes. Standardized coefficient β indicates the change of the dependent variable 
(in SD) that is induced by 1 SD change in the determinant. Receiver operating 
characteristic (ROC) analysis was performed to establish the potential of the tested 
markers to predict MACE and their incremental value when compared to CCTA. Areas 
under the ROC curve (AUROC) were compared using the Hanley and McNeil’s method. 
Statistical analyses were performed using IBM SPSS Statistics 20.0.0 (SPSS Inc., IL, 
USA) and GraphPad Prism 6.0a (GraphPad Software Inc., CA, USA).  
 
RESULTS 
Clinical Characteristics 
We studied 282 patients (183 males; 64.9%) with chest discomfort symptoms, 
suspected for CAD. The median age of the study population was 60 years (min-max 
34-83 years). A total of 245 patients underwent both coronary calcium score scan and 
CCTA. In the remaining 37 patients, CCTA was waived because of an extremely high 
CCS. Baseline characteristics are presented in Table 1. The prevalence of absent, mild, 
moderate and severe CAD was 18.1%, 26.6%, 26.2% and 16.0%, respectively. The 37 
patients (13.1%) who did not undergo CCTA are considered as a separate category 
and are labeled as “Extremely Calcified” in all Tables and Figures. 
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Table 1. Baseline characteristics of the study population, stratified by severity of CAD. 
 
All 
patients 
No    
CAD 
Mild 
CAD 
Moderate 
CAD 
Severe 
CAD 
Extremely 
calcified* 
 
Characteristics (n=282) (n=51) (n=75) (n=74) (n=45) (n=37) P 
Age, median  
(min-max) 
60 
(34-83) 
55 
(36-76) 
60 
(34–78) 
61 
(43–83) 
60 
(37–79) 
64 
(42–78) 
0.004 
Male gender 
183 
(64.9) 
31 
(60.8) 
40 
(53.3) 
46 
(62.2) 
37 
(82.2) 
29 
(78.4) 
0.017 
BMI, kg/m2  
27 
(25–29) 
27 
(25–29) 
26 
(24–29) 
26 
(24–29) 
27 
(26–29) 
27 
(24–30) 
0.595 
Creatinine, μmol/l 
79 
(70–88) 
80 
(70–88) 
78 
(70–88) 
80 
(72–90) 
82 
(70–91) 
76 
(65–88) 
0.558 
Smoking 
70 
(24.8) 
9 
(17.6) 
17 
(22.7) 
18 
(24.3) 
14 
(31.1) 
12 
(32.4) 
0.482 
Diabetes mellitus 
29 
(10.3) 
5 
(9.8) 
9 
(12.0) 
4 
(5.4) 
4 
(8.9) 
7 
(18.9) 
0.565 
Family history of 
premature CAD  
105 
(37.2) 
16 
(31.4) 
35 
(46.7) 
27 
(36.5) 
15 
(33.3) 
12 
(32.4) 
0.280 
VKA therapy 
40 
(14.2) 
3 
(5.9) 
14 
(18.7) 
7 
(9.5) 
10 
(22.2) 
6 
(16.2) 
0.046 
Aspirin therapy 
93 
(33.0) 
15 
(29.4) 
24 
(32.0) 
21 
(28.4) 
19 
(42.2) 
14 
(37.8) 
0.432 
Lipid-lowering 
therapy 
101 
(35.8) 
11 
(21.6) 
30 
(40.0) 
26 
(35.1) 
20 
(44.4) 
14 
(37.8) 
0.087 
Antihypertensive 
therapy 
66 
(23.4) 
5 
(9.8) 
19 
(25.3) 
19 
(25.7) 
12 
(26.7) 
11 
(29.7) 
0.114 
Involvement score 
2 
(0–5) 
0 
(0–0) 
2 
(1–4) 
5 
(2–6) 
5 
(3–7) 
--- <0.001 
Calcified plaques 
1 
(0–3) 
0 
(0–0) 
1 
(0–2) 
2 
(1–4) 
2 
(1–4) 
--- <0.001 
Mixed plaques 
1 
(0–2) 
0 
(0–0) 
0 
(0–1) 
1 
(1–2) 
2 
(0–2) 
--- <0.001 
Non-calcified 
plaques 
0 
(0–1) 
0 
(0–0) 
0 
(0–0) 
0 
(0–1) 
0 
(0–1) 
--- <0.001 
Coronary calcium 
score 
88 
(1–356) 
0 
(0–0) 
44 
(5–102) 
168 
(63–355) 
197 
(46–501) 
1211 
(948–2295) 
<0.001 
Categorical variables are presented as numbers (percentages). Continuous data are expressed as median 
(interquartile range), unless otherwise indicated. BMI, body mass index; CAD, coronary artery disease; CCTA, 
coronary CT-angiography; VKA, vitamin K antagonists. * Patients with no CT-angiographically confirmed 
coronary atherosclerotic plaques as a result of severe coronary calcification. 
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Increased Levels of Circulating dsDNA, Nucleosomes and MPO-DNA Complexes 
in Patients With Severe Coronary Atherosclerosis 
Figure 1A shows individual double-stranded (dsDNA) levels in patients according to 
the presence and severity of CAD. Extreme coronary artery calcification (CAC) is 
shown as a separate group of patients. The release of extracellular dsDNA into the 
circulation was significantly greater in patients with severe CAD (69.59 ng/ml (41.25–
87.75); P=0.003) or abundant CAC (79.37 ng/ml (57.97–92.60); P<0.001) compared 
with individuals with no angiographically detected CAD (50.09 ng/ml (13.91–63.92)). 
Whereas the median fold change in free plasma nucleosomes over NPP was 1.32 
(1.05–2.09) in the no CAD group, there was a significant fold increase in nucleosome 
release into the circulation in both the severe CAD (2.02 [1.55–3.51]; P<0.001) and 
extremely calcified groups (2.36 [1.60–3.41]; P<0.001; Figure 1B). A similar significant 
increase was observed with respect to plasma levels of MPO-DNA, VWF and TAT 
complexes (Figures 1D and 2D and 2E). Circulating levels of polymorphonuclear 
(PMN) elastase-α1-proteinase inhibitor (PI) complexes were significantly higher in 
the extremely calcified patient group (64.21 ng/ml [20.79–91.04]) compared with the 
other groups (P<0.05 for all comparisons; Figure 2A). Citrullinated histone H4, 
CXCL4/platelet factor 4, and sCD163 levels in plasma did not significantly differ 
among the groups (Figures 1C and 2B and 2C). There was a positive association 
between the severity of luminal stenosis, assessed by CCTA, and several plasma 
parameters, including dsDNA (Spearman’s rho=0.316; P<0.001), nucleosomes levels 
(Spearman’s rho=0.271; P<0.001), MPO-DNA (Spearman’s rho=0.215; P=0.001), TAT 
complexes (Spearman’s rho=0.216; P=0.001), and VWF (Spearman’s rho=0.186; 
P=0.003; data not shown). To evaluate the strength of associations between all tested 
variables and CAD severity, we performed multinomial logistic regression, in which a 
main effects model was implemented (Table 2). Increasing TAT formation robustly 
predicted all levels of severity of coronary artery stenosis: mild CAD (OR: 1.36; 95% CI 
1.09–1.68; P=0.005), moderate CAD (OR: 1.31; 95% CI 1.06–1.62; P=0.013) and severe 
CAD (OR: 1.33; 95% CI 1.06–1.68; P=0.015), respectively. In addition to established 
risk factors, such as age and male gender, nucleosome (OR: 2.14; 95% CI 1.26–3.63; 
P=0.005) and VWF (OR: 7.31; 95% CI 1.33–40.07; P=0.022) levels independently 
predicted the presence of severe coronary stenosis,  (Table 2). 
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Figure 1. Circulating DNA, nucleosome fragments and markers of neutrophil extracellular traps 
according to the presence and severity of coronary artery disease (CAD). Patients were divided in 
categories, based on the severity of CAD, as assessed with coronary computed tomographic 
angiography (CCTA). Patients who did not undergo CCTA because of a high calcium score were 
considered as a separate category (Extremely Calcified). A total of four markers were measured in 
all patients (panels A-D). Shaded area demonstrates the range of the measured markers in plasma 
from healthy controls (n=10). Normal pooled plasma (from n=85 healthy volunteers) is indicated 
by a horizontal dotted line. * P<0.05; ** P<0.01; *** P<0.001. dsDNA indicates double stranded 
DNA.  
 
 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Plasma levels of markers of leukocyte, platelet, endothelial and coagulation activation 
according to the presence and severity of coronary artery disease (CAD). Patients were divided in 
categories, based on the severity of CAD, as assessed with coronary computed tomographic 
angiography (CCTA). Patients who did not undergo CCTA because of a high calcium score were 
considered as a separate category (Extremely Calcified). A total of five markers were measured in 
all patients (panels A-E). Shaded area demonstrates the range of the measured markers in plasma 
from healthy controls (n=10). Normal pooled plasma (from n=85 healthy volunteers) is indicated 
by a horizontal dotted line.* P<0.05; ** P<0.01; *** P<0.001. MPO, myeloperoxidase; PMN, 
polymorphonuclear; α1-PI, alpha 1-proteinase inhibitor; PF4, platelet factor 4; TAT, thrombin-
antithrombin; VWF, von Willebrand factor. 
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Table 2. Multinomial logistic regression models for CAD severity as dependent variable. 
 Multinomial logistic regression: Main effects model 
 
Mild CAD 
Stenosis: 1–50 % 
Moderate CAD 
Stenosis: 50–70 % 
Severe CAD 
Stenosis: >70% 
Variable OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Reference, no CAD 
(stenosis 0%) 
1.0 (Reference) 1.0 (Reference) 1.0 (Reference) 
Age 
1.04 
(0.99–1.10) 
0.097 
1.09 
(1.03–1.14) 
0.002 
1.07 
(1.01–1.14) 
0.030 
Gender  (male = 1) 
1.07 
(0.37–3.05) 
0.904 
1.49 
(0.51–4.38) 
0.464 
5.85 
(1.47–23.34) 
0.012 
Body Mass Index 
0.94 
(0.84–1.05) 
0.250 
0.99 
(0.89–1.11) 
0.885 
1.06 
(0.93–1.20) 
0.393 
Creatinine 
1.00 
(0.97–1.04) 
0.826 
1.00 
(0.97–1.04) 
0.817 
0.99 
(0.95–1.03) 
0.614 
Smoking  (yes = 1) 
1.72 
(0.61–4.89) 
0.306 
1.82 
(0.61–5.38) 
0.280 
2.69 
(0.78–9.24) 
0.116 
Family history of 
CAD (yes = 1) 
2.44 
(1.02–5.82) 
0.045 
1.89 
(0.76–4.65) 
0.168 
1.58 
(0.52–4.84) 
0.420 
Diabetes mellitus  
(yes = 1) 
1.13 
(0.28–4.65) 
0.862 
0.44 
(0.09–2.11) 
0.306 
0.82 
(0.15–4.60) 
0.823 
dsDNA 
0.99 
(0.97–1.00) 
0.058 
1.01 
(0.99–1.02) 
0.269 
1.01 
(1.00–1.03) 
0.094 
Nucleosomes 
1.02 
(0.62–1.68) 
0.933 
1.41 
(0.88–2.27) 
0.153 
2.14 
(1.26–3.63) 
0.005 
Citrullinated  
histone H4 
0.74 
(0.33–1.66) 
0.469 
0.85 
(0.44–1.66) 
0.638 
1.04 
(0.50–2.14) 
0.925 
MPO–DNA  
complexes 
1.04 
(0.20–5.37) 
0.962 
1.40 
(0.28–7.00) 
0.682 
1.74 
(0.28–10.78) 
0.554 
TAT complexes 
1.36 
(1.09–1.68) 
0.005 
1.31 
(1.06–1.62) 
0.013 
1.33 
(1.06–1.68) 
0.015 
VWF 
1.44 
(0.39–5.32) 
0.582 
1.78 
(0.48–6.67) 
0.390 
7.31 
(1.33–40.07) 
0.022 
PMN elastase–α1–
PI complexes 
0.99 
(0.97–1.00) 
0.146 
0.99 
(0.97–1.01) 
0.207 
0.99 
(0.97–1.01) 
0.229 
sCD163 
1.00 
(1.00–1.00) 
0.581 
1.00 
(1.00–1.00) 
0.695 
1.00 
(1.00–1.00) 
0.399 
CXCL4/PF4 
1.11 
(0.76–1.62) 
0.577 
0.95 
(0.64–1.42) 
0.808 
0.77 
(0.47–1.27) 
0.312 
VKA therapy  
(yes = 1) 
2.59 
(0.59–11.31) 
0.205 
0.93 
(0.19–4.54) 
0.933 
3.62 
(0.67–19.56) 
0.135 
Lipid-lowering 
therapy (yes = 1) 
2.34 
(0.87–6.30) 
0.092 
1.43 
(0.52–3.92) 
0.485 
1.54 
(0.48–4.92) 
0.470 
Antihypertensive 
therapy (yes = 1) 
1.90 
(0.59–6.15) 
0.282 
2.24 
(0.68–7.33) 
0.184 
2.84 
(0.75–10.80) 
0.126 
Aspirin therapy  
(yes = 1) 
1.02 
(0.41–2.51) 
0.973 
0.72 
(0.28–1.85) 
0.494 
1.93 
(0.60–6.18) 
0.266 
dsDNA, double stranded DNA; MPO, myeloperoxidase; PF4, platelet factor 4; α1–PI, α1–proteinase 
inhibitor; PMN, polymorphonuclear; VWF, von Willebrand factor; VKA, vitamin K antagonists. 
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Associations Between Markers of Cell Death and NETosis and the Extent and 
Phenotype of Coronary Atherosclerosis 
In all patients who underwent CCTA, we were able to assess the number of coronary 
artery segments affected by atherosclerosis, the degree of luminal stenosis and 
characteristics with respect to plaque morphology. In this population, we found a 
significant positive association between the number of diseased coronary artery 
segments and plasma dsDNA (Spearman’s rho=0.242; P<0.001), nucleosomes 
(Spearman’s rho=0.219; P=0.001), MPO-DNA (Spearman’s rho=0.337; P<0.001), TAT 
complexes (Spearman’s rho=0.330; P<0.001), and VWF levels (Spearman’s rho=0.155; 
P=0.015; data not shown). Using a multiple linear regression model (Table 3) and 
adjusting for various confounding factors, we examined the independent relationships 
between candidate determinants and the extent of coronary atherosclerosis in all 
patients who underwent CCTA. Standardized regression coefficients β are reported in 
Table 3. The involvement score (number of affected coronary segments) was mainly 
determined by male gender, statin use, elevated plasma nucleosomes (β=0.140; 
P=0.026), MPO-DNA (β=0.134; P=0.041) and TAT levels (β=0.164; P=0.016). Age, 
family history of premature CAD, and dsDNA remained of borderline statistical 
significance. With respect to phenotype of coronary plaques, nucleosomes (β=0.152; 
P=0.022) and TAT complexes (β=0.151; P=0.036), but also age, male gender, and 
family history of premature CAD, were found independently associated with the 
number of calcified plaques, quantified by CCTA (Table 3). We also observed an 
independent relationship among circulating dsDNA (β=0.201; P=0.005), TAT 
complexes (β=0.176; P=0.015), CXCL4/platelet factor 4 (β=0.128; P=0.042), male 
gender, and the number of mixed plaques. Free plasma dsDNA (β=0.224; P=0.003), 
MPO-DNA complexes (β=0.150; P=0.040) and VWF (β=0.152; P=0.022) were further 
associated with a non-calcified coronary atherosclerotic plaque phenotype. 
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Table 3. Multiple linear regression models for the extent and CAD phenotype as dependent 
variables. 
 
Number of 
segments with CAD 
Number of 
calcified lesions 
Number of 
mixed lesions 
Number of non-
calcified lesions 
Determinants β P  β P  β P  β P  
Age 0.128 0.052 0.154 0.027 0.103 0.138 -0.124 0.089 
Gender (Male = 1) 0.220 0.002 0.196 0.009 0.163 0.030 0.014 0.856 
Body Mass Index 0.060 0.312 0.064 0.309 0.004 0.948 0.045 0.497 
Creatinine -0.015 0.827 -0.007 0.920 0.001 0.989 -0.040 0.602 
Smoking (Yes = 1) 0.068 0.258 0.049 0.436 0.054 0.395 0.028 0.670 
Family history of 
CAD (Yes = 1) 
0.101 0.097 0.128 0.045 0.015 0.812 -0.002 0.979 
Diabetes mellitus  
(Yes = 1) 
-0.037 0.525 -0.025 0.686 -0.008 0.894 -0.059 0.362 
dsDNA 0.123 0.065 -0.033 0.644 0.201 0.005 0.224 0.003 
Nucleosomes 0.140 0.026 0.152 0.022 0.046 0.487 0.030 0.665 
Citrullinated  
histone H4 
-0.080 0.181 -0.092 0.147 -0.051 0.423 0.041 0.542 
MPO–DNA  
complexes 
0.134 0.041 0.109 0.117 0.036 0.602 0.150 0.040 
TAT complexes 0.164 0.016 0.151 0.036 0.176 0.015 -0.101 0.182 
VWF 0.088 0.141 0.007 0.915 0.098 0.122 0.152 0.022 
PMN elastase–α1- 
PI complexes 
0.051 0.425 0.061 0.369 0.032 0.636 -0.031 0.660 
sCD163 -0.065 0.274 -0.015 0.805 -0.065 0.303 -0.095 0.149 
CXCL4/PF4 0.005 0.938 -0.078 0.208 0.128 0.042 0.018 0.782 
VKA therapy  
(Yes = 1) 
0.069 0.263 0.102 0.121 -0.021 0.751 0.016 0.816 
Lipid-lowering 
therapy (Yes = 1) 
0.145 0.021 0.094 0.156 0.111 0.095 0.102 0.142 
Antihypertensive 
therapy (Yes = 1) 
0.020 0.736 0.029 0.646 0.010 0.876 -0.022 0.741 
Aspirin therapy  
(Yes = 1) 
-0.007 0.910 -0.018 0.786 -0.002 0.977 0.027 0.694 
Standardized coefficient β indicates the change of the dependent variable (in SD) that is induced by 1 SD 
change in the determinant. Abbreviations see Table 2. 
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Extracellular DNA Is an Independent Determinant of a Pronounced 
Prothrombotic State 
Because extracellular DNA, nucleosomes and neutrophil extracellular traps (NETs) 
have been functionally implicated in a number of prothrombotic mechanisms both in 
vitro and in vivo [3,12,25], we investigated the associations between extracellular 
dsDNA and TAT and VWF levels, which are considered well-established 
prothrombotic markers in various clinical conditions, including atherosclerosis and 
atherothrombosis [26]. In the entire study population, significant positive correlations 
were observed between TAT formation and dsDNA (Spearman’s rho=0.367; P<0.001), 
nucleosomes (Spearman’s rho=0.195; P=0.001), citrullinated histone H4 (Spearman’s 
rho=0.231; P<0.001), MPO-DNA complexes (Spearman’s rho=0.322; P<0.001), PMN 
elastase-α1-PI complexes (Spearman’s rho=0.274; P<0.001) and VWF (Spearman’s 
rho=0.127; P=0.033; data not shown). In a multiple linear regression model, after 
accounting for various confounding factors (Table 4), dsDNA (β=0.306; P<0.001), 
MPO-DNA (β=0.230; P<0.001) and PMN elastase-α1-PI complexes (β=0.177; P=0.003) 
independently predicted thrombin generation.  
 Plasma levels of VWF showed significant positive associations with dsDNA 
(Spearman’s rho=0.171; P=0.004), nucleosomes (Spearman’s rho=0.132; P=0.026) 
and citrullinated histone H4 levels (Spearman’s rho=0.322; P<0.001). As shown in 
Table 4, VWF levels were independently determined by both dsDNA (β=0.146; 
P=0.037) and CXCL4/platelet factor 4 (β=0.200; P=0.001) levels in plasma. Overall, 
there seems to be a strong relationship among extracellular DNA generation (dsDNA), 
markers of NETosis (MPO-DNA complexes; citrullinated histone H4) and the presence 
of a prothrombotic state, as determined by the increase in TAT and VWF levels (Fig 3). 
 
High Baseline Levels of Circulating DNA, Nucleosomes and Markers of NETs Are 
Significantly Associated With the Occurrence of Major Adverse Cardiac Events 
During a median total follow-up of 545 days (interquartile range 446–666), 27 (9.7%) 
patients suffered from MACEs (11 PCIs, 10 CABGs, 4 ACS, 2 cardiac deaths). MACEs 
occurred more frequently in men (92.6%), with a median age of 59 years (min-max: 
42-76), who were overweight (66.7%) and who were less often diabetic (14.8%).  
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Table 4. Multiple linear regression models: prothrombotic markers as dependent variables. 
 TAT complexes Von Willebrand Factor 
Determinants β P value β P value 
Age 0.050 0.408 -0.005 0.937 
Gender (Male = 1) -0.008 0.902 0.056 0.432 
Body Mass Index 0.020 0.713 -0.064 0.296 
Creatinine -0.088 0.154 -0.032 0.654 
Smoking (Yes = 1) -0.027 0.628 0.052 0.409 
Family history of CAD (Yes = 1) 0.029 0.592 -0.057 0.358 
Diabetes mellitus (Yes = 1) -0.022 0.685 0.025 0.686 
dsDNA 0.306 <0.001 0.146 0.037 
Nucleosomes 0.041 0.486 0.056 0.398 
Citrullinated histone H4 0.037 0.499 0.084 0.174 
MPO–DNA complexes 0.230 <0.001 0.032 0.634 
TAT complexes --- -0.027 0.699 
Von Willebrand Factor -0.021 0.699 --- 
PMN elastase–α1-PI complexes 0.177 0.003 0.018 0.788 
sCD163 0.069 0.197 0.083 0.176 
CXCL4/PF4 0.050 0.351 0.200 0.001 
VKA therapy (Yes = 1) 0.001 0.992 0.094 0.150 
Lipid-lowering therapy (Yes = 1) -0.041 0.463 -0.039 0.546 
Antihypertensive therapy (Yes = 1) 0.056 0.317 0.073 0.246 
Aspirin therapy (Yes = 1) 0.032 0.573 0.045 0.495 
Standardized coefficient β indicates the change of the dependent variable (in SD) that is induced by 1 SD 
change in the determinant. --- = The parameter was excluded from the model. Abbreviations, see Table 2. 
 
Two patients died because of non-cardiac reasons and were excluded from the 
outcome analyses (Table 5). Significantly elevated baseline levels of circulating dsDNA 
(P=0.0016), nucleosomes (P=0.0013), MPO-DNA (P=0.0169), TAT (P=0.0042) and 
PMN elastase-α1-PI complexes (P=0.0011) were observed in the group who suffered a 
MACE compared with the event-free group (Figure 4). 
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Figure 3. Relationship among extracellular DNA generation, NETosis markers, and a 
prothrombotic state. Panels A and B show the relationship among levels of double-stranded DNA 
(dsDNA), citrullinated histone H4, and mean thrombin-antithrombin (TAT) levels (panel A) or 
mean von Willebrand factor (VWF) levels (panel B), respectively. Panels C and D show the 
relationship among levels of myeloperoxidase (MPO)-DNA, citrullinated histone H4, and mean TAT 
levels (panel C) or mean VWF levels (panel D). Elevated levels of both extracellular DNA 
generation (dsDNA) and NETosis markers (MPO-DNA complexes; citrullinated histone H4) are 
associated with the presence of a prothrombotic state, defined by increased TAT and VWF levels. 
NPP indicates normal pooled plasma; and T indicates tertile. 
 
To gain further insight into the predictive value of low versus high levels of the tested 
markers, we dichotomized all continuous predictor variables into two groups by using 
a median split. High baseline values (≥ total group median) of dsDNA (OR: 3.12; 95% 
CI 1.27–7.63; P=0.013), nucleosomes (OR: 2.59; 95% CI 1.09–6.14; P=0.030), MPO-
DNA (OR: 3.53; 95% CI 1.38–9.03; P=0.009), TAT (OR: 2.59; 95% CI 1.09–6.14; 
P=0.030) and PMN elastase-α1-PI complexes (OR: 3.22; 95% CI 1.31–7.88; P=0.011) 
were significantly associated with the occurrence of MACEs (Table 6). 
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Table 5. Major adverse events. 
Major adverse cardiac events Patients 
Percutaneous coronary intervention (PCI)  11 
Coronary artery bypass grafting (CABG) 10 
Acute coronary syndrome (ACS) 4 
Cardiac death 2 
  
Major adverse non-cardiac events  
Cerebrovascular death 1 
Death due to cancer 1 
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Figure 4 (previous page). All tested plasma markers according to the occurrence of MACEs. 
dsDNA, double stranded DNA; MPO, myeloperoxidase; NPP, normal pooled plasma; PF4, platelet 
factor 4; α1-PI, alpha 1-proteinase inhibitor; PMN, polymorphonuclear; TAT, thrombin–
antithrombin; VWF, von Willebrand factor. * P<0.05; ** P<0.01; *** P<0.001. 
 
Table 6. Dichotomized plasma markers (high versus low values). 
Predictors Relative risk OR (95% CI) P value 
dsDNA  3.12 (1.27-7.63) 0.013 
Nucleosomes 2.59 (1.09-6.14) 0.030 
Citrullinated H4 1.51 (0.67-3.43) 0.324 
MPO-DNA complexes 3.53 (1.38-9.03) 0.009 
TAT complexes 2.59 (1.09-6.14) 0.030 
VWF 1.66 (0.73-3.77) 0.225 
PMN elastase–α1–PI complexes 3.22 (1.31-7.88) 0.011 
sCD163 1.49 (0.67-3.34) 0.333 
CXCL4/PF4 0.51 (0.23-1.17) 0.111 
High values ≥ total group median, while low values < total group median. Abbreviations, 
see Table 2. 
 
In addition, we investigated CAD characteristics in all 245 patients that underwent 
CCTA. Patients developing MACE had a significantly higher involvement score: 5.7 vs. 
2.8, P<0.001. These patients showed significantly more mixed plaques (1.9±1.4 versus 
0.9±1.2; P=0.002), as well as more calcified plaques (3.2±2.5 versus 1.6±2.0; P=0.003). 
As expected, ROC analysis indicated that CT score (stenosis >70%) is very useful to 
discriminate between patients with or without MACEs (AUROC: 0.83; 95% CI 0.71–
0.95; P<0.001). In comparison, measurement of dsDNA, nucleosomes, MPO-DNA, TAT 
and PMN elastase-α1-PI complexes also showed the potential to significantly predict 
MACE during follow-up (AUROC: 0.76; 95% CI 0.68–0.89; P<0.001). There was no 
significant difference between the predictive capacity of CCTA and the 
aforementioned plasma biomarkers (difference between AUROCs, 0.04; P=0.571).  
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However, the addition of these biomarkers to CT score (stenosis >70%) improved its 
predictive value, whereas the difference between the AUROCs as compared to CT 
score alone indicated a trend toward statistical significance (AUROC, 0.92; 95% CI 
0.87–0.96; P<0.001; difference between AUROCs, 0.09; P=0.086). 
 
Table 7. One-way analysis of variance (ANOVA) and multiple comparisons. 
Dependent variable sCD163 – Tertiles P value 
dsDNA 
T1 T2 1.000 
 T3 0.157 
Nucleosomes 
T1 T2 1.000 
 T3 1.000 
Citrullinated histone H4 
T1 T2 1.000 
 T3 0.148 
MPO–DNA complexes 
T1 T2 1.000 
 T3 1.000 
  
Dependent variable PMN Elastase – Tertiles P value 
dsDNA 
T1 T2 1.000 
 T3 <0.001 
Nucleosomes 
T1 T2 0.222 
 T3 0.002 
Citrullinated histone H4 
T1 T2 1.000 
 T3 0.214 
MPO–DNA complexes 
T1 T2 1.000 
 T3 <0.001 
Statistical significance at the P<0.05 level (post-hoc Bonferroni multiple 
comparison test). dsDNA, double stranded DNA; MPO, myeloperoxidase; T, tertile. 
 
Both neutrophil and monocyte hyperactivation have been demonstrated to play a key 
role in the initiation of prothrombotic responses [27].  
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To provide a better understanding on the potential origin of extracellular DNA traps, 
we performed additional analyses by stratifying all cell death and NETs markers by 
tertiles of either plasma PMN elastase-α1-PI complexes or sCD163, considered 
sensitive markers of neutrophil and monocyte activation, respectively. Although 
extracellular DNA might originate from different cell types, here we focused on 
neutrophils and monocytes because of their significant role in the pathogenesis of 
atherosclerosis, their involvement in ETosis, but also due to the fact that neutrophils 
are the most predominant white blood cell type in circulation. Our data suggests that 
the increase in plasma nucleosomes and MPO-DNA complexes is strictly specific to 
neutrophil activation and thus might be considered potential markers of NET 
formation (Table 7). Platelet activation, as reflected by CXCL4/platelet factor 4 levels, 
showed a weak positive correlation with citrullinated histone H4 only (Spearman’s 
rho=0.138; P=0.020). Significant positive associations were observed between 
neutrophil activation marker PMN elastase-α1-PI complexes and dsDNA (Spearman’s 
rho=0.257; P<0.001), nucleosomes (Spearman’s rho=0.209; P<0.001) and MPO-DNA 
complexes (Spearman’s rho=0.240; P<0.001). 
 
DISCUSSION 
The current cross-sectional observational prospective clinical study is the first to 
examine the relationship among plasma markers of extracellular DNA, circulating 
nucleosomal fragments, NET formation and the severity, extent, and phenotype of 
CCTA-defined coronary atherosclerosis in individuals with suspected CAD.  
 The principal finding in this study is the independent association between 
increased levels of circulating markers of cell death and NETosis and the severity and 
extent of CAD in patients with chest discomfort symptoms. Furthermore, we provide 
new data of potential clinical relevance, which demonstrate an independent 
relationship between extracellular DNA generation and the presence of a 
prothrombotic state in patients with CAD. Increased baseline levels of circulating 
dsDNA, nucleosomes and markers of NETosis were also significantly associated with 
the occurrence of MACEs during follow-up. Importantly, these biomarkers could 
potentially aid in the prediction of MACE in patients with chest discomfort. 
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Endothelial injury or dysfunction, driven by distinct hemodynamic, oxidative, 
biochemical and proinflammatory insults (eg, smoking, perturbed lipid metabolism, or 
hypertension), precedes the onset of atherosclerosis [28]. In response to tissue injury, 
the host defense system promotes wound healing by triggering a variety of 
inflammatory and hemostatic reactions, designed to restore the homeostatic 
equilibrium [29]. A state of persistent activation and cross talk between inflammation 
and coagulation can result either in exacerbation of tissue injury (eg, atherosclerotic 
plaque progression) or thrombosis [30,31]. In fact, chronic inflammation and 
hypercoagulability are considered integral mechanisms in the pathogenesis of both 
atherosclerosis and thrombosis [30,32]. A complex network of cellular and molecular 
interactions, bridging innate and adaptive immunity in atherogenesis, orchestrate all 
proinflammatory, fibroproliferative and prothrombotic changes in the arterial vessel 
wall [33,34]. Neutrophils are the most abundant white blood cell type responsible for 
the early response to tissue injury. Neutrophils migrate to the site of tissue damage 
and extrude decondensed chromatin threads (NETs), consisting of nuclear histones 
and azurophilic granule proteins, such as MPO and PMN elastase [4]. Histone 
degradation and citrullination, driven by PMN elastase and peptidylarginine 
deiminase 4, respectively, are key processes, which comprise the cornerstone of 
chromatin decondensation and subsequent NET formation [3,35]. 
 Histological studies have reported the presence of NETs within the luminal portion 
of human atherosclerotic vessels, but also in coronary thrombosuction specimens 
obtained from patients after acute myocardial infarction [36,37]. There are various 
potential pathways via which extracellular DNA traps might induce either initiation or 
exacerbation of atherosclerosis. Extracellular DNA represents a link between the 
innate and adaptive immune systems and may aggravate atherosclerosis through 
activation of T lymphocytes and antigen-presenting cells [38,39]. The chronic 
inflammatory atherosclerotic environment can induce neutrophil priming, resulting in 
enhanced neutrophil activation and MPO-dependent respiratory burst [40]. Elevated 
MPO levels independently predict endothelial dysfunction, the risk of CAD and ACS in 
patients [41]. Here, we demonstrate an independent association among increased 
MPO-DNA levels, a marker of NETosis, and the extent of CAD and presence of a 
hypercoagulable state.  
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Neutrophils can undergo apoptosis during inflammation. Macrophages play a crucial 
role in the clearance of apoptotic neutrophils, thus resulting in resolution of 
inflammation. This process is also known as efferocytosis. In patients with ACS, 
delayed neutrophil apoptosis is a commonly observed phenomenon [42,43]. 
Inflammation can be exacerbated as a result of overloaded efferocytosis [44]. 
Interestingly, extracellular histones (H3 and H4) significantly impair the clearance of 
apoptotic neutrophils by macrophages, and activated protein C, known to cleave 
histones, restores the efferocytotic capacity of macrophages [6,45]. Hence, 
extracellular DNA trap formation may have deleterious effects by aggravating chronic 
inflammation during atherosclerosis progression. There are several clinical studies 
demonstrating a significant increase in circulating deoxyribonuclease I (DNase I) 
levels during acute coronary events [46,47]. Since DNase I is an endonuclease, which 
selectively cleaves DNA and contributes to extracellular chromatin degradation, this 
may be considered additional indirect evidence, suggesting a role for extracellular 
DNA in the pathogenesis of myocardial infarction [48]. Recent experimental studies 
show that administration of DNase I prevents thrombus formation in mouse models of 
deep vein thrombosis [8,49]. 
 Extracellular DNA and histones also exert powerful prothrombotic effects in vitro 
and in vivo [3]. Nucleosomes and histones can promote thrombin formation through 
the activation of either extrinsic or intrinsic coagulation pathways and through 
platelet activation [7,12,49-51].  
In addition, excess of extracellular histones can affect the function of the anticoagulant 
protein C pathway by inhibiting protein C activation, thus resulting in enhanced 
thrombin formation [52]. PMN elastase, which is an integral component of NETs, 
cleaves tissue factor pathway inhibitor and promotes thrombin generation in a factor 
Xa-dependent manner [53]. To our knowledge, this is the first clinical study to 
demonstrate an independent association among increased extracellular DNA 
generation, TAT formation, and VWF release in cardiac patients. We show that 
steadily increasing TAT levels are also independently linked to an increased degree of 
coronary artery stenosis and plaque extent, also comparable to our previous findings 
[54]. Thrombin is a key molecule that is important to hemostasis, and also to 
atherogenesis [30,55,56]. Hence, one can postulate that circulating DNA, chromatin, 
and possibly NETs might exacerbate atherosclerosis via coagulation activation.  
 
131 
Our data demonstrated that increased levels of plasma nucleosomes, which indicate 
ongoing chromatin decondensation, predicted the number of calcified plaques and 
were not associated with any other plaque phenotype. However, it seems that other 
cell death markers, such as dsDNA, were not phenotype specific. None of the markers 
more specific to NET formation (citrullinated histone H4 and MPO-DNA complexes) 
were independently associated with an increased risk of any type of CAD. MPO-DNA 
complexes seemed a useful tool only in patients with confirmed CAD, as they 
predicted the extent and number of non-calcified lesions [57,58]. 
 Not all studied patients underwent CCTA. In 37 patients the coronary calcium 
score scan already revealed an extremely high calcium score. In those patients, CCTA 
was waived because of the very high a priori chance for a nondiagnostic test result. 
Predominantly as a result of blooming artifacts, reliable estimation of the severity of 
the coronary plaque becomes greatly impaired. Furthermore, it is known that 
blooming can lead to overestimation of the severity of CAD [59]. We know at least that 
these patients have calcified plaques, but it is conceivable and even plausible that they 
also have mixed and non-calcified plaques. However, we were not able to prove this 
because CCTA was waived. Despite the fact that we can not exactly say to what extent 
these patients have obstructive CAD, it is known that a high calcium score is 
associated with an increased risk for severe stenosis and cardiovascular events. In 
fact, it is even considered to be a better predictor than the Framingham risk score 
[60]. Instead of excluding these patients, we therefore considered them as a separate 
high-risk group.  
 Our data indicate that measurement of biomarkers, such as dsDNA, nucleosomes, 
MPO-DNA, TAT and PMN elastase-α1-PI complexes, may be useful for the evaluation 
of patients with chest discomfort. Although the addition of these five biomarkers to CT 
score did not significantly improve risk stratification, we observed a trend in 
increasing the prediction capacity of traditional CCTA. However, one should consider 
that CT score provides significant prognostic information, thus it might be difficult to 
establish an incremental value for any plasma biomarker measured.  Larger studies 
with a longer follow-up are needed to better assess the sensitivity and specificity of all 
tested biomarkers to identify vulnerable plaques in patients with coronary 
atherosclerosis, as well as to study their potential to predict the occurrence of MACEs.  
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It also remains of interest to further test whether levels of the different markers 
predict adverse outcomes within a single CAD phenotype, as determined by CCTA. 
Because some of these tests (eg, dsDNA) are inexpensive and technically simple to 
determine, a broader use might be considered even before CCTA, if they prove useful 
as diagnostic and prognostic tools in patients suspected of having CAD.  
 The relatively short-term follow-up may be considered a limitation, which resulted 
in smaller numbers of recorded composite end points. Although not established in this 
cohort of patients, it remains of interest to also study the relationship among 
extracellular DNA and chromatin release, NETosis, and neutrophil counts. High 
neutrophil counts are considered a potent inflammatory marker for risk stratification 
in patients with coronary atherosclerosis. Although we found independent 
associations between elevated markers of cell death and NETosis and the occurrence 
of MACEs, it is too early yet to use these markers in daily clinical practice. Longitudinal 
prospective studies will unravel their prognostic power, whereas mechanistic studies 
are needed to establish whether there is a causal relationship between NET formation 
and atherosclerotic plaque progression. 
 
CONCLUSION 
Our report provides evidence demonstrating that elevated levels of markers of 
extracellular DNA, chromatin, and NETosis are independently associated with the 
severity, extent and phenotype of coronary atherosclerosis and with the occurrence of 
MACEs. Our data reveal potential clinical application of these biomarkers to predict 
cardiovascular risk in patients. Further experimental and clinical studies are 
necessary to explore the involvements of NETs in the pathogenesis of atherosclerosis 
and atherothrombosis.  
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BACKGROUND 
Vitamin K-antagonists (VKA) are treatment of choice and standard care for patients 
with venous thrombosis and thromboembolic risk. In experimental animal models as 
well as humans, VKA have been shown to promote medial elastocalcinosis. As vascular 
calcification is considered an independent risk factor for plaque instability, we here 
investigated the effect of VKA on coronary calcification in patients and on calcification 
of atherosclerotic plaques in ApoE-/- mice. 
METHODS 
A total of 266 patients (133 VKA users and 133 gender and Framingham risk score 
matched non-VKA users) underwent 64-slice MDCT to assess the degree of coronary 
artery disease (CAD). ApoE-/- mice (10 weeks) received a Western type diet (WTD) for 
12 weeks, after which mice were fed a WTD supplemented with vitamin K1 (VK1, 1.5 
mg/g) or vitamin K1 and warfarin (VK1&W; 1.5 mg/g & 3.0 mg/g) for 1 or 4 weeks, 
after which mice were sacrificed. 
RESULTS 
VKA-users developed significantly more calcified coronary plaques as compared to 
non-VKA users. Warfarin significantly increased frequency and extent of vascular 
calcification in ApoE-/- mice. Also, plaque calcification comprised microcalcification of 
the intimal layer. Furthermore, warfarin treatment decreased plaque expression of 
calcification regulatory protein carboxylated matrix Gla-protein, increased apoptosis 
and, surprisingly outward plaque remodeling, without affecting overall plaque 
burden. 
CONCLUSION 
VKA use is associated with coronary artery plaque calcification in patients with 
suspected CAD and causes changes in plaque morphology with features of plaque 
vulnerability in ApoE-/- mice. Our findings underscore the need for alternative 
anticoagulants that do not interfere with the vitamin K cycle. 
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INTRODUCTION 
Vitamin K antagonists (VKA) are the most frequently prescribed drugs to control 
blood coagulation of patients with thrombosis and patients at risk of thromboembolic 
events. VKA block the vitamin K epoxide reductase complex that drives conversion of 
certain glutamate residues of vitamin K-dependent coagulation factors into γ-
carboxyglutamic acid (Gla)-residues [1]. VKA therapy may have undesired side-effects 
in addition to risk of bleeding because a number of proteins outside the coagulation 
system also require γ-glutamylcarboxylation to become biologically active [2].  
 Matrix Gla-protein  (MGP) is a vitamin K-dependent protein not related to blood 
coagulation but also affected by VKA [3]. Animal models showed that MGP is a strong 
inhibitor of calcification of arterial vessel wall and cartilage [4]. In arteries, MGP acts 
as a local inhibitor of media calcification [5,6]. Its inhibitory mechanism is still not 
fully understood but involves inhibition of bone morphogenetic protein 2 and 4 (BMP-
2 and -4) [7,8], suppression of osteochondrogenic transdifferentiation of vascular 
smooth muscle cells [9] and direct inhibition of calcium-crystal growth [10,11]; in all 
cases MGP requires vitamin K-dependent γ-carboxylation [10]. Concordantly, clinical 
studies and case reports revealed that VKA treatment is associated with arterial 
calcification and upregulation of uncarboxylated MGP (ucMGP) [12-15].  
 MGP expression is increased in human atherosclerotic lesions [16] and vascular 
smooth muscle cells (VSMCs) are predominantly involved in intimal calcification [17]. 
Overexpression of MGP in the apoE-/- mouse model of atherosclerosis reduced both 
intimal and medial calcification of atherosclerotic plaques whereas gene deletion of 
MGP in apoE-/- mice accelerated intimal calcification of plaques [18]. BMP-2 transgenic 
apoE-/- mice displayed increased calcification of intima of atheromatous lesions, 
suggesting a key role for MGP in suppressing BMP-2 induced vascular calcification 
[19]. Since intimal calcification of atherosclerotic plaques is considered a risk factor 
for plaque rupture [20,21] we were interested in effects of VKA on atherosclerotic 
intima calcification. The aim of this study was to investigate the effects of VKA on 
calcification of coronary atherosclerotic lesions in patients, using coronary CT-
angiography (CCTA). CCTA allows quantifying calcification of vascular tissue but is 
insufficient to distinguish between medial and intimal calcification. Therefore, we 
investigated effects of VKA on calcification of atherosclerotic plaque in apoE-/- mice.  
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METHODS 
Study Population 
Between January 2008 and April 2010, a total of 1,973 patients underwent a coronary 
calcium score scan as well as coronary computed tomographic angiography (CCTA) in 
our medical center. All patients were referred from the cardiology outpatient 
department because of cardiac symptoms suspected for CAD. CCTA was performed as 
part of the diagnostic work-up in these patients. Included were patients with complete 
data regarding their cardiac risk profile in order to calculate the Framingham Risk 
Score (FRS). The FRS is used to estimate the 10-year risk of cardiovascular disease 
and takes the following risk factors into account: age, gender, diabetes mellitus, 
smoking status, systolic blood pressure (treated as well as untreated), total 
cholesterol and high-density lipoprotein (HDL). Excluded were patients presenting to 
the emergency department because of acute chest pain. Patients with a known history 
of CAD, especially a history of myocardial infarction or coronary revascularization, 
were also excluded from this analysis. Patients were asked if they are using VKA. The 
duration of VKA use was verified in medical records. The VKA users (n=133) were 
divided into tertiles, based on duration of VKA use (Table 1). Each VKA user was 
individually matched with a non-VKA user, based on equal FRS (Table 2). This study 
complies with the guidelines for good clinical practice and was performed in 
accordance with the Declaration of Helsinki.  
 
Risk Factor Assessment 
Cardiac risk factors were prospectively collected by the referring cardiologists. 
Patients were classified as diabetics if they were treated with hypoglycemic 
medication or in case of a fasting plasma glucose ≥ 6.7 mmol/L (≥ 121 mg/dL). 
Patients were classified as smoker if they were current smoker. A positive family 
history was defined as having a first degree with a history of myocardial infarction or 
sudden cardiac death before the age of sixty. Total cholesterol, HDL, triglycerides and 
glucose were measured with the Synchron LX20 (Beckman Coulter, Brea, CA, USA). 
LDL was calculated using the Friedewald equation. 
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CCTA Acquisition 
Scans were performed using a 64-slice MDCT-scanner (Brilliance 64, Philips 
Healthcare, Best, the Netherlands) with a 64x0.625-mm slice collimation, a gantry 
rotation time of 420 ms and a tube voltage of 80 to 120 kV, depending on the patient’s 
height and weight. Patients received 50 mg Metoprolol tartrate orally, two hours 
before CCTA. When indicated, an additional dose of 5-20 mg Selokeen (AstraZeneca, 
Zoetermeer, the Netherlands) was given intravenously to lower the heart rate <65 
beats per minute (bpm). All patients received 0,8 mg nitroglycerin spray (Pohl-
Boskamp, Hohenlockstedt, Germany) sublingually just prior to CCTA to achieve 
optimal vasodilatation. Heart rate and ECG were monitored during the scan.  
A non-enhanced scan was performed to determine coronary calcium score using 
the Agatston method [22]. Subsequently, CCTA was performed using 85–110 mL of 
contrast agent (Xenetix 350; Guerbet, Roissy CdG Cedex, France), which was injected 
in the antecubital vein at a flow rate of 6.0 mL/s, directly followed by 40 mL 
intravenous saline (6.0 mL/s) using a dual-head power injector. The most appropriate 
scan protocol was chosen based on the patient’s heart rate. In patients with a stable 
heart rate <65 bpm, a prospective ECG-gated ‘step and shoot’ protocol was used.  In 
patients with a heart rate >65 bpm, a retrospective ECG-gated ‘helical’ protocol with 
dose modulation was used.  
 
Coronary Plaque Assessment 
All scans were independently analyzed by two experienced imagers (IJ, EL), blinded 
for patient details, using source images in the Cardiac Comprehensive Analysis 
software (Philips Healthcare, Best, The Netherlands). In case of disagreement, 
consensus was reached by reviewing findings jointly.  
The coronary calcium score was expressed as the Agatston score using dedicated 
calcium-scoring software (Philips Healthcare, Best, the Netherlands). All consecutive 
pixels (minimal total area of 1 mm2) with a threshold of 130 Hounsfield Units (HU) 
within the coronary arteries are considered as coronary calcification. The software 
automatically detects these coronary calcifications. The Agatston score for each 
calcification is calculated by multiplying the area of the lesion (mm2) by a weighting 
factor, which depends on the maximum density of the pixels.  
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The total Agatston score is calculated by summing all individual calcifications [23]. 
The coronary artery tree was analyzed for the presence and severity of coronary 
artery disease, according to the 16-segment classification of the American Heart 
Association. Coronary plaques were defined as visible structures within or adjacent to 
the coronary artery lumen, which could be clearly distinguished from the vessel 
lumen and the surrounding pericardial tissue. Plaques were categorized as calcified 
(exclusively content with density >130 HU), non-calcified (exclusively content with 
density <130 HU) or mixed (characteristics of both calcified and non-calcified 
plaques). The degree of stenosis was classified as absent (no luminal stenosis), mild 
(<50% luminal stenosis), moderate (50-70% luminal stenosis) or severe (>70% 
luminal stenosis). 
 
Follow-up 
Follow-up was performed in all patients regarding the occurrence of coronary 
revascularization procedures, cardiac mortality and acute coronary syndromes (ACS), 
including myocardial infarction and unstable angina requiring hospitalization. ACS 
was defined as typical angina pectoris, troponin T elevation (>0.01 μg/L) and ST-
segment elevation/depression of ≥1 mm, or at least two of these characteristics 
together with invasive angiographic confirmation of a culprit lesion [24]. Patients 
were seen by their cardiologist on a regular basis, and all hospital visits, both 
outpatient department visits as well as emergency room visits, were recorded in the 
electronic patient records. Additionally, the national mortality records were checked. 
 
Animals & Diet 
Both male and female apoE-/- mice were purchased from the Maastricht University. 
Mice were aged 10 weeks when entering the study and all animals were housed in 
normal cages with free access to water and the provided foods. Irradiated (0.9Mrad) 
vitamin K-deficient WTD (0.25% cholesterol and 15% cocoa butter) was from Arie 
Blok, Woerden, the Netherlands. Vitamin K1, dissolved in corn oil, was added to the 
vitamin K-deficient food in the required amounts. The VKA warfarin was added 
directly to the food. The Experimental Animal Experimental Committee of the 
Maastricht University approved all described animal protocols. 
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The VKA/vitamin K1 model is based on high doses of VKA administered to mice with 
concomitant administration of vitamin K1 to overcome the antagonism of VKA in liver 
but not in extrahepatic tissues such as the vasculature [25].  Thus the effects of VKA on 
extrahepatic tissues can be studied without the animals suffering from major 
bleedings. To induce atherosclerosis, mice (n=40) received a WTD containing vitamin 
K1 (1.5 mg/g food) for three months. After 12 weeks of treatment, 8 mice were 
sacrificed to monitor baseline atherosclerosis (t = 0; baseline group). The remaining 
mice were divided into two groups of 16 mice. The first group continued the WTD + 
vitamin K1 (1.5 mg/g food) (VK1 group), the second group received the WTD + vitamin 
K1 (1.5 mg/g food) + warfarin (3.0 mg/g food) (VK1&W group). These two diets were 
continued for another week and 8 mice from each group were sacrificed. The 
remaining mice continued the VK1 and VK1&W diet and were sacrificed 4 weeks after 
the start of the experimental diets. 
 
Experimental Animal Procedures 
Thirty minutes prior to sacrificing the mice, annexin A5-biotin [26] was injected via 
the tail vein (16 µg/gram body weight). After 30 minutes, mice were anesthetized 
with 4% isoflurane and kept anesthetized using isoflurane 1.5–2.5%. Blood was 
collected in 105 mM trisodium citrate via the portal vein and plasma aliquots were 
frozen at –80°C. Before collecting all required tissues, the vasculature was perfused 
with a sterile vasodilating saline solution (150 mM saline, 2.5 mM CaCl2, and 100 pM 
sodium nitroprusside in HEPES, pH 7.3) via the portal vein. The aortic arch, thoracic 
and abdominal aorta (bifurcation till one cm above), and right and left carotid artery 
were dissected, transferred to a physiological salt solution in a silicon-coated Petri 
dish, and adipose and connective tissue were carefully removed. The abdominal aorta 
was frozen in liquid nitrogen for assessment of the calcium content. The aortic arch 
and right carotid artery were fixed in 4% (v/v) HEPES buffered formaldehyde 
containing 2.5 mM calcium and 150 mM saline and transferred after one hour to 1% 
(v/v) HEPES-buffered formaldehyde containing 2.5 mM calcium and 150 mM saline 
and kept at 4°C for 24 hours. Vascular tissue was next transferred to 70% ethanol 
before use for embedding and subsequent immunohistochemistry.  
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The thoracic aorta was snap frozen in liquid nitrogen and stored at –80°C for alkaline 
phosphatase (ALK) analysis. The left carotid artery was snap frozen in liquid nitrogen 
and stored at –80°C for mRNA analysis. 
 
Analysis of Vascular Lesions in ApoE-/- Mice 
Cryosections and paraffin sections, 4 µm thick, were cut from the abdominal aorta 
starting (bifurcation of iliaca till one cm higher) and aortic arch. Cryosections were 
stained with hematoxylin/eosin (HE) for histochemical analysis. Masson’s trichrome 
stain and von Kossa stain were performed. Quantitative analysis of lesions was 
performed using ImageJ histomorphometry software on at least 4 sections from each 
mouse.  
 
Antibodies And Chemicals 
Parallel sections were stained with monoclonal rat anti- mouse Mac3 (1:30, BD 
Pharmingen, #S2031-30), aSMactin (1:200, Abcam, #AB-15734), BMP2 (1:50, Santa 
Cruz, #sc-6895), cleaved caspase-3 (1:100, Cell signaling tech, #9661S), Collagen 
type2 (1:100, Developmental Studies Hybridoma Bank, #II-II6B3), MGP (against 
various epitopes, Vascular Products BV, Maastricht, the Netherlands), designated as 
anti-cMGP (1:250, recognizing carboxylated MGP; cMGP), and anti-ucMGP (1:250, 
recognizing uncarboxylated MGP; ucMGP), respectively. 
 Biotinylation of mono- and polyclonal antibodies, and subsequent streptavidin-
HRP labeling were performed using the Dako-Kit System-HRP (LSAB2, #K0673). 
Antibodies were visualized with a Nova-RED substrate (Vector #SK-4800, Vector 
Laboratories, Inc). In case of annexin A5-biotin, staining was performed using 
streptavidin-AP. Visualization was done using AP-vector red or AP-vector blue. 
Sections were counterstained with hematoxylin (Klinipath, #4085-9002) and 
mounted with imsol (Klinipath, #7961) and entellan (Merck #7961). In negative 
controls, incubation with primary antibody was omitted.  
 Vitamin K1 and warfarin were purchased from Sigma (Saint Louis, USA). All 
chemicals were of analytical grade or better.  
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Biochemical And Immunohistochemical Measurements of ApoE-/- Tissues 
Tissue calcium was determined after lyophilization and expressed per mg dry weight; 
the freeze-dried tissues were extracted with a tenfold excess (v/w) of 10% formic acid 
(overnight at 4°C) and calcium concentrations were measured using atomic 
absorption-spectrometry (AAS, Department of Clinical Chemistry, University Hospital 
Maastricht, The Netherlands). For the ALK assay, part of the vessel was homogenized 
in ice-cold TBS supplemented with protein inhibitor cocktail using a Polytron-type 
homogenizer. ALK activity was measured colorimetrically at 405 nm using a p-
nitrophenyl phosphate substrate (Sigma). The total ALK level per vessel part was 
normalized to the protein content for comparisons. Immunohistochemistry was 
performed after embedding the vascular tissues in paraffin and subsequent sectioning 
(4 µm thick). Each seventh section was used for calcium detection by von Kossa 
staining. Each antibody staining was performed in one batch. Annexin A5-biotin was 
stained using streptavidin-AP, after blocking for endogenous peroxidase. Appropriate 
negative controls were used for antibody and annexin A5 staining. The relative extent 
of staining was measured using a microscope coupled to a computerized 
morphometry system (quantimed 570, Leica, the Netherlands). Quantification was 
expressed as area in mm2 or as percentage staining of the total plaque area. To 
reliably compare staining of different antibodies both microscope and camera 
adjustments were kept constant [6,27]. Calcium, phosphate, cholesterol, and 
triglycerides were measured in plasma. Lipids were measured at the end of the 
experiments by standard enzymatic techniques. 
 
RNA Isolation And Quantitative Reverse Transcription Real-time PCR 
Messenger RNA was extracted using RNeasy Mini Kit for kidney and lung tissues and 
RNeasy Fibrous Tissue Kit with proteinase K digestion before RNA extraction for aorta 
to maximize mRNA yield. mRNA concentration and 260nm/280nm ratio were 
measured by Nanodrop 1000 (Thermo Scientific, USA). Integrity and amount of mRNA 
were analyzed by capillary electrophoresis (Agilent Bioanalyzer 2100; Agilent 
Technologies, Germany). Reverse transcription and real-time PCR were performed 
using the TaqMan Gene Expression Master Mix (PE, Applied Biosystems, USA) and the 
7500 Fast Real Time PCR System according to the manufacturer’s instructions.  
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The following temperature profile was used: 2 min at 50°C, 10 min at 95°C, and 40 
cycles at 95°C following 60°C. All primers (TaqMan Gene Expression Assays) were 
from Applied Biosystems, including MGP, SM22-α, RunX2, VEGF, BMP-2, BMP-4, MMP-
2 and MMP-9. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
housekeeping target. The expression of each target gene was normalized to GAPDH. 
For calculating relative expression levels the ∆Ct (cycle threshold) method was used. 
 
Statistical Analysis 
Statistical analyses were performed using SPSS software (version 17.0, SPSS Inc., 
Chicago, IL, USA). Categorical baseline characteristics are expressed as numbers 
(percentages) while continuous variables are expressed as means ± SD. To test 
differences between patients in the tertiles for statistical significance, we used the 
Pearson chi-square test for categorical variables and analysis of variance (ANOVA) for 
continuous variables. Values in animals are expressed as mean ± SD. The difference 
between two groups was determined by Kruskal Wallis test. Differences for multiple 
comparisons were determined by ANOVA with Bonferroni correction. Differences 
were considered to be significant at P<0.05. 
 
RESULTS 
Coronary Calcification in Patients 
133 VKA users and 133 individually age, gender and FRS matched non-VKA users 
were included in this study. Of the 133 VKA users, 52 patients had no plaque and of 
the 133 non-VKA 41 patients had no plaque at time of screening. VKA users were 
divided in tertiles based on duration of VKA use. The mean duration of VKA use is 2.5 
± 1.5 months in the first tertile (T1), 18.7 ± 8.8 months in the second tertile (T2) and 
86.4 ± 47.1 months in the third tertile (T3). The categorization of the VKA users into 
tertiles distributed the non-VKA users also in three groups because each non-VKA 
user was individually matched with a VKA user. Tables 1 and 2 summarize the 
baseline characteristics of the tertiles of non-VKA users and VKA users, respectively. 
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Table 1. Baseline characteristics of patients on VKA treatment. 
 1st Tertile 2nd Tertile 3rd Tertile  
Variable (n=44) (n=44) (n=45) P value 
Male gender 29 (65.9) 27 (61.4) 35 (77.8) 0.231 
Age (years) 57.6 ± 10.8 59.7 ± 10.1 63.6 ± 8.5 0.016 
Smoking 7 (15.9) 7 (15.9) 3 (6.7) 0.325 
Diabetes mellitus 3 (6.8) 1 (2.3) 3 (6.7) 0.560 
Positive family history 10 (22.7) 11 (25.0) 10 (22.2) 0.948 
Systolic BP (mmHg) 140 ± 16 142 ± 21 140 ± 18 0.861 
Total cholesterol (mmol/L) 5.5 ± 1.1 5.3 ± 1.2 5.2 ± 1.1 0.294 
LDL-cholesterol (mmol/L) 3.5 ± 1.0 3.3 ± 1.2 3.3 ± 1.0 0.537 
HDL-cholesterol (mmol/L) 1.3 ± 0.5 1.3 ± 0.5 1.2 ± 0.4 0.349 
Triglycerides (mmol/L) 1.7 ± 1.3 1.7 ± 1.0 1.8 ± 1.3 0.981 
Framingham Risk Score 21.6 ± 15.6 21.4 ± 13.9 29.8 ± 17.2 0.017 
Agatston score 79.6 ± 159.8 142.4 ± 306.0 252.5 ± 399.3 0.029 
Continuous variables are presented as mean ± SD. Categorical variables are expressed as number (%).  
BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
 
Coronary calcification was quantified as the Agatston score. There were no significant 
differences between the mean Agatston score in the tertiles of non-VKA users 
(p=0.965; Figure 1A). On the other hand, the mean Agatston score increased 
significantly in VKA users, as the duration of VKA use increased (p=0.029; Figure 1B).  
Next, we analyzed all coronary segments in each patient to assess plaque morphology 
and the degree of luminal stenosis. Plaques were categorized as calcified, mixed or 
non-calcified plaque. Plaque morphology did not differ significantly between the three 
tertiles of non-VKA users (Figure 1C). In contrast, the fraction of calcified coronary 
plaques increased significantly with prolonged VKA use. Fifty percent of the plaques in 
the 1st tertile of VKA users were calcified, compared to 61.5% in the 2nd tertile and 
68.5% in the 3rd tertile (p<0.01; Figure 1D). Follow-up information was available for 
all patients (mean follow-up time 2.9  0.6 years). 
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Table 2. Baseline characteristics of patients not on VKA treatment. 
 1st Tertile 2nd Tertile 3rd Tertile  
Variable (n=44) (n=44) (n=45) P value 
Male gender 29 (65.9) 27 (61.4) 35 (77.8) 0.231 
Age (years) 57.6 ± 8.9 59.8 ± 9.4 59.2 ± 9.5 0.536 
Smoking 11 (25.0) 7 (15.9) 9 (20.0) 0.569 
Diabetes mellitus 5 (11.4) 1 (2.3) 4 (8.9) 0.247 
Positive family history 23 (52.3) 17 (38.6) 16 (35.6) 0.238 
Systolic BP (mmHg) 140 ± 17 146 ± 19 145 ± 20 0.354 
Total cholesterol (mmol/L) 5.3 ± 1.1 5.2 ± 1.1 5.5 ± 1.4 0.581 
LDL-cholesterol (mmol/L) 3.3 ± 1.0 3.3 ± 1.0 3.5 ± 1.3 0.470 
HDL-cholesterol (mmol/L) 1.3 ± 0.4 1.3 ± 0.4 1.1 ± 0.3 0.111 
Triglycerides (mmol/L) 1.7 ± 0.8 1.5 ± 0.8 2.1 ± 1.3 0.022 
Framingham Risk Score 21.6 ± 15.6 22.2 ± 14.1 28.7 ± 17.2 0.065 
Agatston score 153.4 ± 261.4 156.0 ± 285.1 167.8 ± 263.0 0.965 
Continuous variables are presented as mean ± SD. Categorical variables are expressed as number (%).  
BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
 
In the group of VKA users, 2 patients underwent coronary revascularization, 1 patient 
suffered an acute coronary syndrome and 2 patients died as a result of coronary 
artery disease. In the group of non-VKA users, 5 patients underwent coronary 
revascularization, no patients suffered an acute coronary syndrome and 1 patient died 
as a result of coronary artery disease.  
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Figure 1 (partly previous page). Duration of VKA treatment significantly increases the amount 
of coronary calcification and number of calcified plaques. Panel B shows a significant increase in 
Agatston score in VKA users (P=0.029), as patients use VKA for a longer time. This increase is not 
visible in matched patients not on VKA (panel A; P=0.965). In patients using VKA, a significant 
trend (P=0.009) was seen towards a higher percentage of calcified plaques in those patients 
treated longest with VKA (panel D). In contrast, this was not the case for the non-VKA users (panel 
C). T indicates tertile.  
 
We also checked other medication use between VKA and non-VKA patients. VKA users 
were using Verapamil significantly more often compared to non VKA users (P<0.005). 
This suggests that the difference in Agatston score between the VKA users and non 
VKA users may be even larger, since Verapamil is an inhibitor of calcification [28]. 
There were no significant differences in other frequent used drugs such as beta 
blockers, aspirin and statins between VKA and non VKA users. 
In conclusion, these results indicate that VKA use is associated with an increase of 
atherosclerotic plaque calcification. Size and location of calcium deposits are 
important determinants for plaque stability. Unfortunately, due to the limited spatial 
resolution of MDCT and the presence of blooming artifacts, it is not possible to assess 
if these calcium deposits are localized in the intima or the media of the arterial wall. 
Therefore we performed a more detailed study of effect of VKA on plaque calcification 
in an established model of atherosclerosis, the apoE-/- mice. 
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Effect of Warfarin on Atherosclerotic Burden of apoE-/- Mice 
40 apoE-/- mice entered the experimental scheme at the age of 10 weeks. Vitamin K1 
(VK1) and warfarin (most prescribed VKA) supplementation to the Western type diet 
(WTD) did neither change plasma cholesterol, calcium and phosphate levels nor body 
weight as compared with WTD supplemented with VK1 only demonstrating that 
warfarin was well tolerated (Table 3). Vitamin K1 was co-administered because 
warfarin alone would cause internal bleeding of mice. Vitamin K1 counteracts 
warfarin’s antagonistic activity in liver but not in extrahepatic tissue [25]. We 
quantified intimal plaque area in the aortic arch by histomorphometry of 
hematoxylin/eosin (HE) and Masson’s trichrome stained sections. Both H/E and 
Masson’s trichrome staining showed that dietary supplementation of warfarin did not 
change plaque expansion during the 4 weeks treatment regimen (Figure 2A) and 
neither number nor size distribution of plaques were affected. Additionally, collagen 
content of the plaques did not differ significantly. 
 
Table 3. Characteristics of apoE-/- mice at baseline, and after one and four weeks of treatment. 
 Baseline Control Warfarin 
Variable 3 month WTD 1 week 4 weeks 1 week 4 weeks 
Cholesterol 11.0 ± 0.3 11.0 ± 0.4 10.9 ± 0.5 11.1 ± 0.5 11.0 ± 0.3 
Calcium 2.29 ± 0.04 2.28 ± 0.05 2.29 ± 0.03 2.27 ± 0.03 2.27 ± 0.03 
Phosphate 1.94 ± 0.04 1.93 ± 0.04 1.95 ± 0.04 1.94 ± 0.03 1.94 ± 0.02 
Weight male 21.7 ± 0.6 21.3 ± 1.2 23.7± 0.6 22.3 ± 0.6 23.0 ± 1.0 
Weight female 31.7± 0.6 31.7 ± 1.5 32.3 ± 2.3 29.7 ± 1.2 31.3 ± 2.3 
WTD, Western type diet. 
 
Effect of Warfarin on Plaque Calcification 
We quantified vascular calcification of the thoracic aorta using two different 
techniques. Atomic absorption spectrometry (AAS; Department of Clinical Chemistry, 
University Hospital Maastricht, The Netherlands) revealed that calcium levels were 
already elevated at one week post-baseline and increased further 4 weeks post-
baseline if warfarin was added to the WTD (Figure 2B).  
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Figure 2. Warfarin treatment of apoE-/- mice on Western type diet (WTD) does not influence 
plaque size but increases vascular calcification. ApoE-/- mice developed atherosclerotic lesions 
when maintained on WTD for 12 weeks. From baseline mice were fed with WTD plus vitamin K or 
WTD plus vitamin K and warfarin for the duration of one week or four weeks. Growth of intimal 
area was not significantly affected by warfarin (A). Vascular calcium was determined by AAS and 
revealed significant increase in calcium at 1 and 4 weeks warfarin treatment (B). * P<0.05, ** 
P<0.01. 
 
Whereas AAS measures overall calcium of tissue, von Kossa staining allows 
pinpointing the actual location and morphology of intra-plaque calcium deposits. Von 
Kossa analysis of serial sections showed that calcium deposits were mainly confined 
to intimal layers of atherosclerotic lesions. No medial calcification was observed at 
baseline but warfarin induced significant calcification of the medial layer of the plaque 
(Figure 3A,C). In all cases intimal calcification was more prevalent than medial 
calcification (Figure 3B,D). Warfarin treatment significantly increased number of 
plaques with intimal calcification and also increased calcification nodule area (Figure 
3B). We were also able to discriminate between microcalcifications (<2 μm) and 
macrocalcification (>50 μm) (Figure 3E,F). Macrocalcification was often accompanied 
by microcalcification (Figure 3F). Microcalcifications were also observed in absence of 
macrocalcification (Figure 3E). We conclude that warfarin accelerates both medial and 
intimal calcification of atherosclerotic plaque. 
 
 
A B 
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Figure 3. Warfarin treatment rapidly increases medial and intimal plaque calcification in apoE-/- 
mice. Von Kossa stained calcified plaques were scored for medial (A,C) and intimal plaque 
calcification (B,D). In addition calcification was categorized as microcalcification (E, arrow heads) 
and macrocalcification (F, arrows). Microcalcifications occur either alone or in conjunction with 
macrocalcification. * P<0.05, ** P<0.01, *** P<0.001. a, adventitia; i, intima; l, lumen; m, media. 
 
Effect of Warfarin on Plaque Phenotype 
Histochemistry of calcified plaques in the 4 weeks warfarin treated animals revealed 
abundant presence of chondrocyte like cells in close proximity to macro calcium 
deposits (Figure 4A). The presence of bone-associated proteins in these plaques was 
confirmed by collagen type-II staining (Figure 4B, C) as well as alkaline phosphatase 
measurement (Figure 5A) and staining (Figure 5B,C). Of note, warfarin treatment (4 
weeks) did not only augment calcification but also significantly increased the presence 
of both chondrocytic markers.  
 As carboxylated MGP was previously shown to inhibit chondrogenesis via 
inactivation of BMP2 [7], we stained aortic plaques for the presence of carboxylated 
versus uncarboxylated MGP. Warfarin treatment caused a dramatic decrease in 
carboxylated MGP with a concomitant increase in uncarboxylated MGP (Figure 6A-F). 
mRNA expression levels of MGP were not affected by warfarin (Table 4).  
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These results suggest that warfarin interferes with calcification phenotype in the 
plaque by inhibiting carboxylation of MGP. We also measured mRNA expression levels 
of MMP-2 and MMP-9 which were also not significantly different by 4-weeks warfarin 
administration compared to baseline (Table 4). 
 
 
 
 
 
 
 
 
Figure 4. Warfarin induces atherosclerotic calcification which induces a chondrogenic plaque 
phenotype. To characterize cells calcified or adjacent to the calcification area we closely examined 
stained von Kossa sections (A). Calcified cells in the atherosclerotic plaque displayed chondrocyte 
features. To confirm the presence of chondrocytes we stained for collagen type-II, a specific marker 
for chondrocytes. Areas in the plaque with suspected chondrocytes stained positive for collagen 
type-II (B). Quantification revealed that after 4 weeks of warfarin treatment a significant increase 
was measured (C). * P<0.05. a, adventitia; i, intima; l, lumen; m, media. 
 
 
 
 
 
 
 
 
Figure 5. Warfarin upregulates alkaline phosphatase activity in atherosclerotic plaque. To further 
characterize the calcified lesions we measured (A) and stained for alkaline phosphatase (C). Areas 
positive for von Kossa (B) often co-stained for ALK (C). Therefore we analyzed the ALK content of 
the different treatment groups (A). After one week of warfarin treatment a significant increase in 
ALK was already noticed, which further increased after 4 weeks of warfarin.  ALK expression 
indicates an osteo–/chondrogenic differentiation of VSMCs. * P<0.05, **P<0.01. p, plaque. 
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Table 4. mRNA expression levels of aortic tissue (n=3) of calcification biomarkers at control 
and warfarin treatment at 4 weeks time point. 
 Control Warfarin and K1  
Marker Mean SD Mean SD P value 
SM22α 1.4 0.7 1.4 0.5 0.783 
Runx2 2.0 0.7 1.9 1.1 0.946 
BMP–2 1.3 0.6 1.4 0.3 0.967 
BMP–4 2.2 1.6 2.2 0.9 0.825 
MGP 1.3 0.7 1.9 0.4 0.292 
VEGF 1.4 0.6 1.3 0.3 0.938 
MMP–2  1.2 0.5 1.4 0.5 0.891 
MMP–9 1.3 0.6 1.9 0.5 0.204 
BMP indicates bone morphogenetic protein; MMP, matrix metalloproteinase; MGP, matrix Gla protein; 
VEGF, vascular endothelial growth factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Control: cMGP           Control: ucMGP 
          Warfarin: ucMGP           Warfarin: cMGP 
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Figure 6 (previous page). Warfarin affects carboxylation of MGP in atherosclerotic plaque. To 
confirm action of warfarin locally in the plaque we stained plaques for ucMGP and cMGP. UcMGP is 
the result of vitamin K-deficiency. Within one week of warfarin treatment, the amount of cMGP (A) 
decreased significantly and decreased even further after 4 weeks. The decrease in cMGP was 
accompanied by an increase in ucMGP (B). Immunohistochemistry for cMGP and ucMGP (E,F) 
showed increased amounts of ucMGP compared with cMGP in apoE-/- mice on warfarin, whereas 
apoE-/- mice on control diet had predominantly cMGP (C,D). * P<0.05, ** P<0.01. cMGP indicates 
carboxylated MGP; ucMGP, uncarboxylated MGP; i, intima; l, lumen; m, media. 
 
Vascular calcification has been associated with apoptosis, both in media and intima 
[6,29-32]. Therefore we quantified apoptosis using two methods. Apoptosis was 
measured by caspase-3 staining (Figure 7A) and by annexin A5-biotin (Figure 7B), 
which was injected intravenously 30 minutes before sacrificing the mice. Warfarin 
caused a significant increase of apoptosis after 4 weeks of treatment. Similar to the 
calcium deposits, apoptotic cells were predominantly observed in plaques. Positive 
caspase-3 staining was noticed both in the plaque core and shoulder (Figure 7C). 
Likewise, annexin-A5-biotin positive staining was observed in the core, shoulders and 
the fibrous cap of the plaque (Figure 7D, inset and 7E,H) and co-localization with Mac3 
revealed that part of the annexin A5 positivity was associated with macrophages, 
especially in the shoulder of the plaque (Figure 7D, inset, and 7F). At baseline, annexin 
A5-biotin staining was not significantly present (Figure 7G). We also measured the 
ratio of plaque macrophage / VSMC number but this ratio was not significantly 
different between the groups (data not shown). 
 The intimal plaque vascular smooth muscle cells (VSMCs) are thought to be 
derived from the vascular media after having switched from a contractile into a 
synthetic phenotype. Therefore we measured VSMC number and elastin integrity in 
the medial layer underneath the atherosclerotic plaque. In warfarin treated animals, 
VSMCs were lower in number in the vascular media (Figure 8A,C), suggesting loss of 
elasticity and stability of the vascular media. Congruent with this finding, warfarin 
treated animals had significantly more outward remodeled plaques as demonstrated 
by disorganized tissue bulging outward through breaks of the elastic lamina (Figure 
8B,D). 
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Figure 7. Warfarin treatment of apoE-/- mice increases apoptosis in atherosclerotic plaque. Vascular 
calcification is closely linked to apoptosis. Therefore we stained sections for caspase-3. Moreover, all animals 
were injected with annexin A5-biotin, a protein with high affinity for phosphatidylserine (PS). Both cleaved 
caspase-3 (A,C) and annexin A5-biotin (B,D) increased in the warfarin treatment, with annexin A5 
accumulation significantly increased after 4 weeks of warfarin treatment (B). Annexin A5 staining using AP 
vector blue confirmed PS externalization at different sites in the atherosclerotic plaques. Activated and 
apoptotic macrophages are known to express PS on their surface. We found co-localization of macrophages in 
the shoulder of the atherosclerotic plaque (Mac3; F) and PS (annexin A5 stained with AP vector red; E), 
indicating activated and apoptotic macrophages. In the inset annexin A5 (blue) localizes with Mac-3 staining 
(red/brown), indicating activated macrophages. Moreover, at baseline annexin A5 was only incidentally 
present at the surface of the plaque (G), whereas at the 4 weeks warfarin treatment, annexin A5 stained 
significantly positive (H). * P<0.05. i, intima; l, lumen; m, media. 
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Figure 8. Warfarin induces medial VSMC loss and increases outward remodeling of 
atherosclerotic plaques, both indications of an instable rupture-prone plaque phenotype. An 
unexpected feature of warfarin treatment was the significantly increased number of outward 
remodeled plaques (B,D). To explain this phenotype induced by warfarin we stained sections for 
the VSMC marker αSMactin. We found that warfarin treatment was associated with a significant 
loss of medial VSMCs (A,C). * P<0.05, ** P<0.01. i, intima; l, lumen; m, media. 
 
DISCUSSION 
The present study demonstrates that VKA treatment is associated with accelerated 
calcification of atherosclerotic plaques in humans and is the first to demonstrate in a 
mouse model of atherosclerosis that VKA affects plaque phenotype negatively by 
enhancing features of plaque instability.  
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Vascular calcification precipitates in media of arteries along elastic fibers, also known 
as Mönckeberg’s sclerosis. Media calcification is closely linked with uremic risk 
factors. Calcification of intima is associated with atherosclerotic lesions. Calcium 
precipitates in close vicinity with lipid deposits and necrotic debris. It has been 
suggested that mechanisms of the two types of vascular calcification are distinct 
[33,34]. A recent study reported a significant relationship between VKA treatment and 
coronary calcium score in atrial fibrillation patients without CAD [13]. This study did 
not address localization of calcium deposits in coronary arteries and, hence, could not 
provide insight into the arterial site affected by VKA treatment. Animal studies suggest 
that VKA treatment causes medial calcification similar to Mönckeberg’s sclerosis 
[25,35,36].  
 The present study investigated effects of VKA treatment on coronary calcium score 
in patients with suspected CAD, who underwent MDCT. Our study confirmed the 
relationship between VKA treatment and coronary calcification in this group of 
patients. Furthermore, MDCT offers the possibility to non-invasively assess lesions of 
the coronary arteries on morphology, degree of luminal stenosis and presence of 
calcium deposits [37]. Our data convincingly show that use and duration of VKA 
treatment correlate significantly with coronary plaque calcification. Although amount 
of coronary calcification was reported to have predictive value for cardiovascular 
events in subsets of patients [38,39], the actual impact of calcification on plaque 
stability is controversial. In our patient population we did not find a clinical relevant 
difference in the occurrence of cardiovascular events (coronary revascularization, 
acute coronary syndrome, cardiovascular death) between VKA users and non VKA 
users. There are a few reasons contributing to the absence of a difference in 
cardiovascular events. First, we studied a small patient population. Secondly, the 
follow-up is relatively short (2.9 ± 0.6 years) and it is not inconceivable that the 
follow-up period is too short to follow-up on cardiovascular event. Moreover, in case 
of the presence of coronary artery disease, patients were treated (life style changes, 
medication use) to prevent a cardiovascular event.  
 Recently it was postulated that increased risk for acute coronary events depends 
on size and location of calcium deposits. For instance, calcifications adjacent to or 
beneath the lipid necrotic core were assumed to be stabilizing [40].  
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On the other hand, elevated calcium scores were seen to be predictive of acute 
coronary events [41,42] and culprit plaques often contain more but smaller calcium 
deposits (so-called spotty calcification) than stable plaques [20,37,43]. From 
biomechanical studies it was inferred that micro-calcifications in the fibrous cap have 
a destabilizing effect [21]. MDCT allows to map calcification to vascular anatomy and 
to distinguish calcified spots at millimeter resolution, insufficient to pick up micro-
calcifications and to pinpoint localization. In order to reveal impact of VKA treatment 
on plaque stability we studied effects of warfarin on plaque calcification and 
phenotype in the apoE-/- mouse model of atherosclerosis. 
 In this paper we demonstrate for the first time that warfarin increases plaque 
calcification in the apoE-/- model. Warfarin-induced plaque calcification starts already 
after 1 week of administration, indicating that vitamin K-dependent mechanisms 
operate in developing plaques to suppress and limit pro-calcifying processes. cMGP is 
a well-known suppressor of vascular calcification [44], and a deficiency was 
previously shown to result in medial calcification [4,5]. Transgenesis causing 
overexpression of MGP in apoE-/- mice inhibited calcification of atherosclerotic lesions 
[18] demonstrating MGP’s modulating role in plaque calcification and indicating 
shared mechanisms by intimal and medial calcification. We observed a warfarin-
induced downregulation of cMGP with concomitant upregulation of ucMGP in the 
plaque without affecting MGP-mRNA levels. Hence, we conclude that warfarin affects 
plaque calcification by inhibiting post-translational γ-carboxylation of MGP. This is in 
agreement with previous in vitro studies from our group demonstrating that warfarin 
treatment causes ucMGP production by VSMCs [10]. A recent study showed positive 
correlation between calcification of human coronary plaques and ucMGP expression 
in the plaque [45], strongly indicating that warfarin causes accelerated plaque 
calcification in human by a mechanism similar to that observed in the mouse model. 
 cMGP antagonizes BMP and is consequently linked to signaling networks 
regulating inflammation [46] and inducing VSMC differentiation [19] and apoptosis 
[47]. Thus, warfarin potentially affects plaque phenotype more profoundly than solely 
accelerating plaque calcification. We observed that warfarin treatment did not affect 
BMP-2 and -4 expression but increased collagen type-II and ALK expression 
concurring MGP regulated chrondrocytic trans-differentiation of VSMC [4,48].  
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Furthermore, warfarin caused increased plaque apoptosis and loss of VSMC, both have 
been linked to calcification [30,49] and progression towards unstable plaque [50,51]. 
Thus, the loss of VSMCs underneath the plaque seen in our model may link to the 
observed increased number of outward remodeled plaques. In addition, it was 
recently shown that warfarin treated rats displayed increased MMP-9 activity in the 
vasculature which related to elastin degradation and vascular calcification [52]. 
Outward remodeled plaques have been linked to vulnerability of the plaque to rupture 
[53].  
 
CONCLUSION 
We conclude that VKA ignite a cascade of responses leading to progressive 
calcification and destabilization of atherosclerotic plaques. Although the use of VKA 
thus may impart a risk factor for acute coronary events, the relatively safe historical 
profile of VKA suggests, however, otherwise. Detrimental effects of VKA could well be 
masked by their potent inhibitory effects on the coagulant system, an important 
determinant in atherothrombosis [54]. Nevertheless our findings support the growing 
need for alternative anticoagulants and underscore a need for anticoagulants that do 
not interfere with the vitamin K-cycle [55]. 
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CORONARY ARTERY DISEASE 
Coronary artery disease remains one of the leading causes of morbidity and mortality 
in developed as well as in still developing countries, and is accompanied by high 
healthcare expenditures [1,2]. Although the process of initiation and progression of 
coronary atherosclerotic plaques has been extensively described [3], we are still not 
able to prevent end-organ damage of coronary atherosclerosis. Unfortunately, a 
myocardial infarction (MI) or sudden cardiac death is often the first symptom of 
already existing CAD [4]. Identification of these ‘accidents waiting to happen’ is a key 
goal for risk stratification in general and coronary artery imaging in particular [5].  
Nowadays, we have access to various tools which can help us to identify patients at 
risk for a major adverse cardiovascular event (MACE). However, detecting the 
‘vulnerable patient’ in daily clinical practice remains an ongoing challenge. This thesis 
provided more insight in risk stratification in patients with chest discomfort 
symptoms, suspect for CAD. Therefore, we combined the use of several (bio)markers 
with characteristics of CAD, as assessed with coronary CT-angiography (CCTA).  
 
RISK PROFILING ALGORITHMS 
Risk stratification is important and the premise in order to find individual patients 
with an increased risk of CAD and accordingly MACE. Detection of these patients in an 
early phase is important, since they may benefit from a tailored treatment to prevent 
adverse events [6]. Multiple clinical risk profiling algorithms have been developed to 
estimate the long-term cardiovascular risk in patients. Well known examples are the 
Framingham risk score (FRS), the PROCAM risk score and the SCORE risk score. These 
risk scores differ from each other in terms of included risk variables, outcome 
measurement and geographical location of included patients: 
 The Framingham risk score predicts 10- year risk of developing cardiovascular 
disease (CVD) events including coronary heart disease, stroke, peripheral artery 
disease and heart failure. This score is gender specific and incorporates age, 
smoking, diabetes mellitus (DM), systolic blood pressure, treatment for 
hypertension, total cholesterol and high-density lipoprotein cholesterol [7]. 
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 The PROCAM risk score predicts 10-year risk of developing acute coronary events 
including MI and sudden cardiac death. The risk score includes age, smoking, DM, 
systolic blood pressure, family history of premature MI, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol and triglycerides. The study was 
performed in middle-aged men of European descent [8]. 
 The SCORE risk score predicts 10-year risk of cardiovascular mortality. This score 
takes gender, age, systolic blood pressure, smoking and total cholesterol into 
account. The study included datasets from 12 European cohort studies, mainly 
carried out in general population settings [9].  
 
In a previous study by our research group, these three risk score algorithms were 
compared in order to test their ability to predict for CAD, as assessed with CCTA, and 
to test their ability to predict MACE. The study population consisted of 1,296 patients 
who visited the cardiology outpatient department because of stable chest discomfort 
symptoms, suspect for CAD. All patients were followed-up for a mean of 19 ± 9 
months for all cardiovascular events, including acute coronary syndrome (ACS), 
mortality and revascularization >90 days after CCTA. ROC-analysis to predict for any 
coronary plaque as well as for obstructive CAD showed significantly higher areas 
under the curve for FRS and SCORE compared to PROCAM. Moreover, in the low-risk 
FRS group, less patients with any plaque, obstructive CAD and cardiovascular events 
were found as compared to the low-risk PROCAM and low-risk SCORE group. 
Therefore, the FRS seems to be the safest risk stratification algorithm in patients with 
stable chest discomfort symptoms [10]. 
 The most important disadvantage of the use of clinical risk profiling algorithms is 
that it is an epidemiologic concept, meant to be used in patient populations rather 
than in individuals. On the other hand, it also has compelling advantages. In addition 
to the fact that risk profiling is cost- and time-efficient, one of the major strengths is 
that multiple risk factors are combined in order to calculate the cardiovascular risk. 
When combined, risk factors increase the cardiovascular risk not in a linear but in an 
exponential way. Although risk factors are insufficient to identify absolute risk, they 
are strongly associated with the presence of CVD and explain 75-90% of events 
[11,12]. Therefore, risk profiling is recommended in clinical practice [13].  
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GENDER DIFFERENCES IN CORONARY ARTERY DISEASE 
Although health statistics show that relatively more females die due to CVD as 
compared to males, CVD is still often considered as a male problem [14]. As a 
consequence, the risk of CVD is underestimated in women, resulting in 
underdiagnosis, undertreatment and even a decreased survival [15-17].  
 In chapter 2 of this thesis we described gender differences in clinical risk profile as 
well as gender differences in extent and degree of CAD. We found that men had a 
significantly higher coronary calcium score as compared to women. Men also had 
significantly more coronary plaques, irrespective the degree of CAD. Importantly, 
although women had more individual cardiovascular risk factors, their FRS was 
significantly lower compared to men, regardless the extent and degree of CAD. This 
suggests that relative to men, the FRS underestimates the extent and degree of CAD in 
women. All risk factors used to calculate the FRS have a gender specific weighting 
factor. The observation that women had a lower FRS may therefore be explained by 
the fact that male gender is an important risk factor in the FRS algorithm, resulting in 
much higher FRS. Our findings are supported by other studies, concluding that a 
majority of women are classified in the low risk Framingham category although a 
significant proportion of them had significant CAD [18,19]. Because the FRS 
underestimates the extent and degree of CAD in women, clinicians should consider all 
traditional risk factors in women, rather than only calculating the FRS.  
 In the future, it would definitely be of interest to develop a more precise risk 
stratification algorithm focused on women. In the recent 2011 AHA prevention 
guidelines for women, it has already been proposed to introduce an additional 
category of “ideal cardiovascular health” to the FRS [20].  
 
NON-TRADITIONAL CARDIOVASCULAR RISK FACTORS 
The discussed risk profiling algorithms focus on traditional risk factors, which are 
independently related to CAD and MACE [21]. Apart from these risk factors there are 
non-traditional cardiovascular risk factors including chronic inflammatory diseases 
[22], imbalance of the coagulation system, and chronic renal insufficiency [23].  
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It is well elucidated that end-stage renal disease is associated with an increased 
prevalence of coronary calcification and CAD. Moreover, CVD is the primary cause of 
mortality in these patients [24]. More recently, also earlier stages of chronic kidney 
disease (CKD) have been associated with a decreased prognosis [23]. Although several 
previous studies found an inverse association between renal function and 
calcification, it remains unclear if this association is independent from traditional 
cardiovascular risk factors [25,26].  
 We investigated whether mild to moderate CKD is independently associated with 
CAD beyond traditional cardiovascular risk factors in a large cohort (n=2,038) of 
patients with chest discomfort symptoms. As described in chapter 3, patients with 
mild CKD (eGFR 60-89 mL/min/1.73m2) and moderate CKD (eGFR 30-59 
mL/min/1.73m2) significantly more often harbored coronary plaques compared to 
patients with a normal renal function (eGFR ≥90 mL/min/1.73m2). Obstructive CAD, 
defined as coronary plaques with >70% luminal stenosis, was also significantly more 
often present in patients with mild CKD (OR 1.67, 95% CI 1.16-2.40) as well as in 
patients with moderate CKD (OR 2.36, 95% CI 1.35-4.13), both P<0.01. The coronary 
calcium score increased with decreasing renal function in accordance with previous 
studies. Interestingly, after adjustment for traditional cardiovascular risk factors, the 
association between impaired renal function and the presence of CAD were no longer 
statistically significant. Age, gender and smoking remained the only independent risk 
factors for obstructive CAD in this population. Question remains if there is added 
value of renal function over traditional cardiovascular risk factors in predicting MACE. 
Due to the relatively short follow-up time in this cohort, we were not yet able to 
answer this question.  
 
BIOMARKERS IN CORONARY ARTERY DISEASE 
Above we discussed risk stratification by means of (non-)traditional risk factors. 
Although traditional cardiovascular risk factors are validated for the diagnosis and 
treatment of CVD, they do not completely explain incident CVD. Moreover, underlying 
mechanisms for the associations between cardiovascular risk factors and CVD are not 
fully elucidated [27].  
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In general, biomarkers are a powerful tool to better understand the different areas of 
CVD including screening, diagnosis, prognosis and therapy [28]. Importantly, they 
have the potential to improve clinical risk stratification [29]. Therefore, there is 
considerable interest in the development of novel biomarkers in the area of 
inflammation, thrombosis, hemostasis and oxidative stress, in order to identify 
individuals at increased risk for MACE. Biomarker research can also contribute to 
disentangle novel pathways of disease [30]. Now, we will discuss high-sensitivity 
cardiac troponin as a biomarker and the relation between atherosclerosis, coagulation 
and the immune system.  
 
The Meaning of An Elevated Cardiac Troponin Concentration 
Cardiac troponins (cTn), both cardiac troponin T (cTnT) and cardiac troponin I (cTnI), 
are cardiac specific biomarker which is released into the blood as a result of 
cardiomyocyte injury. The introduction of cTn has led to major improvements in 
diagnosis and risk stratification in patients with symptoms of chest discomfort. 
Diagnosis of a MI requires detection of a rise and/or fall of a cardiac biomarker, 
preferably cTn, with at least one value above the 99th percentile upper reference limit 
in combination with at least one of the following criteria: ischemic symptoms, ECG 
changes (new ST-T segment changes or new left bundle branch block), development 
of pathologic Q waves, imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormalities or identification of an intracoronary thrombus by 
angiography or autopsy [31]. The pattern of rise and fall is essential to differentiate 
acute elevations from chronic elevations. Chronic elevations are associated with 
structural heart disease and are present in patients with renal failure, heart failure 
and left ventricular hypertrophy [31]. Although cTn is a cardiac specific biomarker, 
elevations can also occur in alternative conditions such as sepsis, pulmonary 
embolism, stroke, pericarditis, myocarditis or cardiotoxic chemotherapy [31-33]. 
 
High-sensitivity Cardiac Troponin Immunoassays 
Recently, high-sensitivity cardiac troponin (hs-cTn) immunoassays have become 
commercially available. Compared to the previous generation cTn immunoassays, 
these hs-cTn assays improved sensitivity and diagnostic accuracy in the lower range. 
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This may be important since previously undetectable cTn concentrations appeared to 
be associated with structural heart diseases and an increased mortality risk in the 
general population [34]. Moreover, recent studies in patients with suspected ACS 
showed that hs-cTn assays substantially improved the early diagnosis of an acute MI 
[35,36].  
 
Association Between High-sensitivity Troponin and Severity of CAD 
A previous study by our research group revealed that the severity of CAD is associated 
with increasing concentrations of hs-cTnT in patients (n=615) with stable chest pain 
symptoms, not suspicious for a MI [37]. The more severe CAD, the higher the hs-cTnT 
concentration (Figure 1A). We also found gender differences in hs-cTnT 
concentrations (Figure 1B), in accordance with previous research [38], which can be 
explained by pathophysiological differences in ACS between males and females. 
Endothelial dysfunction, microvascular disease and diffuse CAD are frequent causes of 
ischemia in females, while in male patients, plaque ruptures are usually responsible 
for repetitive thrombus embolization and subsequent increased cTnT concentrations 
[39]. Remarkably, high-sensitivity C-reactive protein (hsCRP) did not show a clear 
trend in this population, while N-terminal pro-B-type natriuretic peptide (NT-
proBNP) showed a modest correlation with CAD (Figures 1C and 1D). 
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Figure 1 (partly previous page). hs-cTnT concentrations show a progressive increase with 
increased severity of CAD (A), with a distinction between male gender (stripes) and female gender 
(dots) (B), in contrast to hsCRP (C) and NT-proBNP (D). Indicated are the significant differences 
between groups (*, as compared with the No CAD group; O, as compared with the multivessel 
severe CAD group.) § indicates n=2 [37]. 
 
Question remains what the explanation is for the observed increase in circulating cTn 
concentrations. Several mechanisms are postulated, including: 1) myocyte necrosis; 2) 
apoptosis; 3) normal myocyte turnover; 4) cellular release of proteolytic troponin 
degradation products; 5) increased cell wall permeability; and 6) formation and 
release of membraneous blebs [40]. Obstructive CAD does not necessarily have to be 
present, since non obstructive CAD can also lead to cTn release, possibly due to 
repeated plaque rupture with distal embolization [41]. 
 
Prognostic Value of High-sensitivity Troponin in Patients With Stable Chest Pain 
Most prognostic studies have focused on the value of hs-cTnT in elderly or general 
population [34,42,43]. These studies found an association between elevated hs-cTnT 
and the incidence of heart failure, MI and mortality. The value of hs-cTnT in 
symptomatic patients with stable chest pain is less well known. In chapter 4 we 
described the prognostic value of hs-cTnT in stable chest pain patients and the 
additional value of hs-cTnT in combination with FRS, CCS and CCTA to predict MACE. 
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The composite endpoint of cardiac events included the occurrence of late coronary 
revascularization (>90 days), ACS and cardiac mortality. The mean follow-up time of 
the study was 2.2 years. Over three times as much events were found in patients with 
hs-cTnT concentrations in the 4th quartile, as compared to patients with hs-cTnT 
concentrations in the lower quartiles (HR 3.55, 95% CI 1.88-6.70, P<0.001). Survival 
analysis showed that hs-cTnT had significant predictive value on top of FRS, CCS and 
CCTA outcome. In conclusion, hs-cTnT seems to be a useful prognostic biomarker for 
stable chest pain patients presenting at the outpatient department. This is in line with 
a study showing that hs-cTn provides prognostic information for future MI and 
cardiovascular death in a stable high-risk population [44]. Interestingly, Omland et al 
found also a significant association between hs-cTnT, cardiovascular death and heart 
failure but not with MI in patients with stable chest pain [45]. Further research is 
needed to define the role of hs-cTn in different populations, including patients with 
symptoms, suspicious for ACS, presenting at the chest pain unit. 
 Chest pain units are developed to optimize care for patients with chest pain. The 
main goal is to filter those patients who need direct intervention and those who can 
safely be sent home, making patient care more cost-efficient. On the other hand, 
patient evaluation is still time-consuming and labor-intensive [46]. The future will 
bring us answers regarding the potential role for the new hs-cTn assays. Advantage 
will be that patients with a normal hs-cTn concentration can be safely discharged, 
possibly without additional testing. Disadvantage will be that a substantial part of the 
patients will present with an increased hs-cTn concentration due to a non-ACS cause. 
Potentially, these patients will undergo more tests. It will be a challenge for clinicians 
to deal with these developments. 
 
ATHEROSCLEROSIS, COAGULATION AND THE IMMUNE SYSTEM 
Atherosclerosis is a multifactorial vascular disorder [47], which has close interactions 
with the hemostatic, immune and inflammation system. In the vulnerable plaque 
concept, thrombosis plays an important role [48]. However, not only thrombin, but 
also neutrophils are important actors in the coagulation-inflammation interplay 
during atherogenesis.  
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Neutrophils, part of the innate immune system, appear to have pro-atherogenic and 
tissue destructing capabilities, through which they can contribute to plaque 
destabilization and subsequent plaque rupture [49,50]. 
 
Association Between Atherosclerosis and Thrombin Generation 
Thrombin, the most central coagulation protein, is a strong pro-inflammatory 
mediator, which can induce an array of pro-atherogenic and plaque destabilizing 
effects [51]. Direct inhibition of thrombin attenuates the development of 
atherosclerosis and promotes lesion stability in ApoE-deficient mice [52,53]. In 
hypercoagulable mice, direct thrombin inhibition protects against severe plaque 
progression [54]. Less is known about the association between atherosclerosis and 
thrombin generation in humans. 
 In chapter 5 we provided novel clinical evidence indicating a positive independent 
association between thrombin formation in vivo and the presence and severity of 
CAD. Patients with CAD showed significantly higher thrombin-antithrombin 
complexes (TATc), which is a measure of in vivo thrombin formation, as compared 
with patients without CAD. Moreover, TATc concentrations were independently 
associated with the severity of both CCS and CAD, after adjustment for traditional 
cardiovascular risk factors. Despite this study was not designed to unravel the exact 
mechanism, these results suggest that thrombin plays a role in the pathophysiology of 
coronary calcification and CAD in humans. Although addition of TATc as a marker to 
the FRS improved the predictive value for the presence of CAD, it is too early yet to 
consider TATc as a general risk factor. Moreover, TATc measurement is of course no 
substitute for CCTA. Due to the small cohort and the short follow-up time we were 
unfortunately not yet able to analyze the relevance of TATc in predicting MACE. The 
future will show whether there is such a relationship. 
 Recently, new oral anticoagulants became available in daily practice, including 
direct factor-IIa (thrombin) inhibitors (e.g. Dabigatran). These drugs may be 
prescribed to patients with non-valvular AF with additional risk factors, in order to 
prevent cerebrovascular events and systemic embolization. A recent study 
investigated the effect of AF on atrial thrombogenesis [55]. Rapid atrial rates and AF 
in humans both resulted in increased platelet activation and thrombin generation. 
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Prothrombotic activation occurs to a greater extent in the left atrium compared with 
the systemic circulation. In addition, AF also induces endothelial dysfunction and 
inflammation. In this context, it would be interesting to investigate the effects of direct 
factor-IIa inhibitors on the extent and degree of CAD in patients with AF.  
 
Association Between CAD and Markers of Extracellular DNA Formation 
Formation of neutrophil extracellular traps (NETs), as a consequence of platelet-
neutrophil interaction, is part of the innate immune response in order to eliminate 
infections. NET’s are a network of extracellular DNA fibers, carrying histones and 
granule proteins, which are able to trap and kill bacteria [56]. Moreover, NETs can 
cause platelet activation, adhesion and aggregation in vitro [57]. NETs can generate 
red blood cell rich thrombi by binding red blood cells and platelets, which are 
associated with deep-vein thrombosis. Accordingly, it is not inconceivable that NET-
platelet interactions and the subsequent thrombus formation may play a role in the 
pathogenesis of atherosclerosis and atherothrombosis [56]. However, there is only 
limited clinical evidence supporting this hypothesis.  
 In chapter 6 we showed that elevated levels of markers of extracellular DNA traps 
are independently associated with the extent and severity of CAD. Levels of double-
stranded DNA (dsDNA), nucleosomes and MPO-DNA complexes were significantly 
increased in patients with severe CAD, while high plasma nucleosome levels were 
independently associated with severe CAD even after adjustment for confounding 
factors. Moreover, nucleosomes, dsDNA, MPO-DNA complexes and TATc levels were 
independent predictors of the extent of CAD after adjustment for confounding 
variables. These observations demonstrate that the formation of NETs might be 
important in the atherosclerotic process. However, more evidence is needed to 
confirm this and further research is required to investigate the possible contribution 
of NETs in development of MACE. Far ahead of these matters, but interesting, is a 
recent study on colchicines [58].  
 Colchicine is a drug, prescribed to treat gout, with anti-inflammatory actions on 
different cells including neutrophils. The objective of the study was to determine 
whether a low-dose colchicine is able to reduce the risk of cardiovascular events in 
patients with clinically stable CAD.  
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Patients received 0.5 mg colchicine/day in addition to standard secondary prevention 
therapies including aspirin and statins. After a median follow-up period of 3 years, 
5.3% of patients on colchicine suffered an event (ACS, out of hospital cardiac arrest, 
noncardioembolic ischemic stroke) compared to 16.0% of patients not on colchicine. 
Therefore, colchicine appeared effective for the prevention of CVD events in patients 
with stable CAD. This study is a potentially breakthrough for anti-inflammatory 
therapy in CAD. It seems at least that colchicine is a worthy candidate drug for future 
trials regarding patients with stable CAD. 
 
CALCIFICATION AND PLAQUE MORPHOLOGY BY CORONARY CT-ANGIOGRAPHY 
CCTA has evolved as a widely available, highly accurate non-invasive diagnostic 
imaging tool for the assessment of CAD. A coronary CT-scan typically consists of two 
parts. First, a non-contrast-enhanced calcium score scan is performed to determine 
the calcium score (Agatston score), which is a measure for the amount of calcium 
hydroxyapatite in the coronary arteries [59]. Secondly, CCTA is performed to analyze 
the coronary tree for presence, extent, severity and morphology of coronary plaques. 
In terms of plaque morphology we distinguish calcified plaques, non-calcified plaques 
and mixed plaques [60]. These mixed plaques contain both a calcified as well as a non-
calcified component. 
 
Implications and Pitfalls of Calcium Score 
The calcium score is a proven measure of severity of CAD; a good correlation has been 
found between the calcium score and the total amount of CAD, as assessed by 
histology [61,62]. Moreover, an increased calcium score is correlated with an 
increased risk of obstructive CAD and accordingly MACE [63,64]. The calcium score is 
even considered a better predictor of MACE than the FRS, although it is recognized 
that CAD can be present in patients with a zero calcium score [65-67]. However, 
obstructive CAD in absence of coronary calcification is rare. In our database, 
containing >4,500 CT-cases, only 1% of patients with a calcium score of zero had 
obstructive CAD as assessed with CCTA and confirmed by invasive coronary 
angiography (ICA) [68]. CAD in these patients is caused by non-calcified plaques.  
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The Calcium Challenge in Coronary CT-angiography 
Although CCTA is a reliable and proven technique identify coronary calcification, there 
are a few important drawbacks. Due to limitations in spatial resolution it is difficult, 
maybe even impossible, to pick up micro-calcifications and to determine the exact 
location of these micro-calcification.  
 Despite recent advances in reconstruction techniques and the introduction of dual 
energy CT, the presence of coronary calcification leads to high levels of signal 
attenuation, which can cause blooming artifacts [69]. A high calcium score leads to an 
increased risk of blooming artifacts. As a result, it will be more difficult to reliable 
assess the CCTA, possibly leading to a non-diagnostic scan [70,71]. The choice 
whether to proceed with CCTA in the presence of extensive coronary calcification 
remains therefore controversial [72]. Question is if there is additional value of CCTA in 
these patients with a high calcium score. An alternative approach could be to refrain 
from CT-angiography and refer these patients for perfusion imaging or ICA. ICA is still 
the standard of reference for assessment of CAD severity [73]. Advantage of this 
approach is that patients are not repeatedly exposed to ionizing radiation and 
iodinated contrast during both CCTA and ICA.  
According to the most recent appropriate use criteria for cardiac computed 
tomography, it is appropriate to perform CCTA in symptomatic patients if the calcium 
score is below 400 Agatston units [74]. In case of a calcium score >400, it is uncertain 
whether CCTA can offer additional value. The National Institute for Health and Clinical 
Excellence (NICE) recently acknowledged the role of coronary calcium scoring in their 
guideline “Chest pain of recent onset”. They recommend initial calcium scoring in 
patients with chest pain with a low to intermediate risk of CAD. In case of a zero 
calcium score, no further cardiac testing is needed because obstructive CAD has been 
ruled out with a high degree of accuracy. When the calcium score is between 1-400, 
CCTA or myocardial perfusion imaging is recommended. Patients with a calcium score 
>400 can be directly referred for ICA, because CCTA will not likely be informative in 
this category [73].  
In literature however, there is ongoing debate on the use of certain cut-off values 
for calcium score as a gatekeeper for the performance of CCTA. Different cut-off 
values, including values of calcium score >400, are suggested, but there is still no 
consensus [75-78].  
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These higher cut-off values are fed by the observation that a substantial part of 
patients with such a high calcium score do not suffer from ICA proven obstructive 
CAD. Our data show that of all patients with a calcium score >400 who underwent ICA, 
37,5% did not have plaques with ≥50% luminal stenosis, as assessed with ICA. Even 
more extreme is the small part of people with a very high calcium score (> 1,000 
Agatston units), only showing minor wall irregularities during ICA.  
 
The Effects of Vitamin K-antagonists on Calcification 
Previously, vascular calcification was considered as a passive, degenerative process. 
However, nowadays we know that it is an active, well-regulated process [79], 
resulting from an imbalance between calcification promoting and inhibiting factors. 
Matrix Gla Protein (MGP) is a strong, vitamin K dependent, inhibitor of calcification. As 
can be expected, vitamin K deficiency has shown to lead to calcification [80]. More 
recently, some studies showed an association between VKA treatment and arterial 
calcification [81,82]. VKA therapy is a cornerstone in the treatment of venous 
thrombosis and frequently prescribed to patients with atrial fibrillation (AF), in order 
to prevent thromboembolic events in general and ischemic stroke more specific [83]. 
 In chapter 7 we investigated the effect of VKA on coronary calcification in both 
patients and ApoE-/- mice. We compared 133 patients on VKA to 133 age-, gender- and 
FRS-matched non-VKA users. Patients on VKA were divided into three tertiles, based 
on duration of VKA treatment. The mean calcium score increased significantly in VKA 
users as the duration of VKA treatment increased, while the calcium score in non-VKA 
users did not change. Moreover, the proportion of calcified plaques increased 
significantly with prolonged VKA use, a trend which also was not present in non-VKA 
users. In ApoE-/- mice, VKA treatment significantly increased the frequency and extent 
of vascular calcification, including micro-calcification of the intima. Moreover, VKA 
treatment ignite a cascade of responses, resulting in increased apoptosis and outward 
plaque remodeling, which are features of plaque vulnerability.  
 The findings of this study support the need for alternative anticoagulation drugs, 
which are not interfering with the vitamin K cycle. Examples of these so-called novel 
oral anticoagulant drugs are direct factor-Xa inhibitors (e.g. Rivaroxaban, Apixaban) 
and direct factor-IIa (thrombin) inhibitors (e.g. Dabigatran).  
 
182 
These drugs could offer an interesting alternative to VKA treatment, because they do 
not require frequent blood tests for monitoring while offering similar efficacy results. 
Lacking the inhibitory effect on the vitamin K cycle, adverse side effect like vascular 
calcification and fractures can be avoided. If this will be demonstrated, the advantages 
over VKA will be even greater [84].  
  
Vitamin K2: a Possible Fighter of Calcification? 
Coronary calcification is a progressive process. A few studies in which patients 
underwent serial CCTA reported the progression of CAD, including increase in number 
and extent of calcified plaques [85]. An interesting hypothesis in order to decrease the 
progression rate of coronary calcification is administration of vitamin K2. In a 
previous study, a vitamin K2 rich diet was associated with a reduced cardiovascular 
mortality rate. Moreover, it was inversely related with severe aortic calcification [86]. 
Supplementation of vitamin K2 in animals resulted in regression of existing arterial 
calcification [87]. Currently, we are testing this hypothesis in a randomized, double-
blind, placebo-controlled trial of patients with CCTA-established coronary 
calcification. 
 
Characteristics of a Vulnerable Plaque 
Non-calcified plaques with low plaque density (low attenuation plaques) are 
described as vulnerable [88]. Other characteristics of culprit vulnerable plaques, 
associated with ACS, include positive vascular remodeling and spotty calcification [88-
90]. In a prospective CCTA study, it was confirmed that patients demonstrating 
positively remodeled coronary segments with low attenuation plaques were at higher 
risk of ACS developing over time when compared with patients having lesions without 
these characteristics [91]. Recently, we investigated whether the use of a semi-
automatic plaque quantification algorithm (reporting volumetric and geometric 
plaque characteristics) provides additional prognostic value for the development of 
future ACS as compared with conventional CCTA assessment (calcium score, extent 
and degree of luminal stenosis by eyeballing). Therefore, we selected 25 patients who 
developed ACS after CCTA and 101 randomly selected controls who did not develop 
ACS.  
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There were no significant differences between the groups regarding conventional 
CCTA assessment results and baseline characteristics. Using the semi-automatic 
plaque quantification, patients who developed ACS had a higher total plaque volume 
(mm3), total number of plaques and a higher non-calcified plaque volume (mm3), 
P≤0.001. Semi-automatic plaque quantification provided additional prognostic value 
over both clinical risk profiling as well as conventional CCTA assessment. Therefore, it 
can improve risk stratification in patients with chest discomfort symptoms, suspect 
for stable CAD [92].  
 
The Controversy Between Calcified Plaques and Plaque Vulnerability 
In our study, described in the previous paragraph, the calcium score was not different 
between the ACS group and the control group. Moreover, calcification was not 
associated with the occurrence of future ACS.  
 Interesting is the observation that the calcium score is associated with extent and 
degree of CAD and also act as a predictor of MACE, although it is not recognized as a 
characteristic of plaque vulnerability in the majority of CCTA-studies. Spotty 
calcifications may be a characteristic of plaque vulnerability, but are too small to 
provide a huge increase in calcium score. Therefore, the exact role of calcification with 
respect to plaque vulnerability remains controversial.  
 Coronary calcification may represent an attempt to protect threatened 
myocardium by strengthening weakened atherosclerotic plaque prone to rupture 
[93]. Relative stability of calcified lesions has been demonstrated in an intravascular 
ultrasound study [94]. In short term, this attempt will lead to plaque stabilizing. 
However, plaque rupture often occurs at the interface between the calcified and the 
non-calcified component [95]. Due to more extensive calcification these weak points 
may be eliminated with a decreasing risk of plaque rupture [93]. This hypothesis 
partly supports the theory of plaque vulnerability due to spotty calcification. 
Calcifications adjacent to or beneath the lipid necrotic core were assumed to be 
stabilizing, while micro-calcifications in the fibrous cap were assumed to be 
destabilizing [96,97].  
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SOCIAL ECONOMIC CONSIDERATIONS 
As stated previously, CVD is accompanied by high healthcare costs. In the USA, 15% of 
the current total health expenditures are related to CVD, which is more than any other 
major diagnostic group. Between 2013 and 2030, total direct medical costs of CVD will 
increase from $320 billion to $818 billion, while indirect costs (attributable to lost 
productivity) will increase with 52%, from $203 billion to $308 billion [2].  
 The number of people who need medical care is constantly rising; a trend that will 
continue in the (near) future as a consequence of conditions like aging, obesity and 
DM. Currently, already 34.6% of the adult US population is obese (body mass index 
≥30 kg/m2), while another 33.6% is overweight. Among children (2-19 years of age), 
16.9% is obese and another 14.9% is overweight [2]. These numbers are worrisome, 
especially since obesity is not only associated with marked excess mortality, but also 
with excess morbidity, including an increased risk on conditions like DM, CVD, asthma, 
cancer and degenerative joint disease.  
 These numbers pose a challenge for health care professionals. In order to keep our 
healthcare affordable, it is important to be as cost-effective as possible. In the 
diagnostic process it means that clinicians need to choose the most appropriate test 
for a particular patient. The proper use of risk stratification algorithms and 
biomarkers could be the initial step to make a deliberately decision about the further 
diagnostic approach. Importantly, a biomarker will only be cost-effective if it provides 
information which can change the further diagnostic approach and clinical 
management, thereby improving clinical outcome [29]. Another important aspect 
regarding cost-effectiveness is to gain as much information as possible from a certain 
test, in order to avoid unnecessary diagnostic tests. Due to recent technological 
improvements, CCTA is increasingly able to provide information regarding functional 
analysis rather than just anatomical analysis [98]. Fractional flow reserve 
measurement on CT (CT-FFR) is one of the most recent development in order to 
measure the hemodynamic relevance of a coronary plaque [99]. Moreover, software is 
available which can provide more accurate information about atherosclerotic plaque 
characteristics beyond the conventional assessment method [92]. Integrating all this 
information may contribute to an increased cost-effectiveness. 
 
 
185 
DIRECTIONS FOR FUTURE RESEARCH 
Future research and developments are needed in order to further optimize risk 
stratification in patients with chest discomfort symptoms. This research would consist 
of several pillars.  
 One of the pillars is the development of a risk stratification algorithm, 
incorporating not only cardiovascular risk factors but also biomarkers may further 
improve risk estimation. Future research should determine which combination of 
biomarkers will be most suitable. This algorithm could possibly be further extended 
with imaging results, for example the coronary calcium score. Moreover, the risk 
factors in such an algorithm must be up to date. The body mass index for example is 
not included in the current algorithms, but may play an important role. 
 Another pillar of future research is to further decipher underlying patho-
physiologic mechanisms of atherosclerosis, and the association of atherosclerosis with 
other systems including the hemostatic, inflammation and immune system. Biomarker 
studies can help us to better understand these mechanisms.  
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Cardiovascular disease, including coronary artery disease, is still one of the major 
causes of mortality and morbidity in Western and developing countries. After decades 
of decline, it is expected that the proportion of cardiovascular disease will increase 
again, accompanied by high healthcare costs. Therefore, cardiovascular disease is a 
rising major global health problem. Atherosclerosis, a multifactorial chronic 
inflammatory disease, is the main cause of coronary artery disease. Atherosclerosis is 
not limited to the coronary arteries, but is a systemic disease, which can result in 
complications like myocardial infarction, stroke and peripheral artery disease.  
 With the use of coronary CT-angiography it is possible to visualize characteristics 
of coronary artery disease, especially the presence, extent, degree and morphology of 
coronary plaques. Coronary CT-angiography has a reasonable diagnostic accuracy to 
detect obstructive coronary artery disease and a proven prognostic value to predict 
major adverse cardiovascular events. 
 In this thesis, we related characteristics of coronary artery disease, as measured 
with coronary CT-angiography, with (bio)markers, as a first step in order to improve 
risk stratification in patients with suspected coronary artery disease. Furthermore, we 
tried to gain more insight into underlying mechanisms between atherosclerosis, 
coagulation and immunology.  
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Hart- en vaatziekten, waaronder coronairlijden, is een van de belangrijkste oorzaken 
van ziekte en overlijden in zowel de Westere wereld alsook in landen die zich sterk 
aan het ontwikkelen zijn. Jarenlang is er een afname van hart- en vaatziekten geweest, 
maar de verwachting is dat hart- en vaatziekten weer sterk gaan toenemen, wat 
gepaard gaat met een toename van de gezondheidszorgkosten. Hierdoor blijven hart- 
en vaatziekten een belangrijk, wereldwijd gezondheidsprobleem.  
 Atherosclerose is een multifactoriele chronische ontstekingsziekte. Het is de 
belangrijkste oorzaak van coronairlijden. Het komt echter niet alleen in de 
coronairvaten voor, maar is een systemische ziekte die uiteindelijk kan leiden tot een 
hartinfarct, herseninfarct of perifeer vaatlijden. 
 Door middel van cardiale CT-angiografie is het mogelijk om meer inzicht te krijgen 
in de aanwezigheid, ernst en mate van coronairlijden. Bovendien is het mogelijk om 
coronaire plaques beter te karakteriseren wat betreft morfologie. CT-angiografie is 
geschikt voor het aantonen van obstructief coronairlijden. Daarnaast heeft het ook een 
bewezen waarde in het voorspellen van ongewenste cardiovasculaire events. 
 In dit proefschrift hebben we kenmerken van coronairlijden, zoals we die bepaald 
hebben met CT-angiografie, gerelateerd aan (bio)markers. Doel hiervan is om de 
risicostratificatie van patiënten met een verdenking op coronairlijden te verbeteren. 
Daarnaast hebben we ook meer inzicht proberen te krijgen in de onderliggende 
mechanismen tussen atherosclerose, bloedstolling en immunologie. 
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Daar stond tegenover dat we er samen een leuke tijd van hebben gemaakt en dat we 
gezamenlijk coronary CT-angiografie naar een hoger platform hebben weten te 
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